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Abstract
The work carried out in this thesis is focused on the proposal, comparison
and assessment of survival analysis models for epilepsy data. Although the Cox pro-
portional hazards model provides a popular approach to medical recurrent events
modelling, other accelerated life alternatives seem more appropriate when compared
under goodness of fit tests. In our research we apply the Cox proportional hazards
model and two models consisting of a Poisson-Gamma mixture model that could as-
sume the existence of a cure fraction , and which have been developed and proposed
by B. Cowling[11] and J. Rogers[39] respectively. We applied these methods to the
Multicentre study of early Epilepsy and Single Seizures (MESS) data set. In this
epilepsy study, patients with different types of seizures were randomized to either
immediate or delayed treatment, which consisted in being administered one of seven
types of drugs. The aim of the study consisted in producing a prognosis with which
the clinicians and patients could take an informed decision on whether or not it was
preferable to take an anti-epileptic drug.
We investigated the behaviour of the survival function for the Cox proportional
hazards model, the joint model and the joint with cure fraction model under the
epilepsy data set, under the framework of residual analysis studies, as well as em-
pirical vs theoretical survival functions.
As a final contribution of our work, we proposed modification of the accelerated life
models. Since a patient cannot be diagnosed with epilepsy unless he or she presents
at least two un-provoked seizures, we proposed a zero-truncated joint model, which
considers the pre-randomization counts to be strictly positive. This model has been
extended to consider a cure fraction of the population, but is still under devel-
opment, since the corresponding parameter estimations become considerably more
complicated.
xiv
Chapter 1
Introduction
The main motivation of this thesis lies in the study of individual patient epilepsy
data under the framework of point process survival analysis, which includes the
seizure count pre-randomization, seizure recurrence times post-randomization, the
treatment allocation at randomization and individual baseline data such as age,
sex and electroencephalogram outcomes. The patients belonging to this study and
their clinicians are interested in obtaining a scheme which allows them to take an
informed decision on whether or not it is most convenient for the patient to take a
certain type of drug, depending on the characteristics of his or her condition. The
common approach to this kind of medical study in survival analysis considers the
occurrence count as part of the covariates for the model, and provides a population
prognostic where individual seizure recurrence is not considered. For researchers who
are working with epilepsy for the first time, the book by Marson [35] introduces the
causes and characteristics of epilepsy with accuracy and simplicity, based in some
measure on the proper terminology by the International League Against Epilepsy
(ILAE), as described in the paper by Engel[15].
We are interested in taking a statistical approach where the information
provided from the seizure count and the time to event can be used to jointly model
the seizure recurrence probability for individual patients, and in this thesis a variety
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of existing and newly proposed point process survival models are presented, analyzed
and contrasted between one another in an attempt to provide a more informative
prognostic for this condition.
In the first section of this chapter we provide a brief literature review about
survival and residual analysis, followed by a concise overview of the chapters that
comprise this thesis.
1.1 Analysis of Survival Analysis
When considering the modeling of epilepsy data as a count data problem, a logical
approach is to use the Poisson process generalized linear model(McCullagh and
Nelder [36]). However, due to the overdispersion usually observed in lifetime data
such as epilepsy data, the negative binomial distribution for the seizure counts is
a more appropriate model, as discussed in Greenwood & Yule[19]. Hougaard [23]
presents alternative count process distributions for data with overdispersion, such
as the inverse Gaussian distribution.
The literature about the theory and applications for modeling recurrent
events is very extensive. As we will introduce later on more extensively, the models
that are dedicated to study the time from a specific start at which a random unit or
individual from a population will experience a recurrent event are known as ”Live
distributions”, ”Reliability Models”, or as they are more commonly known in life
sciences, ”Survival Models”. An extense discussion and introduction to these kinds
of models can be found in the books by Meeker and Escobar [37], Lawless [31],
Leemis [32], Tobias and Trindade [44] and Collett [7].
The first epilepsy model we study for the epilepsy MESS data was proposed
by Kim et al. [27], which consists of a Cox proportional hazards model under a
set of specific covariates. Traditionally lifetime data such as epilepsy recurrence
are studied under proportional hazards models. The propriety of such usage of the
2
model has been questioned before, for example in the case of cerebral palsy studies
(Kwong & Hutton[30]). This conclusion first arose from the work by Hutton &
Solomon ([25]), in which they use the mixture model proposed by Cox & Reid ([12])
to study mixture models of proportional hazards and accelerated life models.
Cowling, Hutton & Shaw ([11]) have proposed a Poisson-gamma mixture
model, which is discussed in more detail in the thesis by Cowling [10]. The model
in question proposes an individual seizure rate, where pre-randomization counts
and post-randomization seizure times are considered as variables, unlike previous
works in which the pre-randomization counts tend to be used only as covariates.
Rogers([39],[41]) has generalized the model by Cowling by assuming that there is a
proportion of the population who attains remission before the study finishes, or in
other words, patients who do not experience a seizure recurrence after randomiza-
tion. For both models we modify the pre-randomization assumptions, since we know
that in practice all patients must have at least one seizure pre-randomization. This
assumption leads to a zero-truncated model, where the likelihood and score functions
present significant changes. For the theory behind truncated models, the literature
offers comprehensive discussions (Klein & Moeschberger[28], Cohen & Clifford[6]).
1.2 Goodness of Fit
As part of this work, we consider the Cox proportional hazards model proposed
by Kim et al., the joint model proposed by Cowling and the joint model with cure
fraction by Rogers. We have compared the model predictions on the epilepsy data,
after which we carried on to study under a residual analysis for goodness of fit.
Residual analysis is a goodness-of-fit tool frequently used for the generalized
linear model regressions (McCullagh & Nelder[36]), but there is a limited knowledge
of the proper interpretation and behaviour of residual analysis for survival mod-
els. This aspect is extensively discussed by Collett[7], who argues that the residual
3
shapes for bad fits are commonly known, but there is no clear expectation of how
residuals should appear under a good model fit.
1.3 Overview of thesis
We formally present the fundamental definitions characterizing epilepsy in Chapter
2, where we endeavour to provide an intuitive understanding of the types of epilepsy
seizures depending on their onset location and the spreading behavior of the abnor-
mal electrical impulse in the brain. The second section of this chapter consists of
the introduction to the main object of study in the thesis, the MESS epilepsy data
which consists of an individual patient baseline and progression data throughout
a treatment scheme which allocates the individuals randomly either to immediate
or to deferred treatment. The second epilepsy data is based on the SANAD study,
which is devoted to compare drug efficacy between the typical drug (Carbamazepine
for partial seizures, and Valproate for general seizures), and a group of alternative
drugs with the aim of finding the best drug for each type of treatment. The final part
of this chapter is dedicated to the introduction to the fundamental theory of survival
analysis, likelihood theory and the most common parametric survival models.
In Chapter 3 we present a chronological review of the relevant theory behind
the modeling of medical survival data. The first section includes a discussion about
the robustness of regression estimates under survival model misspecification, and in
particular, the contrast between proportional hazards models and accelerated life
models for epilepsy, under orthogonal parametrization. The second section presents
an evolution of the survival models that have been proposed for seizure recurrence
in epilepsy, where we reproduce the results under the survival model proposed by
Kim et al[27], the first paper where the MESS data set has been modeled. We aim
with this studies to lead the reader to the final works in survival analysis under
consideration, where the seizure counts and the times to recurrence are modeled
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jointly under a point process framework. These models, proposed by Cowling[10]
and Rogers[39] have been the focus of our attention for the majority of the thesis
research time, and were the object of study of the fifth chapter, which we will
describe below.
From the fitted values analysis under the point process survival models,
we propose in Chapter 4 a zero-truncation of the seizure count density due to
the inherent nature of epilepsy. Given that a patient cannot be diagnosed with
epilepsy unless he has experienced at least two occurrences, the assumption of at
least one pre-randomization seizure should provide a better approximation to the
phenomenon of interest. The seizure count and seizure recurrence time joint model
is presented, along with the corresponding marginal distributions, the log-likelihood
and its derivatives with respect to the parameters of interest. We fit and compare
this model with its non-truncated analogous joint model. In the second section
of this chapter, we introduce a generalization of the joint model by considering a
dependent frailty term, which is characterized by a set of covariates. This general-
ization is still under development, but the main interest lies in that the inclusion of
covariates can produce a more specific measure of the level of heterogeneity between
sub-populations of patients with a particular set of symptoms. In the last section of
the chapter, we develop a zero-truncated version of the model proposed by Rogers,
where the joint density, its likelihood and derivatives with respect to the parame-
ters of interest are shown. Further work is needed to obtain the proper numerical
approximation.
In Chapter 5 of the thesis is dedicated to the goodness of fit study of, mainly,
the Cox proportional hazards model, the joint model proposed by Cowling and
the joint model with a cure fraction proposed by Rogers. The large majority of
this chapter presents a contrast between these models under a residual analysis,
where we aim at finding an improvement on the seizure recurrence prediction when
considering the seizure count as a random variable rather than a covariate. We
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begin by introducing the residual score definitions, and proceed to compare the
corresponding values of the epilepsy residuals under the models under consideration.
Given the variety of results and interpretations of the results under the data, we
carried out a simulation study under the point process models, and discuss the
parameter optimization sensitivity for each case. The second section of this chapter
displays a series of plots contrasting the Kaplan-Meier survival curves against the
theoretical marginal time to seizure survival functions, where we aim to compare
the similarities and differences between the model predictions, as well as observe
possible reasons for the difference in the model fits. The majority of the model
diagnostics carried out in this chapter are focused on the joint models proposed
by Cowling and Rogers due to the chronological order in which the research was
carried, but we are interested on reproducing the residual analysis and the survival
function curves in a further work.
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Chapter 2
Introduction to Epilepsy Data
and Survival Analysis
In the following chapter we aim to introduce the reader to relevant statistical model
concepts and the classification and causes for epilepsy. Later on we present a de-
scription of the MESS epilepsy data set, which will be our object of study, followed
by a quick introduction to the SANAD epilepsy data base. Finally we present the
relevant survival analysis preliminaries from which the models under study have
been developed.
2.1 Introduction to Epilepsy Disease
The presence of epilepsy is a clinical diagnosis which should always involve a series
of tests for the presence of epileptic seizures. The classification of types of epilepsy
has proved to be such a colossal task, that there exist research and medical groups
dedicated to this purpose. Since 1997 the International League against Epilepsy
(ILAE) Task Force on Classification and Terminology has been dedicated to the
evaluation of the pertinent terms and aspects of the classification of epilepsies. We
present here a brief introduction to the terminologies and characteristics of epilepsy,
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based on the works by the ILAE ([15]) and the book by Appleton and Marson ([3]).
An epileptic seizure (also called and ictal event) is an abnormal electrical
discharge in the brain cortex, which consists of the layers of neuron cells laying
on the surface of the brain. These abnormal electrical discharges are caused when
a number of damaged cells fail to communicate properly to neighboring neurons.
Because of the lack of communication, the neurons situated next to the damaged
cells are affected by becoming over-excitable, and produce discharges in a chain
reaction to other neurons, thus causing the seizure. The types of seizures vary
depending on the starting location of the discharge in the cortex.
The large variety of types of seizures makes it difficult to define epilepsy
in a such a broad meaning that it includes all known types of recurrent seizures.
Observe however that the existence of a seizure is not in itself diagnosed as epilepsy.
A person is said to have epilepsy when they experience two or more unprovoked
epileptic seizures, generally during a reasonable span of time. A practitioner might
doubt to diagnose a patient as epileptic if he is known to have experience one
epileptic seizure at five years old, and a second one at seventy-five years old.
Depending on the onset location of the electric discharge in the brain, and
how such discharge travels through the cortex, three types of epilepsy branches
are defined. If a discharge commences in one of the two cerebral lobes and during
expansion remains in the same lobe, then this is said to be a partial or focal seizure.
If the electrical discharge originates on one lobe, spreads towards the center link of
the brain and spreads to the two lobes, it is said to be a partial or focal seizure with
secondary generalization. When the seizure begins at the center of the brain cortex,
it expands to the two lobes and then it is called a generalized or primary seizure.
These three possible types of epilepsy branches stem several epilepsy types:
• Tonic-Clonic seizures: These seizures appear as a result of a generalized
epilepsy or partial with second generalized epilepsy, and consist of two phases.
The first phase is the tonic (contraction) phase, which typically lasts one to
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two minutes. During this phase the person experiences contraction of his mus-
cles over all the body, and because of the loss of control over the muscles, the
patient loses his equilibrium and fall to the ground in a rigid way. Because
the muscles in the trunk are also contracting, this forces the air out of the
lungs and breathing becomes uncoordinated. The sustained contraction of the
muscles causes the oxygen in the body to be quickly used up. Clenched jaws
may cause the patient to bite his tongue or cheeks, and the contractions may
cause incontinence of urine or faeces. The second phase of the seizures is the
clonic (convulsive) phase, which tends to last from two to three minutes. Dur-
ing this period the individual experiences rhythmic bodily jerks, increasing
during the first one or two minutes before they diminish and cease, leaving
the person lying unconscious. When the person regains consciousness, he has
to be helped to sit down and often feels confused, tired and experiences head
aches.
• Myoclonic seizures: these are bodily jerks, often shock-like contractions of the
limbs.
• Typical Absence seizures: These types of seizures last usually from five to ten
seconds, and characterized by a specific type of EEG (electroencephalogram)
reading. This disease is almost always found in children and the symptoms
may not be noticed by the parents or the child himself. It occurs suddenly,
making the person stop talking or doing something in a paused manner, until
he resumes his activities, often not realizing what has happened. With some
frequency these absence seizures are followed by short-lived myoclonic seizures.
• Focal or Partial seizures: these types of seizures are distinguished to have two
main manifestations, depending on the site of the cortex where they affect the
neurons. When the seizure occurs in the motor area of the cortex, there is
an external manifestation of the brain insult. Since the most excitable neu-
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rons in the motor cortex correspond to the thumb, index finger, mouth corner
and the toe, the patient experiences bodily jerks usually in such areas, but
not restricted to them, and in opposite direction of the affected lobe in the
brain. Sometimes the patient starts to turn his head and eyes in the direction
of the damaged lobe (versive seizures) or in the opposite direction (adversive
seizures). In these cases, the body reacts to the seizure but the conscious-
ness of the person remains unchanged, he is aware of what is happening and
his perception remains intact. In these cases, when the consciousness is not
affected, the seizures are called “simple partial seizures”. The second type
of focal or partial seizures occur when the parietal, temporal and occipital
lobes are affected, just behind the motor cortex area. These types of seizures
cause a disturbance of internal rather than external perception, although the
effects depend once more on the area of the brain that is being affected. When
the seizure occurs in the parietal lobe, the person can experience the feeling
known as “pins and needles”, numbness or heaviness of the limbs. When the
occipital lobe is being affected, simple visual hallucinations are experienced
such as seeing colored dots or geometric shapes. Finally, when the temporal
lobe experiences a seizure, smell and taste hallucinations, often unpleasant,
and inexplicable fears are experienced when the anterior part of the lobe is
affected. When the posterior lobe is affected the person experiences complex
visual hallucinations, such as staring at himself from afar. Other possible re-
actions can include emotional distress (such as sudden fear or panic attacks),
vertigo, chest and abdominal sensations, the feeling of something being pre-
viously experienced (known as “dej vu”), loss of memory (amnesia) or au-
tomatic behaviours (such as putting clothes on and off repetitively). When
the dominant lobe of the brain in a person is disturbed by a seizure, speech,
comprehension and communication abilities are affected. Partial seizures in
which the consciousness is affected or disturbed are usually called “complex
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partial seizures”. Some of these partial seizures sometimes can expand to the
center of the brain and then to the other lobe, hence becoming from a second
generalized to a tonic-clonic seizure.
An epilepsy syndrome is not defined solely by the type of epilepsy that a
person experiences. An epilepsy syndrome is defined by a cluster of characteristics
ranging from EEG readings to clinical features such as the age when the seizures
started, the type or types of seizures, family history when possible and developmen-
tal and neurological findings. The identification of an epilepsy syndrome helps to
identify which antiepileptic drugs are most convenient, and to elucidate the possi-
ble prognosis in a patient. The prognosis means that the clinician will be able to
give information about the possible cause of the seizures, if the person may develop
difficulties such as learning impairments and if the epilepsy is likely to be controlled
by drugs or to disappear spontaneously.
2.2 Epilepsy Data
The main interest of this work is to study and model the process that leads to seizure
recurrence for patients presenting epileptic seizures, and to provide a prognostic
analysis in order to assist the patients and their clinicians on deciding which epilepsy
treatment to follow, if need be. The object of study focuses on a multicentre trial
that follows-up 1443 patients with different types of Epilepsy. The data collected
before, at and after randomization of the patients to two treatment schemes is
presented in a summarized fashion.
During the study of relevant covariates (such as age and type of epilepsy), we
were able to fit the models discussed in later chapters to another important epilepsy
data set named SANAD. Such study aimed to observe the patient’s response to two
main types of drugs (Carbamazepine and Valproate), and their respective alternative
drugs. For this reason SANAD has two separate sub-studies or Arms, called Arm
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A for studies for Carbamazepine and Arm B for studies with Valproate.
Mess Study introduction
The Multicentre study of early Epilepsy and Single Seizures (MESS) consists of
a study and its resulting data set. Patients in the study had a history of epileptic
seizures and their clinicians were unsure of the need for an anti-epileptic drug (AED).
Patients were recruited for over five years, and randomized to one of two policies:
deferred or immediate treatment. The aims of this study are:
• to measure the differences in policies
• to define prognostic factors for seizure recurrence
• to define psychosocial outcomes of the policies, and
• to make results available in a form which allows patients to make informed
decisions.
When treating with AEDs, we expect certain advantages such as the reduc-
tion of the number of seizures in the short term, and the remission from epilepsy
in the future. However, from the use of such AEDs the patients risk physical and
psychological damage, sometimes serious. This study developed as an attempt to
assess which policies are optimal for the diverse groups of epilepsy patients. It is of
particular interest to understand what the risk of recurrence is, once a first seizure
has happened, and how the treatment alters that risk.
The patients were eligible for the trial if they presented with a history of one
or more spontaneous, unprovoked epilepsy seizures, were at least one month old,
had not taken AEDs before, and they were, along with their clinicians, uncertain of
needing treatment. Patients with a progressive disease were not considered for the
study.
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MESS randomized patients with single seizures, subjects with infrequent
seizures and patients with more frequent seizures with less severe symptomatology.
Thus, the MESS study randomized patients presenting tonic-clonic seizures pre-
randomization (including primary and secondary generalized seizures), and with
seizures that were simple partial, complex partial, or generalized absence and my-
oclonic seizures.
Between 1993 and 2000, 1847 patients were invited to join the trial, from
UK and non-UK medical centres. Of these 1847 patients, 404 did not consent to
randomization, while subsequently 722 were randomly assigned to immediate treat-
ment, and 721 to deferred treatment. Over five years a total of 1443 patients were
recruited. The randomization process was undertaken by an independent random-
ization centre, that balanced across two factors: centre or region, and number of
seizures at randomization. The recruitement resulted in 56% of the patients having
a single seizure in their history, and the remaining 44% had a history of at least two
epileptic seizures. There were 717 (49.6%) subjects from the UK, and 726 (50.3%)
from other countries, as shown in Table 2.1.
For patients allocated to the immediate policy, their clinicians determined
the optimal AED for the patient and prescribed it as soon as possible. Most of
the patients in this group were treated with Carbamazepine (CBZ, 45%), or with
Valproate (VPS, 45%) and 10% with other AEDs. The remaining patients in the
deferred treatment policy received no drugs until the clinician and patient deter-
mined that treatment was necessary. Of such deferred-located patients, 332 started
treatment during the course of the trial: 134 (40%) with carbamazepine, 142 (43%)
with valproate, and the remaining 37 with another AED.
Of the patient’s history pre-randomization, data such as date of birth, the
times to seizures and total number of seizures prior to randomization, and the type
of epilepsy for each individual was collected. The information gathered at random-
ization included imaging, Electro-encephalogram (EEG) outcome if it was available,
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Immediate trt. Deferred trt.
(n = 722) (n = 721)
Number % Number %
Sex
Male 403 56% 423 58%
Female 319 44% 298 42%
Centre
UK 363 50% 354 49%
Non-UK 359 50% 367 51%
EEG abnormalities
Non-specific abnormality only 83 11% 88 12%
Generalized 131 18% 105 15%
Focal 184 25% 200 28%
Imaging abnormal 71 10% 69 10%
Seizure types pre-randomization
Simple partial 15 2% 20 3%
Complex partial 36 5% 32 4%
Secondary generalized Tonic-Clonic 239 33% 215 30%
Myoclonus only 6 < 1% 5 < 1%
Absence only 3 < 1% 3 < 1%
Tonic-Clonic seizures 375 52% 406 56%
Combinations of generalized seizures 21 3% 19 3%
Other seizures 17 2% 13 2%
No. of seizures pre-randomization
1 404 56% 408 57%
2 183 25% 165 23%
3 50 7% 58 8%
4 28 4% 18 2%
5− 9 30 4% 36 5%
≥ 10 17 2% 28 4%
Clinical and family history
Developmental delay/learning disability 34 5% 23 3%
Neurological deficit 52 7% 40 6%
Previous neurological insult 99 14% 90 12%
Previous febrile seizures 53 7% 52 7%
Previous acute symptomatic seizures 14 2% 19 3%
First-degree family history of seizures 76 11% 86 12%
Table 2.1: MESS study data outcome, tabulated by patients allocated to immediate
and deferred treatment respectively.
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age at randomization, date of randomization. The types of EEG abnormalities, the
allocation to treatment policy, type and dose of drug were also recorded. The pa-
tients’ follow-up lasted up to 8 years. The outcomes were the times to first, second
and fifth seizures post-randomization and the types of seizures. This information is
summarized in Table 2.1, which extracted from Marson et al [35].
Since with the passing of time, patients in the trial died or left the study, it
can be observed that the proportion of patients receiving an AED in the two groups
becomes gradually smaller. At 5 years from randomization, 60% of the patients in
the immediate policy group are still receiving treatment, contrasted with 41% in the
deferred policy group.
Due to the small number of patients presenting with myoclonic, absence,
T-C with generalized or other seizures, these categories were not considered for the
statistical analysis. Additionally, five individuals were taken from the sample, for
whom there was no information of their pre-randomization history. These reductions
resulted in a sample size of 1334 patients. The following tables and plots are based
on these 1334 patients.
In the histogram presented in Figure 2.1, the proportion of patients that
received a type of drug at a certain age is shown. Observe that the majority of pa-
tients are children and young adults from 8 to 31 years old, and that the main AEDs
administered were carbamazepine and valproate, shown in red and yellow respec-
tively. Indeed, in table 2.2 it can be seen that, from the 659 patients receiving an
AED, 316 (47.9%) are treated with carbamazepine and 290 (44.0%) with valproate.
Only 1 person has been treated with oxcarbazepine and 3 more with vigabatrin.
The difference in drug selection is to be expected as valproate is typically a first
line AED for patients presenting with generalized seizures, whilst carbamazepine
is usually the corresponding first line AED for individuals presenting with partial
seizures.
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Drug n Mean age at % % % %
randomization Female Partial 2nd.General T-C
CBZ 316 31.79 (18.7) 44.6 39.5 50.3 10.1
PB 9 10 (8.5) 77.7 0 77.7 22.2
PHT 23 44.7 (21.5) 34.7 4.3 21.7 73.9
VPS 290 27.35 (18.2) 42.0 4.4 22.0 73.4
LTG 17 30.35 (15.6) 70.5 17.6 29.4 52.9
VGB 3 23.33 (7.6) 33.3 33.3 66.6 0
OXC 1 21 − 100 0 100 0
Total 659 29.9 (18.8) 44.3 7.5 36.1 56.3
Table 2.2: MESS study data outcome, tabulating the patients receiving immediate
treatment by the drug type received.
The average age at randomization of the patients in the subgroup of individ-
uals who were treated is consistent to the mean age at randomization of the whole
population, as can be observed from the bean plots in Figure 2.2. Bean plots are
produced from the R package ‘beanplot’ [26], and present an alternative to boxplots
by presenting lines as scatter plots and thus allowing the viewer to identify overlap-
ping values. The second useful feature of such plots is that the empirical density is
presented and the average is shown both for the whole population and for the sub-
groups. In our case, the plot shows that the density of patients with Tonic-Clonic
and second generalized seizures are concentrated around 20 years old although both
share a mean of 30 years old according to the mean of the entire population. For
patients with partial seizures only, the majority of individuals are children and the
number of observations is visibly lower than for the other two types of epilepsy.
Partial seizures tend to be more frequent in children and to manifest more
often than tonic-clonic or second generalized seizures. In Table 2.3 it is shown
that before randomization, of the three types of epilepsies considered, half of the
patients with partial seizures had two seizures, which for the other two types of
seizures half the population only had one. In contrast, there are patients with second
generalized seizures who experience up to 130 seizures prior to being randomized in
the study. Patients with partial seizures had in average almost twice the number
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Epilepsy n Pre-randomization count
type mean s.d. median min. max.
Partial 103 6.049 13.61 2 1 99
2nd.General 453 3.366 10.76 1 1 130
Tonic-Clonic 778 1.515 0.99 1 1 10
Total 1334 2.494 7.47 1 1 130
Table 2.3: In this table we show the number of patients corresponding to each
epilepsy syndrome, and for each group, the general distribution of the number of
seizures pre-randomization is shown.
of occurrences than patients with second generalization, and four times more, in
average, than individuals with tonic-clonic seizures only. However, the number of
recruited patients with tonic-clonic and second generalized seizures are significally
greater than those with partial seizures.
In terms of the times of first seizures post-randomization, shown in Table
2.4, the seizure recurrence seems consistent in the sense that patients with partial
seizures who were treated with CBZ have shown a noticeable improvement over
patients treated with VPS. No patient with partial epilepsy under CBZ treatment
has had a seizure before 13 days from the randomization, as opposed to any other
group under treatment, and by the time half the population had had a seizure, it
was 2.7 times longer than the same time observed for the population with partial
epilepsy under VPS. For the population of patients with Tonic-Clonic seizures only,
the effect of the two drugs at a simple glance is not apparent. For the patients with
second generalized epilepsy, however, the mean and median indicate an improvement
of those patients treated with VPS over those under CBZ.
SANAD study
The SANAD study is an unblinded randomized controlled trial in hospital-based
clinics in the UK. It is divided into two arms, which compared the effects of new
antiepileptic drugs to the standard drugs generally used. Arm A consisted of the
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Epilepsy Drug % Days to first post-randomization seizure
type obs. mean s.d. median min max
Partial CBZ 43.75 856.10 885.92 503 13 2825
Partial VPS 38.47 674.7 977.76 185 1 2922
2nd.General CBZ 57.86 929.6 757.23 932 1 2884
2nd.General VPS 56.25 1231.0 983.04 1230 1 2816
Tonic-Clonic CBZ 64.80 1184.0 928.74 1183 1 3127
Tonic-Clonic VPS 55.86 1090.0 904.47 1072 1 3161
Total 54.81 1036.0 876.47 975.5 1 3161
% obs. denotes the proportion of observed seizure times in the group.
Table 2.4: In this table we show the number of patients corresponding to each
epilepsy syndrome, and their first seizure post-randomization distribution for those
patients in each group receiving Carbamazepine or Valproate as the treatment drug.
study comparing gabapentin (GBP), lamotrigine (LTG), oxcarbazepine (OXC) and
topiramate (TPM) to carbamazepine (CBZ), in which 1721 patients were recruited.
Arm B compared the drugs lamotrigine and topiramate to the typical drug valproate
(VPS), and recruited 716 patients to be studied under this scheme. The study
outcomes are the time to treatment failure and the time to 12 months remission
from seizures. In the analysis presented below, we use the times to treatment failure
overall as the time to event. The data set we are working with consists of the
observations of 959 patients with epilepsy, 737 of which are in Arm A, and the
remaining 213 are in Arm B. This subset of the entire SANAD data base consists
of the patients in the study whose DNA sequence is currently being obtained and
added to the data, with the purpose of studying in the future the correlation between
the epilepsy types and drug responses, with their genetic possible predisposition. As
can be observed in Table 2.5, the proportions of epilepsy seizure types (Generalized
vs Partial) differ across the two arms studied. While Arm A has a great majority
of patients with partial seizures, Arm B directs more attention to patients with
generalized seizures, having about the same number of unclassified cases.
The difference in epilepsy type proportions can be observed clearly in Figure
2.3, where the Kaplan-Meier curves for the estimated survival curves are shown.
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General Partial Unclassified
Full data set 152 677 127
Arm A 8 662 64
Arm B 144 15 63
Table 2.5: Number of patients by syndrome and by Arm.
In the first plot we observe the survival curves corresponding to the epilepsy type,
without specifying the Arm factor. The unclassified-epilepsy patients seem to have a
higher probability of surviving than the patients presenting generalized and partial
epilepsy. Additionally, it can be observed that the patients with generalized and
partial seizures present a higher number of early seizures, as denoted by the steeper
fall of the curves at earlier years.
In the second plot to the right we only consider patients from Arm A, and
stratify by epilepsy type. It is now noticeable that there is are only very few patients
with generalized seizures in this category, while the great majority correspond to
patients presenting partial seizures. In the third plot corresponding only to patients
allocated to Arm B, we observe that in general there are fewer observations in this
Arm, compared to Arm A. For this reason, in the preliminary study we are more
interested in studying the patients with partial seizures in Arm A. In the fourth plot
the survival curves stratified by type of drug can be observed. Except for patients
in Arm A under treatments Topiramate and Oxcarbazepine, all remaining curves
show a high number of early seizures.
In the paper [4] by Bonnett et al, several risk factors were found to be
significant for both modelling the time to treatment failure, as well as modelling the
time to 12 month remission. For the time to treatment failure, which we considered
for the model, the risk factors identified were: sex, treatment history (taking non-
SANAD anti-epileptic drugs vs treatment naive), age, total number of seizures,
electroencephalogram (EEG) results, seizure type, site of onset and the treatment
(the type of drug). In our model, the site of onset and the treatment history factors
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Figure 2.3: Kaplan-Meier survival curves for SANAD study, representing the time
to first seizure since randomization, stratified by different covariates.
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have not been considered, as they need to be better understood from the original
data set. We see, however, in the Kaplan-Meier curves presented as the last plot
in Figure 2.3, that the number of patients without previous treatment represents a
great majority of the data. Indeed, in Table 2.6 we observe, for instance, that in
Arm A there are 593 previously untreated patients, against 128 with monotherapy
and 16 presenting recent seizures.
Arm A Arm B
Monotherapy 128 23
Recent seizures 16 12
Untreated 593 187
Table 2.6: Number of patients by treatment history and by Arm.
For the age factor, we consider the age at randomization of each patient. The
ages range from 5 to 83 years old, with a mean of 38.3 years; for better interpretation
purposes in the analysis, we center the ages at 40 years and divide in decades, so
that our variable will be of the form (age − 40)/10. In Figure 2.4 we observe
these transformed ages at randomization by drug and Arm allocation. Observe that
generally patients from Arm A range from around 30 to 70 years old, while all
patients from Arm B are younger and range about 20 and 30 years old. This is in
turn a result from the behavior of the epilepsy types that usually affect patients in
different age ranges.
In Section (4.1.5) two point-process models are proposed and fitted for this
data set, considering the two arms and a comparable set of covariates to the ones
used under the MESS data set. Although the MESS data set remains the object
of our main interest in terms of model fit and model behavior observation, the fits
corresponding to the SANAD study are done to provide a measure of comparison
of interpretation.
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Figure 2.4: Box-plot of the ages of patients by Arm and Drug. The Box-plots
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2.3 Introduction to Survival Analysis Theory
Suppose we have a population of n independent devices or units which are turned
on or start living at time t0 = 0, and let T > 0 be the time at which a random unit
drawn from the population fails. The theoretical probability models used to describe
the random variable T are known as “Life distributions”, “Reliability Models ”, or
as they are more commonly known in life sciences, “Survival Models”. Let F (t)
be the cumulative distribution function (CDF) of T , and let us denote by f(t) the
probability density function corresponding to F (t). Then F (t) has two possible
interpretations:
1) F (t) is the probability that a random unit drawn from the population fails
by time t,
2) F (t) is the proportion of units that fail by time t.
Since we are more interested in the surviving units, that is to say, those that
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have not failed, we define the Reliability function by
R(t) = 1− F (t),
where R(t) is also written as S(t) in life sciences, after its equivalent name, Survival
function. Such function may be thought of in two ways:
1) As the probability that a random unit drawn from the population is still
running by time t,
2) as the proportion of units from the population that are still operational
by time t.
If n identical and independent units are operating and F (t) describes the
population they come from, the probability that none of the elements has failed by
time t is given by [S(t)]n. Consequently, the probability that at least one element
fails by time t is given by
1− [S(t)]n = 1− [1− F (t)]n .
2.3.1 Hazard Function
Given that we have a population of n independent objects, all of which have the
same reliability R(t), our next natural concern is to find the ”rate of failure” of such
objects. That is, the proportion of units that will fail by unit of time. For this,
observe that the probability that an object has not failed by time t, but fails at time
∆t > t, is
P (fail at ∆t|survive until time t)
∆t
=
F (t+ ∆t)− F (t)
S(t)∆t
,
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and from this, as we make ∆t→ 0, we define the instantaneous failure rate or hazard
function, h(t), as
h(t) =
f(t)
S(t)
.
Observe that the hazard function is always non-negative, but it is not restricted to
be less than one. This hazard function can be integrated to find the Cumulative
hazard function H(t) given by
H(t) =
t∫
0
h(y)dy = − lnS(t),
where “ ln ” denotes the natural logarithm. Let us notice that such integral must
then tend to infinity as time tends to infinity, since F (t) must tend to one as this
happens, and we have the useful identity relating failure rates and CDFs as follows:
F (t) = 1− e−H(t) = 1− e−
∫ t
0 h(y)dy.
Observe, from this result, that then we can obtain all quantities from any of the
expressions f(t), F (t), R(t), h(t) or H(t). They all provide the same information.
The shape of the hazard function indicates how a unit of the population
ages. Intuitively it indicates to how much risk is the unit subjected as time passes.
Although any nonnegative function h(t) whose integral H(t) approaches infinity
as time tends to infinity can be a hazard function, the three usual shapes of such
function are the increasing hazard function (labeled IFR for increasing failure rate),
the decreasing hazard function (labelled DFR after decreasing failure rate) and the
Bathtub shaped hazard function. The IFR failure rate is used to model objects that
tend to fail more often when time increases. Similarly, the DFR failure rate models
cases in which the units tend to fail in the early stages. And finally, the Bathtub
shaped hazard function is used to model the situation in which the individual fails
more frequently at the beginning, then it stabilizes, and due to some degradation
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process, it tends to fail more as time increases. This Bathtub shaped model is
commonly used when dealing with living beings lives.
Since the hazard function h(t) varies over time, the natural way to define the
Average Hazard Rate, or Average Failure Rate (AFR) between time t1 and time t2
is
AFR(t1, t2) =
t2∫
t1
h(t)dt
t2 − t1 =
H(t2)−H(t1)
t2 − t1 =
lnS(t1)− lnS(t2)
t2 − t1 ;
and if the interval under consideration is from 0 to T , the AFR becomes
AFR(T ) =
H(T )
T
=
− lnS(T )
T
.
This quantity tells us how many units will, on average, fail in the interval of time
0 to T . This expression, however, is seldom used in practice, but it is helpful when
we have an interest in the specifications of a unit, for example, in the industry
environment.
In order to define another expression of interest, let us first observe that the
mean of a lifetime distribution is given as
µ =
∞∫
0
tf(t)dt,
which is known as the Mean time to fail (MTTF ). This is the average time to
failure for all the failure times in the population. Now, we may be interested on the
average lifetime of a unit who has survived up until time T0; this is defined as the
Mean residual time (ResidualMTTF ), and is given by the expression
ResidualMTTF (T0) =
∞∫
T0
t
f(t)
S(T0)
dt =
∞∫
T0
S(t)dt
S(T0)
.
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2.3.2 Proportional Hazards and Accelerated Life Models
If we consider a set of covariates x = (x1, x2, ..., xp)
T , then the general proportional
hazards model is defined as
h(t|x1, ..., xp) = h0(t)g(x1, ..., xp),
where h0(·) is the underlying hazard function, also called the base-line hazard func-
tion, and g(x1, ..., xp) represents the effect from the covariates. As a more particular
model, the Cox proportional hazards model assumes that g(x) = exp
(∑p
j=1 bjxj
)
=
exp
(
b
′
x
)
, where b = (b1, ..., bp) are the coefficients of the covariates. This means
that, under Cox’s proportional hazards, the model is of the form
h(t|x) = h0(t) exp
(
b
′
x
)
.
Another popular survival model is the accelerated failure time model, also
known as the accelerated life model. It considers once more that, if b and x are
considered as in the previous definition, then the model is defined as
h(t) = exp(b
′
x)h0(t exp(b
′
t)),
where h0(·) is the base-line hazard function.
When we have a data set in which all the lifetimes of the components are
known, then this is called a complete data set. However, it often happens that, in
lifetime data, it is impractical or impossible to obtain or observe the lifetimes of all
objects in the observed population. We say that an observation is censored when
only one bound of its lifetime is known. From this, we have a censored data set
when such set contains one or more censored observations. In turn, there are two
types of censoring: those with exact failure times or those with Readout time or
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interval (or grouped) data.
Right Censoring
Three special cases of right censoring are often observed in the Survival
models situations. In all three cases, it is possible to record the exact failure times
of the non-censored units.
Right Censoring Type I
This kind of censoring is also called time censoring, for the following reason.
Suppose we have n units that are put on test for a fixed planned duration of time
T , at which the test is put to an end. Say that r < n fail, and their failing times
t1 ≤ t2 ≤ ... ≤ tr ≤ T are recorded. Then, at the end of the test, we have r units
which failing times have been observed, and n−r units that survived the test. From
these n− r objects we only know that their failing times are greater than T , and in
here, the number of failures r is a random quantity.
Right Censoring Type II
This type of censoring, also called the order statistic censoring, corresponds
to terminating the study upon one of the ordered failures. Once more suppose we
have n units on test, and we wait until exactly r failures occur and then stop. Since
r is specified in advance, such quantity is no longer random. However, now the
length of the test is random and open ended, which makes this kind of censoring
much more impractical than the time censoring.
Right random censoring
This occurs when individual items are withdrawn from the test at any time
during the study. It is usually assumed that the ith lifetime ti and the censoring time
ci are independent random variables. This causes that the units are not censored
because they are at unusually high or low risk of failure.
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2.3.3 Readout Time or Interval Data
The recollection of the precise failing times requires instruments that continuosly
monitor the components. However, this may be impractical or too costly in many
cases. That is a reason why the following censoring scheme is very common: suppose
we have n components that are put on test at time zero. At time T1, a ”readout ”
takes place whereby all the components are examined and failures are removed. Let
us say r1 failures are found. Then, n− r1 components go back on the test. At time
T2, after a lapse of time T2 − T1, another readout is performed and once again the
new r2 failures are removed, and so this process goes on. The last readout, at time
Tk = T , takes place at the end of the test.
In this kind of censoring, the readout times are predetermined, but the ex-
act times of failure are never known, which in turn makes us lose precision. An
additional problem with readout data experiments is that the experiment may end
before a sufficient number of failures takes place. Even if there are many failures,
the data may be deficient if these failures occur in too few intervals.
Even with all these drawbacks and the inherent difficulty of analyzing this
kind of data sets, this is probably the most common type of reliability data, since
it is the most practical one in many situations.
Left Censoring
This happens less frequently than Right censoring, and is also a censoring in
which is possible to record the exact failing times of the non-censored units. For a
sample of n units, exact times of failure may occasionally be missing for the earliest
failures. All that is known is that r failures took place before time T , and from
then on, failure or censoring times were recorded on the remaining n−r units. Left-
censored data arise for failures occuring before the first readout for interval data,
and we only know that the failures happened before the first inspection.
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2.4 Likelihood Theory
Let t1, t2, ..., tn be lifetimes sampled randomly from a population of items with a
lifetime distribution having a probability density function f(t; θ). This distribution
has a vector θ = (θ1, ..., θp)
T of unknown parameters associated with it, where p
is the number of unknown parameters. Since the lifetimes are independent, the
likelihood function, L(t, θ), is given by
L(t, θ) = f(t1, ..., tn; θ) =
n∏
i=1
f(ti; θ),
where t = (t1, ..., tn). In turn, the maximum likelihood estimator is given by
θˆ = max
θ∈Θ
L(t; θ).
In practice, it is usually easier to maximize the log-likelihood function logL(t; θ),
by solving the differential equation
S(t; θ) =
(
∂
∂θ1
logL(t, θ), ...,
∂
∂θp
logL(t, θ)
)T
= (0, ..., 0)T ,
where S(t; θ), the vector of partial derivatives of the log-likelihood function, is
known as the Score function. The maximum likelihood estimator θˆ has a variance-
covariance matrix given by the so called Fisher Information matrix:
I(θ) = E
[
S(t; θ)S(t; θ)T
]
.
This matrix has components
E
[−∂2 logL(t; θ)
∂θi∂θj
]
, i = 1, 2, ..., p, and j = 1, 2, ..., p.
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However, we usually use the Observed Information matrix,
O(θˆ) =
[−∂2 logL(t; θ)
∂θi∂θj
]
θ=θˆ
for i = 1, 2, ..., p and j = 1, 2, ..., p.
This point estimation is often used because of its invariance principle, mean-
ing that if there is a one-to-one function τ , then the maximum likelihood estimator
of τ(θ) is τ(θˆ) if θˆ is the maximum likelihood estimator of θ.
2.4.1 Censoring
A typical assumption when constructing the likelihood function for censored data,
is that the lifetimes and the censoring times are independent. If they are not inde-
pendent, some special techniques are required. In the construction of the likelihood
function, we need to consider what kind of information each type of censoring give
us. We know that for the noncensored elements, each observation provides the infor-
mation of the exact time at which the failure occurred. This provides the probability
that the event happened at this time, which is approximately equal to the density
function of X at the failure moment.
For a right-censored observation, all we know is that the failure time is greater
than this time, hence the information is the reliability function evaluated at the
on study time. Similarly, for a left-censored observation, all we know is that the
event has already occurred, so the contribution to the likelihood is the cumulative
distribution function evaluated at the on study time. Finally, for interval-censored
data, we only know that the event occurred within the interval in question, hence
we use the probability that the event time is in the interval.
In other words, the likelihood function may be constructed by putting to-
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gether the component parts as
L(t; θ) ∝
∏
i∈D
f(ti; θ)
∏
i∈R
S(Cr; θ)
∏
i∈L
[1− S(G; θ)]
∏
i∈I
P [(a, b); θ] ,
where we have n observations, t = (t1, ..., tr)
T are the r noncensored failing times, D
is the set of indexes of noncensored objects. R is the index set of the right-censored
units by time Cr, L is the set of indexes of left-censored units by time G, and I is
the index set of the objects with failing times censored in intervals with endpoints
(a, b). The unknown parameters for this setup are denominated by θ = (θ1, ..., θp)
T .
The usual representation of data that comes from a censored experiment is
(T, δ), where T and δ are random variables such that, if X is a lifetime:
δ =
 1 if X is observed,0 if X is not observed, and T =
 X if the lifetime is observed,Cr if the lifetime is right-censored.
Or, in other words, T = min(X,Cr).
We may now construct the likelihood function for the Type I censoring as
follows. For δ = 0,
P (T, δ = 0) = P (T = Cr|δ = 0)P (δ = 0) = P (δ = 0)
= P (X > Cr) = S(Cr).
Now, for δ = 1,
P (T, δ = 1) = P (T = X|δ = 1)P (δ = 1)
= P (T = X|X ≤ Cr)P (X ≤ Cr)
=
(
f(t)
1− S(Cr)
)
(1− S(Cr)) = f(t).
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These expressions can be combined into the single form
P (t, δ) = [f(t)]δ[S(t)]1−δ.
If we have a random sample of pairs (Ti, δi), i = 1, 2, ..., n, then the likelihood
function is
L(t1, ..., tn, δ) =
n∏
i=1
P (ti, δi) =
n∏
i=1
[f(ti)]
δi [S(ti)]
1−δi ,
where
∑n
i=1 δi = r. Since we can write f(ti) = h(ti)S(ti), we can write the likelihood
function as
L(t1, ..., tn, δ) =
n∏
i=1
[h(ti)]
δi exp[−H(ti)].
In a very similar way, we find that the likelihood function corresponding to
the observation of exact and left-censored data, is given by
L(t1, ..., tn, δ) =
n∏
i=1
[f(ti)]
δi [1− S(ti)]1−δi .
And finally, for data coming from an interval-censoring, if we censored all items with
failing times falling outside of the intervals (ai, bi) for i = 1, ..., n, then the likelihood
function for this kind of censoring is
L(t1, ..., tn, δ) =
n∏
i=1
[f(ti)]
δiP [(ai, bi)]
1−δi .
2.5 Parametric Lifetime Models
Three types of parameters are used in the distributions described later on: location,
scale and shape. Location (or shift) parameters are used to shift the distribution
to the left or right along the time axis. If c1 and c2 are two values of a location
parameter of a lifetime distribution with survival function S(t; c), then there exists
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a real constant α such that S(t; c1) = S(t+ α; c2). A familiar example of a location
parameter is the mean of the normal distribution.
Scale parameters are used to expand or contract the time axis by a factor of
α. If λ1 and λ2 are two values of a scale parameter for a lifetime distribution with risk
function S(t;λ), then there exists a real constant α such that S(αt;λ1) = S(t;λ2).
A familiar example of a scale parameter is λ in the exponential distribution. The
probability density function always has the same shape, and the units on the time
axis are determined by λ.
Shape parameters are appropriately named since they affect the shape of
the probability density function. Shape parameter values may determine whether
a distribution belongs to a particular distribution class such as IFR (Increasing
Failure Rate) or DFR (Decreasing Failure Rate). A familiar example of a shape
parameter is κ in the gamma distribution.
2.5.1 Exponential Distribution
The exponential distribution is presented first due to its simplicity. This distribution
has a single positive scale parameter λ, often called the failure rate, and its proba-
bility density function and cumulative probability distribution are, respectively,
f(t;λ) = λe−λt, for t > 0 and λ > 0,
F (t;λ) = 1− e−λt.
Since R(t;λ) = 1 − F (t;λ) = e−λt, the failure rate function or hazard function for
this distribution is
h(t;λ) =
f(t;λ)
R(t;λ)
=
λe−λt
e−λt
= λ.
This result shows that the exponential failure rate function reduces to the value λ
for all times. This is a characteristic property of the exponential distribution. The
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only distribution with a constant hazard function is the exponential, since
F (t;λ) = 1− e
∫ t
0 h(y)dy,
if h(y) = λ, a constant, the integral becomes
H(t;λ) =
∫ t
0
λdt = λt,
then we have F (t;λ) = 1− e−λt, or the exponential CDF.
The exponential distribution has often been used to model the lifetime of
electronic components and is appropriate when a used component that has not
failed is statistically as good as a new component. A brand new unit has a expected
lifetime until failure described by the MTTF :
MTTF =
∞∫
0
R(t)dt =
∞∫
0
e−λtdt =
1
λ
.
We interpret this result as follows: the MTTF for a population with a constant
failure rate λ is a reciprocal of the failure rate or 1/λ.
Although 1/λ is the average time to failure, it is not the same as the time
when half the population would have failed. This median time to failure, T50, gives
us
F (T50) = 0.5 = 1− eλT50 ,
taking natural logarithms and solving for T50, we have
T50 =
ln 2
λ
=
0.693
λ
.
If we feel that a unit under test has no significant wear-out mechanisms,
at least for its intended application life, and either we do not expect many early
defect failures or we intend to separate these out and treat them separately, then
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the exponential is a good initial choice for a life distribution model.
Estimation of the Exponential Failure rate λ
When data come from an exponential distribution, there is only one param-
eter, λ, to estimate. The best estimate for complete or censored samples is
λˆ =
number of failures
total unit test hours
.
The denominator is the sum of all the operation hours of every unit on the test,
including both failures and those that have completed the test without failing. For
a complete sample, this expression reduces to the reciprocal of the sample mean.
Thus, we have λˆ = 1/(sample mean time to failure), just as we had λ = 1/MTTF .
The maximum likelihood estimators of λ, considering the Type I right-
censored experiment, will be described as follows. Remember that the likelihood
equation consists of two parts: (1) the product of the r PDFs for each failure time,
and (2) the survival probability at the end of test raised to the power of the number
surviving, n− r:
L(t;λ) ∝
[
r∏
i=1
f(ti)
]
[1− F (T ;λ)]n−r
= λr exp
(
−λ
r∑
i=1
ti
)(
e−λT
)n−r
,
Then, the log-likelihood is given by
l(t;λ) = −(n− r)λT − λ
r∑
i=1
ti + r lnλ.
In turn, the Score function is then found and equaled to zero:
S(t;λ) =
δ
δλ
l(t;λ) =
r
λ
− (n− r)T −
r∑
i=1
ti = 0
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and by solving such equation we obtain
λˆ =
r
r∑
i=1
ti + (n− r)T
,
where T is the pre-specified end of test time and t1, t2, ..., tr are the exact failure
times of the r units that fail before the test ends.
If the test is censored Type II (ends at rth failure time tr), the same rule
yields
λˆ =
r
r∑
i=1
ti + (n− r)tr
.
When we have readout data, we can no longer exactly calculate the denom-
inator in order to estimate λ. In this case, graphical methods can be used, which
also apply as an alternative approach, when exact times are available.
Exponential Distribution Closure Property
A system model where n components operate independently and the system
fails with the first component failure is called a series model. It can be shown that the
system failure rate, or hazard function hs(t), is the sum of the n component hazard
functions h1(t), h2(t), ..., hn(t). When the components have exponential lifetimes
with parameters λ1, λ2, ..., λn, then the system has a constant failure rate equal to
λs =
n∑
i=1
λi
This result establishes the exponential closure property since a constant hazard
function implies an exponential distribution. If the components are all the same,
each having hazard function λ, then the system has a hazard function nλ and an
MTTF of 1/nλ.
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2.5.2 Weibull Distribution
The exponential distribution is limited in applicability because of the memoryless
property. The assumption that a lifetime has a constant failure rate is often too
restrictive or inappropriate. Mechanical items typically degrade over time and hence
are more likely to follow a distribution with a strictly increasing hazard function.
The Weibull distribution is a generalization of the Exponential distribution that is
appropriate for modeling lifetimes having a constant, strictly increasing, and strictly
decreasing hazard functions.
The probability density function (pdf) f(t;κ, λ), the risk function R(t), the
hazard function h(t) and the cumulative hazard function H(t) corresponding to the
Weibull distribution are as follows:
f(t;κ, λ) = κλκtκ−1e−(λt)κ , S(t) = e−(λt)κ ,
h(t) = κλκtκ−1, H(t) = (λt)κ,
for all t ≥ 0, where λ > 0 and κ > 0 are the scale and shape parameters of the
distribution, respectively.
Observe that, when κ = 1, the hazard function is a constant. Thus, the
Weibull reduces to an exponential with hazard function λ.
The Weibull CDF equation has four quantities that may be known, assumed,
or estimated from data. These include the cumulative fraction failed F (t;κ, λ), the
time t , the shape parameter κ, and the scale parameter λ. If any of these three are
known, the fourth can be calculated. Now, using maximum likelihood estimation,
observe that, if t1, ..., tn are the failure times, c1, c2, ..., cn are the censoring times,
and xi = min{ti, ci} for i = 1, ..., n, and U is the set of uncensored units, then the
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log-likelihood function is
l(t;κ, λ) = logL(t;κ, λ) =
∑
i∈U
log h(xi;κ, λ)−
n∑
i=1
H(xi;κ, λ)
=
∑
i∈U
(log κ+ κ log λ+ (κ− 1) log xi)−
n∑
i=1
(λxi)
κ
= r log κ+ κr log λ+ (κ− 1)
∑
i∈U
log xi − λκ
n∑
i=1
xκi ,
and the 2× 1 Score vector has elements
Sc1(λ, κ) =
∂ logL(t;λ, κ)
∂λ
=
κr
λ
− κλκ−1
n∑
i=1
xκi
and
Sc2(λ, κ) =
∂ logL(t;λ, κ)
∂κ
=
r
κ
+ r log λ+
∑
i∈U
log xi −
n∑
i=1
(λxi)
κ log(λxi).
When this are set equal to zero, the simultaneous equations have no closed-form
solution for λˆ and κˆ. To avoid solving a 2 × 2 set of nonlinear equations, the
fortunate event is that the first equation can be solved for λ in terms of κ as follows:
λ =
 rn∑
i=1
xκi

1/κ
.
Using this expression, Sc2(λ, κ) now does not depend on λ, and we obtain a single
expression with κ as the only unknown. Applying some algebra, this equation
reduces to
g(κ) =
r
κ
+
∑
i∈U
log xi − r
∑n
i=1 x
κ
i log xi∑n
i=1 x
κ
i
= 0,
which must be solved iteratively. One technique that can be used here is the Newton-
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Raphson procedure, which uses
κi+1 = κi − g(κi)
g′(κi)
,
where κ0 is the initial estimator. The iterative procedure can be repeated until the
desired accuracy for κ is achieved.
The strength of the Weibull lies in its flexible shape as a model for many
different kinds of data. Since for 0 < κ < 1,
lim
t→0
f(t;λ, κ) =∞ and lim
t→∞ f(t;λ, κ) = 0,
the hazard function behaves the same way, making this type of Weibull a useful
model for an early failure mechanism. For κ = 1 the Weibull reduces to a standard
exponential with constant failure rate 1/λ. For κ > 1, the PDF starts at zero and
increases to a peak at λ[1− (1/κ)]1/κ, after which it decreases towards zero as time
increases. The shape is skewed to the right when k is large. The hazard function
also starts at zero but the increases monotonically throughout life. This type of
Weibull is a useful model for wear-out failure mechanisms.
The Weibull also has a closure or reproductive property, similar to the ex-
ponential. If a system is composed of n parts, each having an independent Weibull
distribution with the same shape parameter κ, but not necessarily the same location
parameter, and the system fails when the first component fails (a series system),
then the time to the first system failure also follows a Weibull distribution. If the lo-
cation parameters are λ1, ..., λn and the shape parameter is κ, the system’s location
parameter is given by
λs =
(
n∑
i=1
1
λκi
)1/κ
.
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2.5.3 Gamma Distribution
The Gamma distribution is a second important generalization of the exponential
distribution. The probability density function for the gamma distribution is
f(t;κ, λ) =
λ
Γ(κ)
(λt)κ−1e−λt, t ≥ 0,
where λ and κ are positive scale and shape parameters, respectively. When κ = 1,
the gamma distribution is equivalent to the exponential distribution. Usually it
is difficult to differentiate between the Weibull and gamma distributions based on
plots of their probability density function, since the shape of their plots are similar.
The differences between these two distributions become apparent when their hazard
functions are compared. The cumulative distribution function of a gamma random
variable is
F (t) =
1
Γ(κ)
∫ λt
0
xκ−1e−xdx,
such distribution is called the incomplete gamma function. The Risk function is
R(t) = 1 − F (t), and as before, the hazard function is h(t) = f(t)/R(t) with
cumulative hazard function H(t) = − logR(t). The hazard function can be shown
to be monotone increasing for κ > 1, with h(0) = 0, and
lim
t→∞h(t) = λ.
For 0 < κ < 1, h(t) is monotone decreasing, with
lim
t→∞h(t) = λ and limt→0
h(t) =∞.
Notice that limt→∞ h(t) = λ for all values of κ, indicating that a lifetime with
a gamma distribution will have an exponential tail. Thus, if an item survives far
enough into the right-hand tail of the probability density function, the distribution
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of the remaining time to failure is approximately exponentially distributed by the
memoryless property.
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Chapter 3
Previous Models for Count Data
In this chapter we present a broad introduction to previous models proposed for
the MESS epilepsy data set. An important approach to medical recurrent event
problems lies in the use of survival model analysis. In a large number of cases, due to
familiarity and convenience, researchers tend to prefer choosing Cox’s proportional
hazards model as the underlying model behind such problems. However, more recent
work has suggested that accelerated life models might provide a better fit in some
cases. This poses the question of what is the impact of survival regression model
misspecification on the parameter estimates and the conclusions they can lead to.
Indeed, the paper by Kwong and Hutton[30] addresses this problem, and
mentions that it is not only important to consider the effects of model misspec-
ification, but that it should also be noted that the choice of the baseline family
distribution is often ignored. When working with epilepsy data, several important
questions arise, such as which factors influence the recurrence of seizures, which
base-line distributions best fit this disease, which assumptions must be made about
the model, and how robust the results and interpretations are under base-line and
survival regression model misspecification.
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3.1 Some Historical Background
In 1997, Hutton and Solomon[25] studied the robustness of regression estimates
under misspecification of the survival models. In other words, assuming a regression
analysis on survival data, they were interested in the changes that the regression
parameters would experience if the estimation were carried out under a proportional
hazards model assumption, when the true underlying model was an accelerated
life model, and vice versa. For this purpose, the main interest lies in using the
orthogonality of parameters to study the effects of model misspescification. By
orthogonalizing the parameters of interest from the nuisance parameters, they were
able to obtain an expression of the regression parameters relating their value under
the true model, and the value under the assumed model.
Using the same form of Cox & Reid’s[12] mixture model, the model proposed
in Hutton & Solomon[25] is a mixture of an accelerated life (AL) model, and a
proportional hazards (PH) model:
m(t) =
{
g0 (t) e
β′zG0 (t)
exp(β′z)−1
}ψ {
f0
(
teγ
′z
)
eγ
′z
}1−ψ
,
where the survivor functions F0
(
teγ
′z
)
and G0 (t)
exp(β′z) correspond to the accel-
erated life model and the proportional hazards model respectively; F0 and G0 are
the base-line survivor functions with corresponding densities f0 and g0 . Here z is
the vector of fixed covariates, and β and γ are the associated vectors of unknown
regression parameters for the proportional hazards and accelerated life families of
models. The interest lies in finding expressions for the parameters of interest, β and
γ, while considering ψ as a nuisance parameter.
Now let us consider the following definition:
If θ = (θ1, θ2) where θ1 and θ2 partition θ, and iθiθj corresponds to the ij
th
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entry of the information matrix, then we define θ1 to be orthogonal to θ2 if
iθsθt =
1
n
E
[
∂l(θ; y)
∂θs
∂l(θ; y)
∂θt
; θ
]
=
1
n
E
[
−∂
2l(θ; y)
∂θs∂θt
; θ
]
= 0
for all θs ∈ θ1 and for all θt ∈ θ2.
We have from the Cox & Reid (1987) paper, shown in the Appendix under
“Parameter orthogonalization”, two parameters (ψ, φ) are orthogonal if the following
equation holds
q∑
r=1
i∗φrφs
dφr
dψ
= −i∗ψφs ,
where i∗ψφs = E
[
d2l∗(ψ,φ)
dψdφs
]
, i∗φrφs = E
[
d2l∗(ψ,φ)
dφrdφs
]
and l∗ is the log-likelihood function
corresponding to ψ and φ. These are also called orthogonalizing equations of the
parameters φr and φs. Among several other convenient properties of two orthogonal
parameters ψ and λ, if ψˆ and λˆ are the maximum likelihood estimators of ψ and λ
respectively, then they are asymptotically independent.
In the case of this problem, the exact expressions of this orthogonalizing
equations are not obtainable, hence the mixture function m(t) is normalized and
equated to the likelihood function
L(ψ, β, γ;α, t, z) =
m(t)∫∞
0 m(t)dt
;
where α, which is assumed as known, are the parameters of the base-line survival
distributions.
While the formal computations are shown in the Appendix, it is worth men-
tioning that in order to approximate
∫∞
0 m(t)dt, a Taylor series is used about
(β, γ, ψ) = 0. Observe that this requires the assumption that β and γ are small.
After several approximation steps, it was found that, if the true model is the
accelerated life model, which implies that ψ = 0, but the assumed model is a pro-
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portional hazards model, then the orthogonalizing equations result in the expression
βs = −γs
(
1 +
c4
c2
)
,
where
c2 = Ef0 [logG0(T )] and c4 = Ef0 [T y˙(T ) logG0(T )] ,
where T is the time to occurrence random variable, and y˙(T ) denotes the first
derivative of y(t) with respect to t and evaluated at T .
The expression for the regression parameters are obtained in a similar manner
when the true model is a proportional model, and the accelerated life model is
assumed, which corresponds to the case when ψ = 1. The equation in question is of
the form
γs = −βsd6
d4
,
where
d4 = Eg0 [T y˙(T ) log {g0(T )/f0(T )}] and d6 = Eg0 [T y˙(T ) {1 + logG0(T )}] .
Observe that the relationship between the regression parameters under model mis-
specification, in both cases, is proportional to the first degree. It can be shown that
the expressions can be simplified to
βs
β1
=
γs
γ1
for s = 2, 3, ..., 1,
which means that the ratios of regression coefficients are consistent.
Important results from Hutton & Solomon seem to indicate that, under the
assumption of small regression coefficients, these coefficients are consistent when
facing model misspecification. This result is then reconsidered in the paper by
Kwong & Hutton[30] six years later, with the purpose of investigating the robustness
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of such parameter estimates under model misspecification, also assuming in this work
that the covariate coefficients are small.
In order to investigate the properties of misspecification in a practical manner
this paper addresses two applications: monotherapy for epilepsy and cerebral palsy
studies. For each one of them, four distributions are considered for the base-lines:
the gamma, log-normal, log-logistic and Weibull distributions. Both proportional
hazards and accelerated life models are adjusted and studied.
Although the cerebral palsy data produced results that were consistent with
Hutton and Solomon’s findings, the epilepsy data analysis presented a more com-
plex case. The epilepsy study consisted of 1183 patients from five different trials, in
which each person was randomly assigned either the drug carbamazepine (CBZ) or
valproate (VPS). The outcomes were the times to the first seizure after the random-
ization, and the variables of interest were either categorical (trial, drug and seizure
type) or continuous (age, drug and age interaction, and the number of seizures six
months before randomization). Such variables of interest were selected by compar-
ing the values of −2 log(Lˆ) for all linear combinations of explanatory variables in
Cox proportional hazards models, where L is the maximum likelihood function. Al-
though the Drug variable was not significant in this case, it was considered for the
analysis as it was of special medical interest. From the 1183 patients in the study,
836 (71%) showed a first seizure post-randomization, and the remaining 347 (29%)
patients had censored observations.
Since neurologists believed that CBZ is a more effective drug for patients with
partial seizures, and VPS is better for cases with general seizures, the analysis was
directed to compare the survival between the groups combining CBZ and VPS drugs
with generalized and partial seizures. In all four models considered, it was found
that patients with generalized epilepsy had twice as long until their first seizure
post-randomization than those patients with partial epilepsy.
The proportional hazards model was shown to be a bad model for this study,
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as the proportional hazards constraint on the Weibull base-line distribution failed
to reflect the difference in hazard rates for generalized versus partial epilepsy. If
proportionality constraint were true, the hazards ratio between two groups should
be constant with time, but in the life-table obtained, the estimates of the hazard
function of the generalized epilepsy group and the estimates corresponding to the
partial seizures group did not appear to be this way. The smaller AICs in the gamma,
log-normal and log-logistic models indicated that accelerated life models fitted the
data better than proportional hazards models. When considering the 95th, 90th and
85th percentiles of the survival, the Weibull model is shown to greatly underestimate
the survival.
Finally, for this data, it was observed with a Kaplan-Meier approximation,
that the failure distribution was highly skewed, since there was a large number of
early seizures. As a result, after considering small covariate coefficients, there
is evidence to suggest that the regression estimates under misspecification of the
models were not proportional to first-degree. Thus for this study, the results from
Hutton & Solomon (1997) do not hold. Indeed, observe that, if hAL is the accelerated
life hazard function, then
hAL(t) = e
β′zh0(e
β′zt) ' eβ′zh0
[
(1 + β
′
z)t
]
when approximating eβ
′
z with its first Taylor series term. Furthermore, when ap-
proximating h0 by its Taylor expansion about t, we obtain
hAL(t) ' eβ
′
z
{
h0 (t) + β
′
zth
′
0(t)
}
(3.1)
= eβ
′
zh0(t) + β
′
zteβ
′
zh
′
0(t).
Observe that the first term of (3.1) is an approximation to a Cox proportional hazard
function, and thus Hutton & Solomon’s result will hold only if the second term of the
equation is zero. If the hazard function is decreasing (increasing) rapidly, h
′
0(t) will
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be positive (negative) and large, and cannot be ignored, then the function hAL(t)
is not approximately a Cox’s proportional hazard, and consequentially, Hutton &
Solomon’s consistency of the parameters does not hold. This result also proposes
that estimates of regression parameters corresponding to survival models with late
survival times are robust under misspecification, but if the model was such that
the survival distribution is strongly right-skewed, with a short median survival, the
parameters are not robust.
Precisely in this example of epilepsy data, the survival Kaplan-Meier plots
showed that the hazard decreases rapidly due to the abundance of early seizures.
Indeed, for this case the regression parameters do not appear to be consistent for
proportional hazards and accelerated life models.
After calculating the maximum likelihood parameter estimates for the four
survival models, it was found that the effects of partial epilepsy, age, the natural
logarithm of the number of seizures within 6 months before randomization, and the
drug-age interaction, tend to reduce the time to a first seizure post-randomization,
while VPS and higher age at randomization increase the time to first seizure.
It is worth mentioning that, although there was a small hint that for the
drug effect, VPS is better than CBZ, this effect should not be considered on its own
since the interaction age-drug was very significant. The estimated effect of age is
much more marked with CBZ than with VPS in all models. For young people, the
age below which is best to use VPS varies from 23 years (for gamma and Weibull
models) to 17 years old (log-logistic model).
Taking this result by Kwong and Hutton, the same year Hutton & Monaghan[24]
investigated the effect of misspecifying fully parametric proportional hazards and
accelerated life models, taking special interest in observing the impact on the co-
variate, shape and scale parameters under such models. An important contribution
from this paper is the fact that they do not assume that the regression coefficients
are “small”.
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Three categories of misspecification are considered for this paper: when the
base-line distribution is false, but the covariate effects are well specified, when the
covariate effects are false but the right base-line distribution is considered, and finally
when both covariate effects and base-line distribution are misspecified. Additionally,
the three distributions considered here for the base-line distribution are: log-normal,
log-logistic and Weibull distributions. In this paper, they study the asymptotical
distribution of the maximum likelihood (ML) estimator, under the misspecification
assumption. Once again, further details can be observed in the Appendix, but the
main idea develops from a previous result by (Cox, 1972)[12]; it states that under
misspecification, the ML estimator βˆ of the covariate, shape and location parameters
β, are asymptotically distributed as N(βα,
1
nC(βα)), where C(βα) = A
−1BA−1, A is
the Fisher information matrix and B(α)jk = Ef
[
∂ logL
∂βj
∂ logL
∂βk
]
, with L the likelihood
function. Additionally, βα is the solution of a set of expected score equations.
After all different types of misspecifications are considered and the param-
eters are estimated, a large series of detailed results are stated for every base-line
distribution considered. Among the most important results, it was found here that
the shape and regression parameters are biased when proportional hazards models
are fitted to accelerated life models. Furthermore, the accelerated life model is more
robust to misspecification because of its log-linear form. Consistently with Hutton
& Solomon[25], it was found that the effect of misspecification decreases as the cen-
tre of density of survival times move away from zero, which means that there are
not too many early failures.
3.1.1 Epilepsy seizure recurrence models
From the previous background, we know that the choice of a survival model for
medical recurrent events is important, as well as the choice of the parametric base-
line distribution. When modelling for epilepsy seizure recurrence, the large amount
of information can present a challenge, as it has been demonstrated by previous
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models that fail to utilize all of the available information.
Medical epilepsy studies tend to have information of the patient’s epilepsy
history, previous to being subjected to a treatment. This provides an additional
source of information, that in the past has been considered merely as a covariate for
the model. Later models have considered to approach the epileptic seizure counts
previous to treatment, jointly with the seizure observations after treatment, as time
dependent variables.
Previous approaches have been made to medical problems where the main
interest of study is to model phenomena with recurrent events. Some useful ap-
proaches were considered:
• Hougaard et. al [23] used an overdispersed Poisson distribution to model
epileptic seizure counts, since in this case the mean is usually smaller than the
variance. They used the power variance family as the mixing distribution, but
the models did not adjust for explanatory variables.
• Marshall & Olkin [34] proposed that, if we considered Y1 as a count variable
before randomization, and Y2 as the count variable post-randomization, then
they could be jointly model (Y1, Y2) as
f(y1, y2|z1, z2) =
∞∫
0
fY1(y1|z1, ν)fY2(y2|z2, ν)g(ν)dν,
where f is the probability function of a bivariate negative binomial, f1 is the
probability function of a Poisson distribution with parameter µ1ν and depen-
dent on the covariate vector z1, f2 is a Poisson distribution with parameter
µ2ν, dependent on a covariate vector z2, and g is a gamma distribution with
parameters α and 1/α.
• Cameron & Trivedi [5] considered a bivariate Poisson distribution, and take the
heterogeneity between two event times as correlated, not necessarily identical.
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• Cook & Lawless [8], reviewed the analysis for repeated data with intensity
functions, but did not discuss an analysis of the joint variables (seizure counts,
gap times between seizures).
• Cook & Wei [9] described a bivariate conditional semiparametric approach for
count data, mainly, for the variables event counts and event times.
One paper of particular interest to us is Cowling, Hutton & Shaw[11]. The
main aims of this study were to present a contrast between the treatment effects,
and study the interaction between treatments and the covariates. In this work,
the covariates are age, sex, trial indicator, and type of epilepsy. Although the
standard survival analysis method uses the seizure counts pre-randomization as a
fixed covariate, the model proposed in this paper treats these counts and the post-
randomization counts as jointly distributed. This model is chosen in order to account
for the variation within individuals.
In this paper, the meta-analysis of longitudinal survival data from five trials
of two epilepsy treatments is considered. In such treatments, patients were asked
to recall seizures from at least six months prior a controlled randomization of the
drugs to be administered. In this randomization, the patient would be allocated
either the drug carbamazepine (CBZ) or the drug valproate (VPS), which in this
case, are the main focus of the investigation. The data set contains the number
of seizures suffered per patient during the six months prior to randomization, drug
indicator, age at randomization, sex, type of epilepsy and the individual’s times to
first seizure post-randomization.
It is desired to model, for each individual, an event count over a fixed initial
period, jointly with a survival time following a possible change in event rate.
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3.2 MESS Study First Proposed Analyses
According to Marson et al.[35], almost all patients were prescribed CBZ or VPZ,
92% in the immediate group, and 83% of those receiving AEDs in the deferred
group. This paper introduces and describes the MESS study and endeavours to
supply a prognosis for patients within the study. It is mentioned that the study
was conducted as a randomized, unmasked and pragmatic trial, but later on it was
found that the unmasking does not appear to generate a bias for the study, judging
by the comparison between groups on first seizure recurrence, such recurrence did
not appear to be different between them.
Although the initial intention was to recruit 3000 patients for the study
in order to perform a split-half cross-validation analysis, only 1443 patients were
included and accepted to randomization. As a consequence, this paper focuses on
performing the analysis with the population provided, and suggests that performing
a cross-validation procedure should not carried out, since the power for generating
a validation sub-population diminishes greatly. However, it is noticeable that in a
subsequent paper by Kim et al (2006)[27], this same MESS study is re-addressed
with a cross-validation analysis.
The analysis of the first time to event is performed with a log-rank test,
or Cox’s proportional hazards model when adjusting single versus multiple seizures
at entry. All analyses were by intention to treat, and the results are reported as
absolute differences in proportions or hazard ratios with 95% confidence intervals.
For the times to first and second seizures post-randomization, the difference
between treatment groups (immediate versus deferred) is highly significant, while
for the time to the fifth seizure, there is no perceptible difference between groups.
As for the remission period, the actuarial estimate of achieving a 2 year remission
by the 8th year is very high (over 94% for both treatment groups and single versus
multiple seizures). Although the immediate treatment scheme increased the times
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Immediate (%) Deferred (%) Difference
Single Multiple Single Multiple (95% CI)
Time to first seizure
6 months 18 26 26 44 12 (7.4, 16.5)
2 years 32 43 39 61 11 (6.2, 16.7)
5 years 42 57 51 69 10 (4.5, 16)
8 years 46 60 52 72 9 (2.6, 15.3)
Time to second seizure
6 months 14 19 5 (1.1, 8.9)
2 years 24 32 8 (3.6, 13.3)
5 years 34 40 6 (0.9, 12)
8 years 38 44 5 (−1.4, 12)
Time to fifth seizure
6 months 6 7 1 (−1.3, 3.8)
2 years 12 15 3 (−1.1, 6.2)
5 years 19 22 3 (−1.6, 7.6)
8 years 26 25 −1 (−9.3, 7.8)
2-year remission
2 years 69 57 61 39 12 (6.3, 17.4)
5 years 92 91 92 87 2 (−1.2, 6.1)
8 years 95 94 96 95 1 (−2.5, 3.9)
Table 3.1: MESS study seizure counts, table from Kim et al[27]. The proportion of
patients allocated to deferred or immediate treatment are shown here tabulated by
time to seizure and seizure characterization (either single or multiple seizures).
to first and second seizures post-randomization, and decreased the time to 2 year
remission, there is no significant difference between the immediate and the deferred
treatments for the time to 5 year remission (Table 3.1).
As a general result, in Marson et al[35], it is mentioned that the benefits from
immediate treatment do not impact on the long-term conditions of the patients, but
findings from a subpopulation of 441 UK adult patients show that they do come at
some cost for the patient. Indeed, from the 527 eligible UK patients, 441 of them
returned a quality of life (QOL) question sheet at 100 days from randomization. This
data was later on used to analyse the changes between baseline and 2-year follow-up
for anxiety, depression and mastery (an individual’s perception of control over his
life). The immediate treatment patients reported more adverse events that were
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related to the treatment, such as depression, anxiety, gastrointestinal symptoms,
among others.
One year later, Kim et al[27] considered the effects of the two main anti-
epileptic drugs, carbamazepine and valproate, with the objective of studying the
roles of treatment policies and patient characteristics in the subsequent risk of seizure
recurrence. They took a cross-validation sample using only a subset of the total
population to assess the model, while the remaining subset was then used to validate
such model. From the 1443 patients, 885 of them were assigned as a test sample, 535
patients were used for validation, and the remaining subjects were discarded from
the study, as they had incomplete data. The population was then split into three
categories (low, medium and high risk), and stratified by randomized treatment
policy.
The test sample was used to formulate the prognostic model, which consid-
ered the time from randomization to the first seizure hence, based on a Cox regres-
sion and stratified by treatment allocation. Both backward and forward stepwise
regressions were used to find the predictive value of the baseline covariates of inter-
est. Each stepwise regression gave place to a different model, given that a covariate
was included in the model if they were significant in univariate analysis at p ≤ 0.05
and it was excluded if p ≥ 0.1. Since the number of patients with several types
of neurological disorder was low, all conditions (neurological deficit or impairment,
delayed development and learning disability) were represented under one variable
only, which is termed the Neurological disorder, and is denoted as NDL. In the
same way, the variable called EEG contained three Electro-encephalogram (EEG)
measurements (specific local, generalized epileptiform and slow wave abnormality).
The resulting models were Model 1 and Model 2, where the covariates con-
sidered resulted from the backward and forward stepwise elimination respectively.
Stratification by treatment was used on both models. The hazard ratios for both
models are shown in Table 3.2.
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Variables Model 1 Model 2
Hazards ratios p-value Hazards ratios p-value
Neurological disorder 1.35(1.07, 1.72) p = 0.013 1.36(1.07, 1.73) p = 0.012
Abnormal EEG 1.54(1.27, 1.86) p < 0.0001 1.53(1.26, 1.86) p < 0.0001
Log(Number of seizures) 1.56(1.42, 1.72) p < 0.0001 1.61(1.46, 1.77) p < 0.0001
pre-randomization
Years between seizure 0.92(0.84, 1.02) p = 0.1
and randomization
First degree relative 1.27(0.96, 1.7) p = 0.1
with epilepsy
Table 3.2: Resulting hazard ratios with their respective 95% confidence intervals and
p-values for the forward (Model 1) and backward (Model 2) stepwise elimination,
taken from Kim et al. [27].
The hazard ratios can be interpreted as the relative change in risk for a
unit increase in the prognostic factor. Observe that the second model contains
the variables of the first model and it has two additional variables. However, the
identification of two large outliers in the data resulted in the exclusion of the variable
of years between recent seizure and randomization. Furthermore, since the two
variables added in the second model had a borderline significance of p = 0.1, for
simplicity they were both omitted, which resulted in considering only the first model
as the final model.
A prognostic index was defined as the linear predictor resulting from the
final model. It was the result of the sum of covariate values for a particular patient,
weighted by the corresponding estimated regression coefficients. According to this
prognostic index, the population was split into the three categories, shown in Table
3.3.
Subsequently, the validation sample was also split into these three categories,
and used to measure the predictive accuracy of the model by plotting the observed
proportions of individuals with seizure recurrence, separated by treatment policy and
stratified by risk recurrence levels. These plots were compared to the corresponding
plots from the test sample.
The model and the Kaplan-Meier plots (Figures 3.1 and 3.2) give an in-
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Prognostic index= 0 Prognostic index= 1 Prognostic index= 2 to 4
(Low risk of recurrence) (Medium risk (High risk recurrence)
recurrence)
- A single seizure - 2 to 3 seizures, normal EEG, - 1 seizure, abnormal EEG,
no neurological abnormalities neurological disorder
- A normal EEG - 1 seizure, abnormal EEG, - 2-3 seizures, abnormal EEG,
no neurological disorder no neurological disorder
- Absence of neurological - 1 seizure, normal EEG, - 2-3 seizures, normal EEG,
disorder neurological disorder neurological disorder
- 4 or more seizures.
Table 3.3: Prognostic index as proposed by Kim et al. under a Cox’s model. Table
from Kim et al[27]
dication that, although the benefit of immediate treatment is not obvious for the
low risk population, it does present a delay in the immediate seizure recurrence
for the medium and high risk of recurrence populations. The results also support
Marson et al.’s findings, regarding that there is no clinical benefit from immediate
treatment in late risks, such as three to five years remission. The risk of seizure
recurrence increases with the number of seizures at presentation, abnormal EEG,
and the presence of neurological disorders.
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Figure 3.1: Kaplan-Meier survival plots for the first, second and fifth seizure times
in years of occurrence, categorized by drug allocated to. Observe that the crosses
denote a censored survival time.
In Figure 3.1, we can observe the Kaplan-Meier curves for the time from
randomization to the times to first, second and fifth seizures, for each one of the
different drugs. Observe that for the two drugs of main interest, CBZ and VPS,
the differences between survival functions are not apparent until the fifth seizures.
However, we must keep in mind that the number of patients who experience the
fifth seizure is considerably less than the initial number of patients. In Figure 3.2
the difference between the survival curves is much more clear.
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Figure 3.2: Kaplan-Meier survival plots for the first, second and fifth seizure times
in years of occurrence, categorized by treatment allocation. Observe that the crosses
denote a censored survival time.
3.3 Joint mixed models with and without cure fraction
The aim of this work is to include the information of each individual into the joint
modelling of the number of seizure occurrences and the survival times. For the
following models, some of the baseline covariates that were collected were age at
randomization, sex, the patient’s pre-randomization history, electoencephalogram
(EEG). As part of the patient’s history, their pre-randomization seizures are cate-
gorized as:
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1. Tonic-Clonic seizures: which comprise tonic-clonic seizures only,
2. Secondary Tonic-Clonic seizures: these consist of partial seizures accompanied
by second tonic-clonic seizures,
3. Generalized: which includes any types of generalized seizures, including any
combinations of tonic-clonic and other generalized seizures,
4. Partial group: contains patients with simple or complex partial seizures only,
and
5. Other: this group contains all the remaining seizures that could not be cate-
gorized in any of the other groups.
For each patient i (i = 1, ..., n) in the study, there are recorded a pre-
randomization event count Xi during a period of time ui, a post-randomization
time to first event Yi which has either been observed or censored, and a set of co-
variates such as age, sex, type of drug administered and EEG recordings. From the
nature of both the epilepsy disease and the study development, we assume that the
underlying seizure rate λi for each individual is subjected to a possible modification
due to the post-randomization effect ψi.
In the following sections we present two models proposed by Cowling (2003)
and Rogers (2011).
3.3.1 Joint Mixed Model
The first joint model of interest to us was proposed and developed by Cowling
([11],[10]) for an epilepsy meta-analysis. It considers the point process to be an
overdispersed homogeneous Poisson process with recurrence rate λiνi for every in-
dividual i, where νi is a random variable which partly explains the overdispersion
observed in this kind of recurrent events. The pre-randomization covariates, Z1i,
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are considered to have a log-link relationship with the underlying seizure rate λi,
resulting in the model being a negative binomial Generalized Linear Model.
Given that the underlying count process is considered to be a Poisson process,
the corresponding times to event are thought to follow an exponential distribution
with rate λiψiνi. The treatment allocation is assumed to have a multiplicative
effect on the underlying seizure rate, and it depends on a set of post-randomization
covariates denoted by Z2i. By considering a log-link of the covariates Z2i on the
multiplicative effect, this model can be then summarized in the following formulas.
fX(xi|λi, ui, νi) = (λiuiνi)
xie−λiuiνi
xi!
,
fY (yi|λi, ψi, νi) = λiψiνieλiψiνiyi ,
gν(νi|α) = α
ανα−1i e
−ανi
Γ(α)
,
where
λi = e
β′1z1i ,
ψi = e
β′2z2i .
Observe that Z2i is related to the post-randomization effect ψi by means of a log-
link, and that it contains an intercept, a treatment indicator and a set of covariates
and interactions considered relevant for the seizure rate change after randomization.
Here, νi is assumed to follow a gamma distribution with mean 1 for identifiability
purposes, and α > 0 denotes the degree of heterogeneity in the population (the
greater the value of α the smaller the heterogeneity will be).
For this model the derivation of the joint distributions for Xi and Yi was
found depending on whether Yi was observed or censored. Let δi be the indicator
which takes value one when the seizure time is observed, and zero when it is censored;
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then for the case when the seizure time is observed, we have
f(xi, yi|ui, λi, ψi, α) =
∫ ∞
0
fX(xi|ui, λi, νi)fY (yi|λi, ψi, νi)gν(νi|α)dνi
=
ααλxi+1i u
xi
i ψi
xi!Γ(α)
∫ ∞
0
νxi+αi exp(−νi(λiui + λiψiyi + α))dνi,
where the integrand in the last expression can be reformulated to take the form of a
Gamma distribution, integrating to unity. Hence, the joint distribution is given by
Γ(xi + α+ 1)α
α(λiui)
xiλiψi
xi!Γ(α)(λiui + λiψiyi + α)xi+α+1
. (3.2)
For the case when Yi is censored, the survivor function of the seizure time
is SY (yi|λi, ψi, νi) = exp(−λiψiνiyi). The joint distribution can now be found in a
similar way to how equation 3.2 was computed. By using the survivor function for
Yi, the joint distribution is found to be of the form
P (Xi = xi, Yi > yi;ui, λi, ψi , α) =
∫ ∞
0
fX(xi|ui, λi, νi)SY (yi|λi, ψi, νi)gν(νi|α)dνi
=
ααλxii u
xi
i
xi!Γ(α)
∫ ∞
0
νxi+α−1i exp(−νi(λiui + λiψiyi + α))dνi
=
Γ(xi + α)α
α(λiui)
xi
xi!Γ(α)(λiui + λiψiyi + α)xi+α
, (3.3)
where the expression in the integrand takes, once again, the form of a Gamma
distribution and can be integrated out.
For this model, the marginal distributions for the seizure counts and the
seizure recurrence time are found to be Negative Binomial and Lomax respectively.
More specifically, the distribution for the Xi is a Negative Binomial with parameters
α and α/(λiui + α),
f(xi|ui, λi, α) = Γ(xi + α)
xi!Γ(α)
(
α
λiui + α
)α( λiui
λiui + α
)xi
; (3.4)
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where the parameter ψi is not involved, since it is regarded as the treatment multi-
plicative change in the seizure rate, which is only available after randomization.
The corresponding marginal distribution for the post-randomization seizure
recurrence time Yi can be found to be of the form:
f(yi|λi, ψi, α) = λiψi
(
α
α+ λiψiyi
)α+1
. (3.5)
3.3.2 Joint Mixed Model with a Cure Fraction
In Rogers and Hutton’s work (Rogers 2011, Rogers and Hutton 2012) it is assumed
that an individual i experiences seizures according to a Poisson process with rate
λiνi, where λi is a function of the baseline covariates, and νi is the frailty term.
They denote by Xi the pre-randomization event count during a period ui, T1i and
T2i are the times for the first and second post-randomization seizure times, and set
Y1i = T1i and Y2i = T2i − T1i, the gap times between post-randomization seizures.
As a result of discussions with the clinicians, it was determined that the number
of days at risk before randomization, ui, would be adjusted so that, if ti is the
time of the first seizure (pre-randomization) and Ti is the time of randomization for
individual i, it would take the following values
ui = max(182, |Ti − ti|).
In this work, the model states that Xi|νi has a Poisson distribution with
parameters λiuiνi, while the gap times follow an Exponential distribution with the
same rate. Note that the unconditional probability of Xi, fX(xi;λi, ui, α), is dis-
tributed as a Negative Binomial. The randomization effect was considered, as in
Cowling et al. (2006), to be multiplicative and denoted by νi, which is distributed
as νi ∼ Gamma(α, α). Additionally, the post-randomization gap times Y1i and Y2i
are both Exponentially distributed with rate λiψiνi, and the two survival times are
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independent given νi. Finally we introduce the cure rates p1i and p2i, which depend
on κ1 and κ2. Here κi represents the rate of increase or decrease of seizures relative
to the susceptible proportion in the reference group, and p1i is the probability that
individual i has a first seizure, and p2i is the probability that individual i has a
second seizure. All this can be stated in the equations that follow:
fX|ν(xi|νi;λi, ui) =
(λiuiνi)
xieλiuiνi
xi!
,
fY1,Y2|ν(y1i, y2i|νi;λi, ψi, p1i, p2i) = p1ip2i(λiψiνi)2e−λiψiνi(y1i+y2i),
fν(νi;α) =
αανα−1i e
−ανi
Γ(α)
,
where
λi = exp(β
′
1z1i), ψi = exp
(
β′2z2i
)
,
p1i =
exp (κ′1ω1i)
1 + exp (κ′1ω1i)
,
p2i =
exp (κ′2ω2i)
1 + exp (κ′2ω2i)
,
(β1, β2, κ1, κ2) are regression paramenters, and z1i, z2i, ω1i, ω2i are vectors of co-
variates, not necessarily distinct. The unconditional joint distribution of the Yij ,
j = 1, 2, is a bivariate Lomax distribution, with each of the marginal Yij having a
univariate Lomax distribution with shape and scale parameters α and α/λiψi re-
spectively. This results in an accelerated failure time model with a Lomax baseline
distribution.
3.4 Model comparisons
In this section we will compare the predictions of the MESS epilepsy data set under
the four principal models described in the two previous sections. For this section,
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as well as for the residual analysis sections in Chapter 5, we will consider four
models for the epilepsy data. The first two will be Cox proportional hazards models,
one considering the set of covariates proposed by Kim et al.[27] and the second
considering the set of covariates that will be used for the other two models, the joint
model proposed by Cowling[10],[11] and the joint model with cure fraction proposed
by Rogers[39],[41].
We will first replicate in the possible measure the results given by Kim et
al., contrast its predictions to the ones provided by the joint and joint with cure
fraction models for the same set of covariates, and at last, contrast the Cox models
with the latter two under another set of covariates.
The approach used in the paper by Kim et al. was a Cox model, that
considered the three covariates, EEG outcome, neurological disorder and the number
of seizures pre-randomization, transformed by a logarithm function. From fitting
such a model, we obtain that the regression coefficient estimates are as they appear in
Table 3.4, where our estimated regression coefficients, their 95% confidence intervals
and their respective p-values are contrasted with the corresponding Kim et al’s
findings. There is a relevant observation that must be made when considering the
results that will be obtained here. While in the paper by Kim et al. the sample is
split into two groups, 885 of patients were assigned as a test sample, 535 patients
were used for validation, we do not split it so, as we do not carry out a cross-
validation analysis. We consider the whole sample and complement the missing
data with the mean values obtained from the remaining values of the population.
βˆ exp(βˆ) exp(βˆKim) p-value p-valueKim
Neurological disorder 0.377 1.46(1.35, 1.57) 1.35(1.07, 1.72) < 2× 10−16 0.013
Abnormal EEG 0.438 1.55(1.22, 1.97) 1.54(1.27, 1.86) 3× 10−4 < 1× 10−4
Log(No. of seizures) 0.287 1.33(1.15, 1.55) 1.56(1.42, 1.72) 2× 10−4 < 1× 10−4
Table 3.4: Contrast between Kim et al.’s([27]) model estimates and our replication
of the model.
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Observe that the estimates are very similar, and the three covariates consid-
ered are deemed significant for the epilepsy recurrence time. The greater width of
the confidence intervals for our reproduction of the fit could be due to the presence
of a larger heterogeneity in the population when considering all patients, and not
omitting individuals with incomplete data. We will now fit the joint and joint with
cure fraction models to the same covariates, where the neurological disorder out-
come is considered as a covariate for the underlying recurrence rate, λi, whilst the
EEG outcome, the treatment allocation and first order interactions are considered
for the post-randomization seizure rate modifier, ψi, and the cure fraction coeffi-
cient, κ. Observe that a fundamental difference between these models and the Cox
model lies in the use of the number of pre-randomization seizures as a variable and
not merely as a fixed covariate. We try to mirror Kim et al.’s considerations, and
fit the models to the data stratified by treatment allocation, and do not consider
interactions of the covariates.
Cowling SE Rogers SE
α 1.095 0.045 1.113 0.046
λ Intercept -4.671 0.032 -4.658 0.032
NDL 0.261 0.105 0.247 0.105
ψ Intercept -2.293 0.077 -0.467 0.099
Trt -0.537 0.090 -0.652 0.119
EEG 0.260 0.090 -0.328 0.122
NDL 0.420 0.153 -0.337 0.209
κ Intercept 0.012 0.087
EEG 0.700 0.146
NDL 0.894 0.329
-Log-likelihood 8881.246 8634.132
Table 3.5: Joint (Cowling) and joint with cure fraction (Rogers) models’ estimates
and standard errors, under the set of covariates proposed by Kim et al.[27].
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From Table 3.5 it can be observed that, under the set of covariates proposed
by Kim et al.[27] and considering the treatment allocation as an additional covari-
ate, all the covariates of interest are found to be statistically significant for the pre
and post-randomization rates, as well as for the cure fraction. From the values
of α, the homogeneity in the population is estimated to be very similar between
the Cowling and Rogers models, albeit the model with a cure fraction estimates a
slightly more homogeneous population. Whilst the pre-randomization estimates do
not present a noticeable difference between one another, the estimated EEG and the
neurological disorder (NDL) coefficients produce an opposite effect on the seizure
rate ψ between the two models. The existence of the cure fraction is supported by
the difference between loglikelihood values, where we observe that the joint model
with a cure fraction provides a better fit for the data, and that in the estimation of
the cure fraction, both the neurological disorder and EEG outcomes are significant.
The difficulty of considering the NDL covariate, however, lies in the fact that the
covariate itself comprises three types of abnormality covariates (neurological deficit
or impairment, delayed development and slow wave abnormality), and their joint
outcomes are recorded for 132 of the 1425 initial number of patients, thus consti-
tuting 10.20% of the population. For this reason, we consider the alternative set of
covariates used for the model fits shown in Table 3.6, shown below.
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Cox SD Cowling SD Rogers SD
α 2.096 0.116 2.060 0.113
Intercept -4.131 0.085 -4.129 0.085
Age -0.005 0.002 -0.005 0.002
T-C -1.085 0.094 -1.075 0.095
2nd.T-C -0.697 0.097 -0.690 0.098
Intercept -5.304 0.564 -4.046 0.615
Age -0.001 0.002 0.004 0.003 -0.001 0.004
Trt 0.310 0.278 1.179 0.532 0.702 0.708
T-C -0.247 0.268 2.945 0.569 3.514 0.626
2nd.T-C -0.379 0.277 2.322 0.576 2.565 0.638
Trt*T-C -0.375 0.282 -1.367 0.532 -1.010 0.715
Trt*2nd.T-C -0.449 0.292 -1.446 0.542 -0.942 0.731
EEG 0.075 0.277 0.059 0.554 0.652 0.712
Trt*EEG -0.548 0.161 -0.808 0.199 -0.860 0.281
EEG*T-C 0.356 0.287 0.410 0.556 -0.514 0.720
EEG*2nd.T-C 0.829 0.297 0.820 0.566 0.481 0.737
Log(No.seiz) 0.376 0.052
κ 0.004 0.076
-Log-likelihood 7031.643 6861.389
Table 3.6: Coefficient estimates for the Cox, Cowling and Rogers models.
In Table 3.6 we compare the Cox proportional hazards model, Cowling and
Rogers models respectively, displaying their corresponding standard deviations and
in the case of the joint models, the log-likelihood value. Since the Cox model only
considers the number of seizures pre-randomization as a fixed covariate, the esti-
mated coefficient for the logarithm of such number is included only for this model in
the table. For this analysis, however, we do not stratify by treatment allocation but
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rather consider an additional covariate for all three models. The reference popula-
tion consists of patients at 30 years of age, under deferred treatment and presenting
partial seizures only, with a normal EEG outcome.
Although the age of the patients at randomization appears to be non signif-
icant or borderline significant for both pre and post-randomization rates under all
models considered, we keep this covariate for clinicians have deemed it relevant for
the seizure recurrence prediction. The type of epilepsy covariates (T-C and 2nd.T-
C) maintain very similar estimated coefficient values under Cowling and Rogers
models for the seizure rate pre-randomization, and remain significant for both the
pre and post-randomization seizure rates. It is noticeable that, in contrast, the T-C
and 2nd. T-C seizure types are borderline significant for the Cox model, as well as
almost all their first-order interactions with EEG outcome and treatment allocation.
Only the interaction of EEG abnormality and 2nd. Tonic-Clonic seems relevant, for
the Cox model as well as for the Cowling model, although this is not so for the joint
model with the cure fraction. Indeed, for the Cox model all factors (T-C, 2nd.T-C,
EEG and treatment) are borderline significant, it is the first-order interactions that
have an effect on the seizure recurrence rate, along with the number of seizures
pre-randomization.
The main difference between the models, in conclusion, lies in the fact that
whilst the joint models show that the two types of epilepsy have a relevant contribu-
tion to the seizure rates, consistently for pre and post-randomization rates, the Cox
model only consider their interactions with the treatment allocation and the EEG
outcome to be of no significance. The EEG outcome factor contributes a significant
change only under the joint model with a cure fraction, but the EEG interaction
with the 2nd. tonic-clonic seizure provides a non-significant contribution only for
this same model. The number of seizures pre-randomization is a very relevant co-
variate for the Cox model, whilst the estimated value of the cure fraction covariate
κ appears to be negligible in relation with its standard deviation. This translates to
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nearly half of the population not experience a seizure post-randomization. Indeed
when κ = 0 the cure fraction of the population is 50%, and from the value of the
standard deviation the estimated cure fraction could vary between 48.2% and 51.9%.
The difference between log-likelihoods between the two models, however, shows an
improvement of the model fit for the data under the assumption of the existence of
a cure fraction of the population.
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Chapter 4
Extensions of the Joint Model
with and without Cure Fraction
4.1 Truncated Joint Model
In previous chapters we have addressed models proposed by Cowling (Cowling, 2003)
and Rogers (Rogers, 2011), which consider an independent seizure process for each
patient with and without a cure rate respectively. These models consider the seizure
count to be Poisson distributed, taking into account patients who have any number
of seizures, including those who have had no seizures. A patient is diagnosed with
an epilepsy syndrome only when he has presented at least two unprovoked epileptic
seizures, and in particular, the population under study have recorded at least one
seizure. This leads us to propose a more realistic version of the previous models.
Let us consider a joint probability model for the number of pre-randomization and
post-randomization times of seizures, conditioned to have at least one seizure, i.e.
Xi > 0 for every individual i. Then the zero-truncated model will be of the form
P (Xi = xi, Yi = yi|Xi > 0) = P (Xi = xi, Yi = yi)
P (Xi > 0)
=
P (Xi = xi, Yi = yi)
1− P (Xi = 0) .
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In the following chapter we produce the derivation of the log-likelihood and
its corresponding derivatives when the underlying point process is considered to be
a zero-truncated Poisson-Gamma mixture model. Under this model, each patient
is assumed to have at least one epileptic seizure pre-randomization, with seizure
recurrence following a Poisson process with an individual seizure rate.
4.1.1 Derivation of the Truncated Joint Distribution
Let us consider the seizure count pre-randomization Xi to be zero truncated Pois-
son distributed with an underlying seizure rate λiνi over a period of time ui, and
considering a frailty term νi which follows a Gamma distribution with mean 1. The
post-randomization effect ψi has a multiplicative effect on the seizure rate, and both
λi and ψi depend on the covariates of individual i with Z1i as the explanatory vari-
ables pre-randomization, and Z2i as the treatment covariate for the multiplicative
factor. The post-randomization times to first seizure Yi are assumed to follow an
exponential distribution with rate λiψiνi, and we will indicate whether or not it is
a censored observation by means of the indicator δi. This means that δi will take a
unit value if the time to first seizure is observed, and zero otherwise.
Zero Truncated Joint distribution with Yi Observed
From the previous chapter in Section 3.3.1, it was shown in equation 3.2 that the
joint distribution function of Xi and Yi, when the seizure time is observed, is of the
form
fXi,Yi(xi, yi;ui, λi, ψi, α) =
Γ(xi + α+ 1)α
α(λiui)
xiλiψi
xi!Γ(α)(λiui + λiψiyi + α)xi+α+1
.
In order to find the corresponding zero-truncated joint distribution of Xi
and Yi, consider that the marginal distribution of Xi is a Negative Binomial of
the form shown in equation 3.4. For simplicity, denote by ζi the expression ζi =
λiui + λiψiyi + α, and by ηi the expression ηi = λiui + α. This leads to the joint
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distribution expression:
fXi>0,Yi(xi, yi) =
Γ(xi + α+ 1)α
α(λiui)
xiλiψi
xi!Γ(α)ζ
xi+α+1
i
/[
1−
(
α
λiui + α
)α]
=
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)(λiui + λiψiyi + α)xi+α+1[(λiui + α)α − αα] . (4.1)
We are now interested in finding the corresponding marginal distributions
of the variables of interest. The marginal distribution of Xi, in contrast to its
non zero-truncated version, has an integral over Yi, which will not separate in an
expression multiplied by a gamma distribution that integrates to one. The marginal
distribution for the pre-randomization seizure count can be found by the following
process:
fXi>0(xi;α, λi) =
∫ ∞
0
fXi>0,Yi (xi, yi|α, λi, ψi) dyi
=
∫ ∞
0
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)(λiui + λiψiyi + α)xi+α+1[(λiui + α)α − αα]dyi.
Observe that only the expression (λiui +λiψiyi +α)
xi+α+1 depends on yi, hence we
have
=
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)[(λiui + α)α − αα]
∫ ∞
0
(λiui + λiψiyi + α)
−xi−α−1dyi,
from which the integral is found, and is evaluated at the limits thus obtaining
=
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)[(λiui + α)α − αα]
×
(
1
−(xi + α)(λiψi)
)[
(λiui + λiψiyi + α)
−xi−α] |∞0
=
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)[(λiui + α)α − αα]
×
(
1
−(xi + α)(λiψi)
)[
0− (λiui + α)−xi−α
]
.
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By re-arranging the terms, we obtain the distribution
=
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)[(λiui + α)α − αα](xi + α)(λiψi)(λiui + α)xi+α ,
which can be re-written in the simpler notation
=
Γ(xi + α+ 1)α
α(λiui)
xi
xi!Γ(α)(xi + α)η
xi
i (η
α
i − αα)
. (4.2)
In the converse fashion, we seek to obtain the cumulative distribution func-
tion of Xi. Let us consider α as an integer number, then, by computing the sum of
the terms given by Equation (4.2) we obtain
FXi(xi;α, λψ) =
xi∑
w=1
fxi(w;α, λi, ψi)
=
xi∑
w=1
Γ(w + α+ 1)αα(λiui)
w
w!Γ(α)(w + α)ηwi (η
α
i − αα)
,
and since, for α an integer number, we have Γ(α) = (α − 1)! and Γ(w + α + 1) =
(w + α)!, the expression takes the form
=
xi∑
w=1
αα
ηα − αα
(
w + α− 1
w
)(
λiui
ηi
)w
.
Let us now factorize the terms that do not depend on the variable of interest, and
complete the sum, to obtain the partial series of terms starting from w = 0:
=
αα
ηαi − αα
[
xi∑
w=0
(
w + α− 1
w
)(
λiui
ηi
)w
− 1
]
,
and since ηi = λiui +α, we complement the terms in the sum to obtain the form of
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negative binomial distribution
=
αα
ηαi − αα
[(
α
ηi
)−α xi∑
w=0
(
w + α− 1
w
)(
λiui
ηi
)w (α
ηi
)α
− 1
]
. (4.3)
Observe that the partial series shown in Equation (4.3) constitutes the cumulative
negative binomial distribution function evaluated at Xi = xi. Consequently when
xi tends to infinity, this sum converges to unity and the cumulative distribution of
Xi for the zero-truncated case is such that
lim
xi→∞
FXi(xi;α, λψ) = lim
xi→∞
αα
ηαi − αα
[(
α
ηi
)−α xi∑
w=0
(
w + α− 1
w
)(
λiui
ηi
)w (
α
ηi
)α
− 1
]
=
αα
ηαi − αα
[(ηi
α
)α
− 1
]
=
ααηαi
(ηαi − αα)αα
− α
α
ηαi − αα
=
ηαi
ηαi − αα
− α
α
ηαi − αα
= 1. (4.4)
Let us remember that ηi = λiui + α, then η
α
i − αα ≥ 0, and the density of Xi
shown in Equation (4.2) is non-negative for all Xi ∈ N. This result joint with the
convergence to unity found in equation (4.4) shows that the zero-truncated function
of Xi is indeed a density function over the space of the natural numbers.
Let us now consider the marginal distribution of Yi for the zero-truncated
model. For α belonging to the natural numbers, the marginal distribution of Yi is
found by summing the joint distribution given in (4.1), over all the possible values
of Xi, resulting in the following expression.
fYi(yi;α, λi, ψi) =
∞∑
xi=1
fXi>0,Yi(xi, yi|α, λi, ψi)
=
∞∑
xi=1
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)(λiui + λiψiyi + α)xi+α+1[(λiui + α)α − αα] .
We proceed to multiply and divide by α in order to obtain the binomial combina-
torial coefficient. In a second step, we complete the sum lower limit by adding and
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substracting a term, producing a partial series which includes the value at xi = 0
=
∞∑
xi=1
Γ(xi + α+ 1)α
α(λiui)
xiλiψiη
α
i
xi!Γ(α)ζ
xi+α+1
i (η
α
i − αα)
× α
α
=
αα+1λiψiη
α
i
(ηαi − αα)ζα+1i
{ ∞∑
xi=0
(
xi + α
α
)(
λiui
ζi
)xi
− 1
}
.
We now multiply and divide the sum in the equation by (1 − λiui/ζi)α, since ζi =
λiui + λiψiyi + α, thus completing the form of a binomial distribution function
=
αα+1λiψiη
α
i
(ηαi − αα)ζα+1i
{(
1− λiui
ζi
)−α ∞∑
xi=0
(
xi + α
α
)(
λiui
ζi
)xi (
1− λiui
ζi
)α
− 1
}
,
and since
(
λiui
ζi
)
< 1 and
(
1− λiuiζi
)
< 1, the sum converges to 1 and we obtain the
expression
=
αα+1λiψiη
α
i
(ηαi − αα)ζα+1i
[(
1− λiui
ζi
)−α
− 1
]
=
αα+1λiψiη
α
i
(ηαi − αα)ζα+1i
[(
ζi
λiψiyi + α
)α
− 1
]
. (4.5)
Observe that, since λi > 0 and ui > 0 for all i ∈ {1, 2, 3, ..., 1334}, we have that
ζi
λiψiyi + α
=
λiui + λiψiyi + α
λiψiyi + α
> 1.
From this we conclude that the marginal density function of Yi obtained in equation
(4.5) is non-negative for all yi ≥ 0.
The corresponding cumulative distribution function for Yi can be found by
integrating the density function obtained in equation (4.5). Let γ ≥ 0, hence distri-
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bution function of Yi evaluated at γ is given by
FYi(γ;α, λi, ψi) =
∫ γ
0
fyi(y;α, λi, ψi)dy
=
∫ γ
0
αα+1λiψiη
α
i
(ηαi − αα)ζα+1i
[(
ζi
λiψiui + α
)α
− 1
]
dy,
where the expression in the integral depends on y through the term ζi, and by
splitting the integral by the sum of the two terms, we obtain
=
∫ γ
0
ζαi λiψiη
α
i α
ζα+1i (η
α
i − αα)
(
α
λiψiy + α
)α
dy −
∫ γ
0
αα+1λiψiη
α
i
ζα+1i (η
α
i − αα)
dy
=
αηαi
ηαi − αα
∫ γ
0
λiψi
ζi
(
α
λiψiy + α
)α
dy − α
α+1λiψiη
α
i
ηαi − αα
∫ γ
0
ζ−α−1i dy. (4.6)
Let us now remember, from Equation (3.5) from the previous chapter, that the
Lomax distribution function has the form
f(yi|λi, ψi, α) = λiψi
(
α
α+ λiψiyi
)α+1
,
hence we complete the term in the first integral of the equation (4.6) to obtain such
a shape. The second integral in the expression can also be directly integrated and
evaluated at the integration limits,
=
αηαi
ηαi − αα
∫ γ
0
λiψi
(
α
λiψiy + α
)α+1 λiψiy + α
αζi
du− α
α+1λiη
α
i
ηαi − αα
(
ζ−αi
(−α)λiψi
∣∣∣∣y
0
)
.
Observe that, λiψiy + α = ζi − λiui, hence the expression in the first integral can
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be rewritten as
=
ηαi
ηαi − αα
∫ γ
0
λiψi
(
α
λiψiy + α
)α+1(ζi − λiui
ζi
)
du+
ααηαi
ηαi − αα
ζ−αi
∣∣∣∣γ
0
=
ηαi
ηαi − αα
[∫ γ
0
λiψi
(
α
λiψiy + α
)α+1
dy
−
∫ γ
0
λiψi
(
α
λiψiy + α
)α+1(λiui
ζi
)
du+ ααζ−αi
∣∣∣∣y
0
]
.
The first integral of the equation now constitutes a Lomax distribution function,
and as such, we find that the expression becomes
=
ηαi
ηαi − αα
{[
1−
(
α
λiψiy + α
)α]∣∣∣∣y
0
+ ααζ−αi |y0 − λiui
∫ γ
0
λiψi
ζi
(
α
λiψiy + α
)α+1
dy
}
,
and evaluating on the integration limits, we obtain
=
ηαi
ηαi − αα
{
1−
(
1 +
λiψi
α
γ
)−α
− 1 +
(
1 +
λiψi
α
0
)−α
+αα
[
1
(λiui + λiψiγ + α)α
− 1
(λiui + α)α
]
− λiui
∫ γ
0
λiψi
ζi
(
α
λiψiy + α
)α+1
dy
}
.
From these equations we arrive at the final form of the zero-truncated distribution
function
FYi(yi;α, λi, ψi) =
ηαi
ηαi − αα
{
1−
(
1 +
λiψi
α
γ
)−α
+ αα
(
ζ−αi − η−αi
)
−λiui
∫ yi
0
λiψi
ζi
(
α
λiψiu+ α
)α+1
du
}
. (4.7)
We leave the zero-truncated cumulative distribution function expressed in terms of
the integral as shown in Equation (4.7), where the integrand consists of a Lomax
density function divided by a linear function of y. Such integral is not straight-
forward to compute, since integration by parts diminishes the power of one term
but increases the power of the other term. One possible interpretation of such an
integral, as γ tends to infinity, would constitute the expectation with respect to a
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Lomax distribution of the form
lim
γ→∞
∫ γ
0
λiψi
ζi
(
α
λiψiy + α
)α+1
dy = E
[
1
λiui + λiψiY + α
]
.
Although the closed form of the cumulative distribution of Yi for a finite value yi
is desirable in order to obtain the survival function, this is left as a project for
future work due to constraints on time. This does not restrain us, however, from
computing the likelihood function of the joint distribution of Xi and Yi, and from
finding the appropriate covariate estimates under the model.
For the asymptotic behaviour of Equation (4.7), let us remember that Fubini-
Tonelli’s theorem states that, for two random variables Z andW with σ-finite spaces,
and g : Z ×W → [0,∞], without loss of generality if
∑
Z
(∫
W
|g(z, w)|dw
)
<∞,
then ∑
Z
(∫
W
g(z, w)dw
)
=
∫
W
(∑
Z
g(z, w)
)
dw.
In Equation (4.4) we proved that the marginal distribution of Xi integrates to one,
hence we have in particular that, for fXi>0,Yi(xi, yi) representing the zero-truncated
joint density function of Xi and Yi as defined in Equation(4.1), the following condi-
tion holds
∞∑
xi=1
(∫ ∞
0
|fXi>0,Yi(xi, yi;α, λi, ψi)|dyi
)
=
∞∑
xi=1
(∫ ∞
0
fXi>0,Yi(xi, yi;α, λi, ψi)dyi
)
= 1.
The first equality between the equations is derived from the fact that for all xi ∈
N and yi ∈ R+, the joint density is non-negative. Fubini-Tonelli’s theorem then
concludes that necessarily
∫ ∞
0
( ∞∑
xi=1
fXi>0,Yi(xi, yi;α, λi, ψi)
)
dyi = 1,
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and since fYi(yi;α, λi, ψi) is non-negative for all yi ∈ R+, it is a density function of
Yi for each patient i in the population.
Zero Truncated Joint distribution with Yi Censored
From equation 3.3 introduced in Section 3.3.1, the joint distribution for the case of
censored seizure times (i.e. δi = 0) was shown to be
fXi,Yi(xi, Yi > yi;ui, λi, ψi, α) =
Γ(xi + α)α
α(λiui)
xi
xi!Γ(α)(λiui + λiψiyi + α)xi+α
.
When dividing by the probability of the seizure count being strictly positive,
we obtain the truncated distribution function
fXi>0,Yi(xi, Yi > yi;ui, λi, ψi, α) =
Γ(xi + α)α
α(λiui)
xi
xi!Γ(α)(λiui + λiψiyi + α)xi+α
/[
1−
(
α
λiui + α
)α]
=
Γ(xi + α)α
α(λiui)
xi(λiui + α)
α
xi!Γ(α)(λiui + λiψiyi + α)xi+α[(λiui + α)α − αα] .
4.1.2 The Full Log-Likelihood and Derivatives
The likelihood function is the product of the density functions over all patients,
using δi to denote whether their survival time has been observed or censored. Let us
remember that the parameters of interest λi and ψi depend, in turn, on the covariate
vectors β1 and β2 respectively in the form λi = exp(z1iβ1) and ψi = exp(z2iβ2). If
x and y are respectively the sets of seizure counts and first seizure times post-
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randomization for all n patients, we obtain the equation:
L(α, β1, β2;x, y) =
n∏
i=1
[
Γ(xi + α+ 1)α
α(λiui)
xiλiψi(λiui + α)
α
xi!Γ(α)(λiui + λiψiyi + α)xi+α+1[(λiui + α)α − αα]
]δi
×
[
Γ(xi + α)α
α(λiui)
xi(λiui + α)
α
xi!Γ(α)(λiui + λiψiyi + α)xi+α[(λiui + α)α − αα]
]1−δi
=
n∏
i=1
Γ(xi + α)α
α(λiui)
xi(λiui + α)
α
xi!Γ(α)(λiui + λiψiyi + α)xi+α[(λiui + α)α − αα]
×
[
(xi + α)λiψi
λiui + λiψiyi + α
]δi
and with the simplified notation, the equation is expressed as
=
n∏
i=1
Γ(xi + α)α
α(λiui)
xiηαi
xi!Γ(α)ζ
xi+α
i [η
α
i − αα]
[
(xi + α)λiψi
ζi
]δi
.
By applying the logarithm to the likelihood function we obtain the log-
likelihood function.
`(α, β1, β2;x, y) = log[L(α, β1, β2;x, y)]
=
n∑
i=1
{log Γ(xi + α)− log Γ(α)− log(xi!) + α log(α) + xi log(λiui)
+α log(ηi)− (xi + α) log(ζi)− log(ηαi − αα)
+δi [log(xi + α) + log(λi) + log(ψi)− log(ζi)]} .
For the purpose of simplifying the expressions corresponding to the first and
second derivatives of the log-likelihood with respect to α, β1 and β2, we show a
middle step in the computations of the derivatives, with the hope of making the
computations easier to follow to the reader. We take into consideration that, for
any constant c,
dαα+1
dα
= (1 + α)αα + αα+1 log(α),
d(c+ α)α+1
dα
= (1 + α)(c+ α)α + (c+ α)α+1 log(c+ α),
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and in particular, for our definition of ζi, its derivation with respect to α yields:
dζα+1i
dα
= (1 + α)ζαi + ζ
(
iα+ 1) log(ζi) = ζ
α
i [1 + α+ ζi log(ζi)].
For the derivations of the various expressions under β1 and β2, observe that from
the definition of λ and ψ, their respective relevant derivatives are of the form:
dλ
dβ1
=
d exp(β1z1)
dβ1
= z1 exp(β1z1) = z1λ,
dψ
dβ2
=
d exp(β2z2)
dβ2
= z2 exp(β2z2) = z2ψ,
which lead to the respective derivatives of ζi with respect to β1 and β2 shown below,
dζi
dβ1
= z1λi(ui + ψiyi) = z1λiηi,
dζi
dβ2
= z2ψiλiyi.
From these considerations and notations, we are able to derive the corresponding
first derivatives of the log-likelihood with respect to the parameters of interest.
∂`(α, β1, β2;x, y)
∂α
=
n∑
i=1
{
∂ log Γ(xi + α)− ∂ log Γ(α)
∂α
+ log(α) +
α
α
+ log(ηi) +
α
ηi
− log(ζi)− xi + α
ζi
− αη
α−1
i + η
α
i log(ηi)− αα[1 + log(α)]
ηαi − αα
+δi
[
1
xi + α
− 1
ζi
]}
=
n∑
i=1
{
∂ log Γ(xi + α)− ∂ log Γ(α)
∂α
+ log(α) + 1 + log(ηi)− log(ζi)
+
α
ηi
− xi + α− δi
ζi
− η
α−1
i [α+ ηi log(ηi)]− αα[1 + log(α)]
ηαi − αα
+
δi
xi + α
}
.
Observe that although the terms in the equation could be further grouped by
the value of δi, it does not provide a greater advantage computationally for the R
package optim. In the following derivatives, we therefore group the terms in the
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equations in a similar way.
∂`(α, β1, β2;x, y)
∂β1
=
n∑
i=1
{
xiuiz1λi
λiui
+
αz1λiui
ηi
− (xi + α)z1λi + z1λiψiyi
ζi
−αη
α−1
i z1λiui
ηαi − αα
+ δi
[
z1λi
λi
− z1λiui + z1λiψiyi
ζi
]}
by factorizing z1λi out of the equation, we obtain the expression
=
n∑
i=1
z1λi
{
xi
λi
αui
ηi
− (xi + α)(ui + ψiyi)
ζi
− αη
α−1
i ui
ηαi − αα
+δi
[
1
λi
− ui + ψiyi
ζi
]}
=
n∑
i=1
z1λi
{
xi + δi
λi
+
αui
ηi
− (xi + α+ δi)(ui + ψiyi)
ζi
− αη
α−1
i ui
ηαi − αα
}
∂`(α, β1, β2;x, y)
∂β2
=
n∑
i=1
{
−(xi + α)z2ψiλiyi
ζi
+ δi
[
z2ψi
ψi
− z2ψiλiyi
ζi
]}
by factorizing z2ψi, the expression becomes
=
n∑
i=1
z2ψi
{
− (xi + α)λiyi + δiλiyi
ζi
+
δi
ψi
}
=
n∑
i=1
z2ψi
{
− (λiyi)(xi + α+ δi)
ζi
+
δi
ψi
}
.
Observe that the partial derivatives of the log-likelihood with respect to β1 and β2
share a similar structure when the denominator is ζi. The main difference resides
in the rest of the terms, which depend solely on λi or ψi respectively.
From these equations we obtain the second order partial derivatives. Al-
though the computations are fairly straightforward, we omit various stages of alge-
braic manipulations, showing in the equations below, the simplified expressions of
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the derivatives.
∂2`(α, β1, β2;x, y)
∂β21
=
n∑
i=1
zT1 z1λi
{
xi + δi
λi
+
αui
ηi
− (ui + ψiyi)(xi + α+ δi)
ζi
− αη
α−1
i ui
ηαi − αα
}
+
n∑
i=1
zT1 z1λ
2
i
{
−xi + δi
λ2i
− αui
ηi
+
(ui + ψiyi)
2(xi + α+ δi)
ζ2i
− α(α− 1)η
α−2
i u
2
i (η
α
i − αα)− (αηα−1i ui)2
(ηαi − αα)2
}
,
∂2`(α, β1, β2;x, y)
∂β22
=
n∑
i=1
{
zT2 z2ψi
[
δi
ψi
− λiyi(xi + α+ δi)
ζi
]
+zT2 z2ψ
2
i
[
(λiyi)
2(xi + α+ δi)
ζ2i
− δi
ψ2i
]}
,
∂2`(α, β1, β2;x, y)
∂β22
=
n∑
i=1
{
∂2 log Γ(xi + α)− ∂2 log Γ(α)
∂α2
+
1
α
+
1
ηi
− 1
ζi
+
ηi − α
η2i
− ζi − xi + α− δi
ζ2i
− α
α(1 + log(α))2 + αα−1
ηαi − αα
− (α+ ηi log(ηi))η
α−2
i (α− 1 + ηi log(ηi)) + ηα−1i (log(ηi) + 2)
ηαi − αα
+
[
ηα−1i (α+ ηi log(ηi))− αα(1 + log(α))
ηαi − αα
]2}
.
These second order derivatives are used in the optimization process carried out in
R. They provide a faster approximation to the maximum likelihood estimates, and
can be directly used to obtain the standard errors for the corresponding covariate
coefficient estimates. It is worth mentioning that the partial derivative functions of
the log-likelihood were checked with numerical estimates found with R.
4.1.3 Maximum Likelihood Estimation
The fitting of this model to a given data set can be carried out by means of an
optimization algorithm, such as the Newton-Raphson approximation method. For
this process the log-likelihood may be found under an iterative process using a
suitable set of initial values of α, β1 and β2, and the first (and possibly the second)
derivatives of such log-likelihood function. For the joint and joint with cure fraction
models, the initial values for the optimization method are found by means of fitting
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a negative binomial generalized linear model to the count data alone. The regression
coefficient estimates are used as the initial values for β1, whilst a survival regression
assuming a log-logistic distribution is used to find the initial values of β2. For the
truncated joint model, the initial values of the parameters have been fitted using
the negative binomial regression estimates, and in a second stance, as the maximum
likelihood estimates obtained from the joint model.
For the approximation of the term log Γ(xi +α)− log Γ(α)− log(xi!) present
in the log-likelihood, we have compared the use of the Stirling formula, the lgamma
function in R and the original set up shown in Rogers (Rogers, 2011), in which the
term is broken into the term
∑xi−1
k=0 log(α + k). It was found that for some cases,
the values of the sums in the method used by Rogers could cause the optimization
to diverge. The Stirling formula alleviates this problem to a certain degree, but the
optimization considering the function lgamma converges both in the epilepsy data
set and in the simulations described in the goodness of fit chapter with a greater
speed.
For the derivation of the corresponding expression,
∂ log Γ(xi + α)
∂α
− ∂ log Γ(α)
∂α
,
we use the R function digamma, which computes the needed first-order derivative.
4.1.4 Application of the Truncated Joint Model to the MESS Data
In this section we fit the joint model, the joint model with a cure fraction and the
joint zero-truncated model to the MESS epilepsy data set. The reference group is
defined as individuals presenting partial seizures pre-randomization, a normal EEG
and randomized to deferred treatment. A positive (negative) regression coefficient
would indicate an increase (decrease) in seizure rate relative to the seizure rate of
the reference group. Similarly, a positive estimate of κ would indicate an increase
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in the susceptible proportion of patients, relative to the reference group. Finally, a
greater value of the estimated α will indicate a large similarity between individuals,
whilst a small value is an indicator of a large heterogeneity in the population.
Considering only the first time to seizure occurrence after randomization, we
obtain the following Table 4.1, which shows the maximum likelihood estimates for
the covariates considered in three models: joint model (Cowling), zero truncated
joint model (Truncated Cowling) and the joint model with a cure fraction (Rogers).
In this case we took the initial values for the optimization of the truncated model
to be based on a combination of the estimate of α from the joint model, and the
rest of the estimates are originated from a negative binomial regression.
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Truncated
Cowling SE Cowling SE Rogers SE
α 2.095 0.116 10.083 0.125 2.060 0.113
λ Intercept -4.131 0.085 -4.411 0.062 -4.129 0.085
Age -0.005 0.002 -0.012 0.001 -0.005 0.002
T-C -1.085 0.094 -1.335 0.076 -1.075 0.095
2nd.T-C -0.697 0.097 -0.738 0.073 -0.690 0.098
ψ Intercept -5.303 0.564 -7.219 1.214 -4.045 0.615
Age 0.004 0.003 0.012 0.004 0.0001 0.004
Trt 1.178 0.532 1.688 1.038 0.702 0.708
T-C 2.945 0.569 3.896 1.215 3.513 0.626
2nd.T-C 2.322 0.576 3.032 1.225 2.565 0.638
Trt*T-C -1.366 0.532 -1.367 1.031 -1.009 0.715
Trt*2nd.T-C -1.446 0.542 -1.655 1.036 -0.942 0.731
EEG 0.059 0.554 0.927 1.093 0.652 0.712
Trt*EEG -0.808 0.199 -1.246 0.270 -0.860 0.281
EEG*T-C 0.409 0.556 0.380 1.089 -0.514 0.720
EEG*2nd.T-C 0.820 0.566 1.292 1.100 0.480 0.737
κ 0.004 0.076
-Loglikelihood 7031.643 6799.428 6861.389
Table 4.1: Cowling, Rogers and Truncated joint model maximum likelihood param-
eter estimates.
The frailty term parameter α takes a larger value for the truncated joint
model, compared to the joint and cure fraction models. The interpretation of this
change is quite intuitive since the model is now not considering the existence of
patients presenting no seizures pre-randomization. By not considering this case,
the truncated density concentrates its mass towards positive values and considers a
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lower heterogeneity between the individuals in the study.
Observe that while the pre-randomization parameter estimates remain es-
sentially similar between the joint model and the joint model with a cure fraction,
in the case of the zero-truncated model the effect of age in the patients has become
more significant, as is the effect of the presence of Tonic-Clonic type of seizure only.
Additionally, the treatment allocation covariate and its interaction with the EEG
outcome appears to be of higher significance, relative to the other two models. Al-
though the significance of the rest of the covariates do not suggest a difference of
interpretation between the three models, the loglikelihood estimation shows that,
in terms of the covariates considered, the joint model with cure fraction presents a
better fit than that of the joint model, but the zero-truncated joint model proposes
a better fit still. According to the size of the log-likelihood, we expect the zero-
truncated model to adjust better than the original Cowling model, but in general
its comparison to the Rogers model could be studied further. A possible next step of
research could then consist of developing a zero truncated joint model considering a
cure rate. In this particular case, the cure rate for the joint model with cure fraction
is found to be
pˆ =
exp(κˆ)
1 + exp(κˆ)
=
exp(0.004)
1 + exp(0.004)
= 0.501,
which indicates that the estimate proportion of the patients in the population who
do not experience a seizure after randomization, is of 50.10%. The corresponding
standard error of the estimate κ, however, is substantially large compared to the
estimated value, hence the cure fraction effect could be negligible.
For the three models, the EEG outcome appears to be non-significant due
to the size of the corresponding standard error, as well as its interactions, in which
only the interaction between EEG and patients presenting second generalized Tonic-
Clonic seizures present a borderline significant decrease of the seizure rate compared
to the reference population, which considers patients with no EEG abnormality and
88
partial seizures only. This borderline significance could be due, however, to the fact
that the treatment allocation effect and its corresponding interactions tend to be
significant. Additionally, the epilepsy types, both Tonic-Clonic only and Second
generalized Tonic-Clonic, have higher estimated coefficients for the truncated joint
model. This could be due to an influence of the epilepsy syndrome on the homogene-
ity level on the population. For this reason, in the following Table 4.2 we partition
the epilepsy data by the syndrome of the patients, and fit the three models to each
subset. A significant difference of the estimates of α between sub-sets indicates that
a model considering a treatment effect on the homogeneity rate could be beneficial.
For the Table 4.2, we partition the epilepsy data by type of epilepsy syn-
drome, leaving us with three data subsets consisting of patients with Tonic-Clonic
seizures only, patients with second generalized Tonic-Clonic seizures and finally in-
dividuals presenting partial seizures only. Observe that the population with Tonic-
Clonic seizures only consists of 778 patients, followed by 453 patients with 2nd.
Tonic-Clonic seizures, and finally we have 103 patients presenting partial seizures
only. Under this comparison between models, the estimated age coefficient attains
in general a higher value for both pre-randomization and post-randomization seizure
recurrence rates for the truncated joint model, being deemed significant for patients
with Tonic-Clonic and second generalized seizures, both for the recurrence rates be-
fore and after randomization. This behavior is not observed in the joint model and
the joint model with cure fraction, where the age covariate seems to have a much
smaller contribution to the seizure rate recurrence.
The clearest difference of homogeneity levels between models is shown for the
population with Tonic-Clonic seizures only. Observe that the estimate of α under the
truncated model is much greater than those under the Cowling and Rogers models.
This could be an indication that, taking away the possibility of not having any
seizures from the model, data set of 778 patients show a much smaller heterogeneity.
The main difference between the three models for this subpopulation, is that for the
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truncated joint model the treatment allocation seems to have little effect compared
to the size of its standard deviation, indicating that the model does not consider
immediate treatment as a significant factor for the change in seizure recurrence rate,
as opposed to the joint and joint with cure fraction models. In contrast, for the
truncated model the EEG abnormality becomes a much more significant indicator
of the seizure recurrence post-randomization.
In the case of patients presenting second generalized Tonic-Clonic seizures,
the truncated joint model continues to show the highest value for the frailty term
α between models, and while the post-randomization factors seem to have a larger
effect on the seizure rate in general, the most noticeable difference between the
models is that the EEG factor and its interaction becomes quite significant, in
contrast to the corresponding estimates given by the joint model with a cure fraction.
For the patients presenting partial seizures only, the frailty term appears to
be the estimate that varies the least between models from the three subpopulations
under consideration. It is also the population for whom the lowest values of α are
estimated, consistently predicting a higher heterogeneity between individuals for the
relatively small population of 103 patients. In the case of the truncated joint model,
there appears to be a correlation between the heterogeneity estimated value and the
significance of the age covariate both before and after randomization, but this could
be more readily explained by the fact that, as observed in the bean-plots in Figure
(2.2), patients with partial seizures range between a few months to 80 years old,
with an empirical density showing a heavier tail than that observed for the other
two subpopulations.
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Cowling SE Truncated SE Rogers SE
T-C only
α 3.306 0.308 22.226 0.189 3.310 0.304
λ Intercept -5.265 0.040 -6.221 0.047 -5.257 0.040
Age -0.006 0.002 -0.022 0.002 -0.006 0.002
ψ Intercept -2.351 0.114 -1.831 0.125 -0.487 0.152
Age 0.006 0.004 0.021 0.004 0.004 0.005
Trt -0.214 0.161 -0.083 0.167 -0.438 0.226
EEG 0.409 0.162 0.762 0.155 -0.004 0.208
Trt-EEG -0.674 0.248 -1.114 0.252 -0.493 0.353
κ 0.0083 0.089
-LogLikelihood 4038.215 3521.900 3939.972
2nd. Generalized
α 1.676 0.143 14.686 0.248 1.619 0.137
λ Intercept -4.815 0.050 -5.203 0.039 -4.807 0.051
Age -0.005 0.003 -0.014 0.003 -0.005 0.003
ψ Intercept -3.014 0.164 -5.060 0.456 -1.581 0.242
Age 0.005 0.005 0.019 0.007 -0.002 0.007
Trt -0.171 0.233 0.424 0.565 0.003 0.363
EEG 0.969 0.229 2.740 0.487 1.313 0.304
Trt-EEG -1.029 0.338 -1.308 0.625 -1.298 0.474
κ 0.015 0.141
-LogLikelihood 2512.854 2682.571 2443.513
Partials only
α 1.049 0.158 1.419 0.383 1.027 0.154
λ Intercept -4.107 0.110 -4.126 0.105 -4.107 0.111
Age -0.001 0.004 -0.0007 0.004 -0.001 0.004
ψ Intercept -5.124 0.722 -10.751 5.198 -3.059 0.937
Age -0.012 0.012 -0.169 0.173 -0.087 0.028
Trt 0.956 0.890 1.418 3.624 2.035 1.121
EEG -0.309 0.832 0.894 2.656 1.171 1.149
Trt-EEG -0.348 1.084 -1.929 4.032 -3.809 1.436
κ -1.109 0.299
-LogLikelihood 451.5491 487.697 436.117
Table 4.2: Cowling, Truncated Cowling and Rogers models fitted to the epilepsy
data partitioned by epilepsy syndrome. The first parameter estimates correspond
to the population presenting Tonic-Clonic seizures only, the second set of parameter
estimates correspond to the patients presenting Second Tonic-Clonic seizures, and
the final set of estimated parameters correspond to the population presenting Partial
seizures only.
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Cowling SE Truncated SE Rogers SE
T-C only
α 3.306 0.154 20.179 0.091 3.310 0.152
λ Intercept -5.265 0.020 -6.191 0.023 -5.257 0.020
Age -0.006 0.001 -0.021 0.001 -0.006 0.001
ψ Intercept -2.351 0.057 -1.866 0.063 -0.487 0.076
Age 0.006 0.002 0.020 0.002 0.004 0.002
Trt -0.214 0.081 -0.108 0.084 -0.438 0.113
EEG 0.409 0.081 0.755 0.078 -0.004 0.104
Trt-EEG -0.674 0.124 -1.126 0.128 -0.493 0.176
κ 0.008 0.045
-LogLikelihood 16152.86 14092.94 15759.89
2nd. Generalized
α 1.675 0.072 13.774 0.124 1.619 0.069
λ Intercept -4.815 0.025 -5.139 0.019 -4.807 0.025
Age -0.005 0.001 -0.014 0.0012 -0.005 0.001
ψ Intercept -3.014 0.082 -5.234 0.241 -1.581 0.121
Age 0.005 0.003 0.019 0.004 -0.002 0.003
Trt -0.170 0.117 0.348 0.303 0.002 0.181
EEG 0.968 0.114 2.654 0.259 1.313 0.152
Trt-EEG -1.029 0.169 -1.342 0.338 -1.297 0.237
κ 0.015 0.071
-LogLikelihood 10051.41 10793.09 9774.052
Partials only
α 1.049 0.056 1.420 0.135 1.027 0.054
λ Intercept -4.107 0.039 -4.125 0.037 -4.108 0.039
Age -0.001 0.002 -0.0001 0.001 -0.001 0.002
ψ Intercept -5.124 0.255 -10.751 1.864 -3.081 0.336
Age -0.012 0.004 -0.167 0.062 -0.087 0.010
Trt 0.957 0.315 1.418 1.309 2.062 0.399
EEG -0.308 0.294 0.894 0.963 1.195 0.410
Trt-EEG -0.349 0.383 -1.929 1.456 -3.839 0.510
κ -1.106 0.106
-LogLikelihood 3612.392 3902.721 3488.937
Table 4.3: coefficient estimates when replicating the data four times for the T-C
and 2nd T-C populations, and eight times for the Partials.
The truncated model for the partials only subpopulation differs from the
other two models mainly in that it does not present the treatment allocation as a
significant covariate for the contribution of ψi. It does produce, however, the lowest
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loglikelihood maximized value of the three models for this and the second generalized
seizure population, where the joint model with cure fraction consistently show the
best fit. The Tonic-Clonic only subpopulation contrasts this finding by presenting
the largest loglikelihood value under the truncated model. These differences in the
corresponding fits, particularly in the case of partial seizures, could be due either
to the small size of the subset under study, or to the fact that patients with par-
tial seizures present much more frequent epileptic attacks than those patients with
general seizures. This will effectively lead to very greater seizure count recordings,
and in this case, the zero-truncated model does not produce a significant beneficial
effect.
In an attempt to observe if the size of the subset only is the cause of the great
discrepancy between models, we fit the three models to the partitioned data sets,
where now each one has been replicated a number of times. The subsets of patients
with Tonic-Clonic and Second Tonic-Clonic seizures have been replicated four times,
whilst the subset of patients with partial seizures has been replicated eight times.
The resulting estimates are shown in Table 4.3. The estimates for the population
with partial seizures only shows that there is no change in the behaviour previously
observed between models, leading us to believe that the size of the population is not
the source of the discrepancy by itself.
4.1.5 Application of the Truncated Joint Model to the SANAD
Data
Let us now remember that, in Section (2.2), we introduced the epilepsy database
SANAD, which consisted of a study of two arms, A and B, dedicated to patients
presenting partial or general seizures respectively. In this section we consider the fit
of the joint model and the zero-truncated joint model for this data. The joint model
with a cure fraction has also been considered for this study, however, as observed
in the Kaplan-Meier plots shown in Figure (2.3), the existence of a cure rate is in
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doubt, and the model therefore does not converge under any of the two arms in
consideration.
In a preliminary analysis of the data it was observed that the number of
seizures in the population ranged from 1 seizure to 30000, having a mean of 157.5
and the 95% quantile of 302.25 seizures. One approach to fit the data is by con-
sidering only the patients who presented less than 300 seizures pre-randomization.
For this subset, we observe in Table 4.4 that a total 62 of cases are left out from
the population, which consists of the 6.48% of the data. 38(5.17%) of these patients
belong to Arm A, and the remaining 24 patients belong to Arm B. This leaves us
with 94.82% of the population in Arm A, and 89.18% of the population from Arm
B.
General Partial Unclassified
Full data set 133 636 125
Arm A 8 624 64
Arm B 125 12 61
Table 4.4: Number of patients by syndrome and by Arm, with less than 300 seizures
pre-randomization.
In the following Table 4.5 and Table 4.6, we summarize the covariates present
for the subset of 624 patients in Arm A with partial seizures and no more than 300
seizures pre-randomization. The first table shows the discrete-valued covariates,
while the second table displays a compendium of the quantiles for the continuous-
valued covariates such as age at randomization, period and time to first seizure. Let
us remember that the age is centered at 40 years of age.
For this reason, in Table 4.7 we show the model estimates both considering
the entire data set, and considering the subset containing the data of patients with no
more than 300 seizures. Observe that the values shown correspond to the estimates
of the Gamma parameter α, the pre-randomization covariate estimates β1 and the
post-randomization covariate estimates β2. In the first three columns we consider
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Sex Number Drug Number
Female 300 CBZ 146
Male 324 GBP 137
EEG LTG 124
Unknown 50 OXC 81
No 302 TPM 136
Yes 272
Table 4.5: Quantity of patients in Arm A with partial seizures only, categorized by
sex, EEG outcome and Drug.
Minimum 1st Quartile Median 3rd Quartile Maximum
(Age (in years)-40)/10 -3.49 -1.75 -0.33 1.26 4.31
Time (in days) 1 7.75 63.00 389.25 2414.00
Number of seizures 1 5 41 70 250
Period (in days) 182 203 516 2066 21366
Rates (in years) 0.103 3.577 7.473 19.890 461.60
Table 4.6: Summary of patients in Arm A with partial seizures only, categorized by
Age at randomization, time of first seizure post-randomization, number of seizures,
period in days and rates in years.
the model with the full data set, setting CBZ as the underlying baseline drug for the
Full model and the Arm A model, and setting VPS as the underlying baseline drug
for the model considering only Arm B. The same drug baselines are considered for
the models Subset, Subset Arm A and Subset Arm B, in which the data has been
restricted only to patients with no more than 300 observed seizures.
It is noticeable that, while the covariate coefficient estimates in general do not
change significantly from the full data to the subset data for the pre-randomization
parameter λ, a significant change is observed for the post-randomization covariate
estimates of ψ, in all three categories (Full, Arm A and Arm B). In particular, we
observe that for the estimates of ψ, the drug effect appears to be non-significant for
the full data and the full data under Arm A only, whilst it appears to be significant
for the full data under Arm B; this significance predictions, however, are reversed
once the patients with more than 302 seizures are removed from the corresponding
data sets, as can be observed by comparing their estimate magnitude and its stan-
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Full Full Arm A Full Arm B Sub. Sub. Arm A Sub. Arm B
α 0.46 (0.02) 0.57 (0.02) 0.36 (0.03) 0.64 (0.03) 0.72 (0.03) 0.57 (0.05)
λ
Interc. -2.92 (0.23) -4.05 (0.24) -2.89 (0.52) -3.86 (0.18) -4.07 (0.21) -4.19 (0.39)
General 1.75 (0.19) -0.28 (0.53) 0.88 (0.27) 1.70 (0.17) -0.24 (0.48) 1.02 (0.25)
Partial 1.02 (0.16) 1.97 (0.18) 1.67 (0.50) 1.43 (0.13) 1.55 (0.17) 1.80 (0.51)
Sex -0.30 (0.10) -0.22 (0.10) -0.53 (0.25) -0.27 (0.09) -0.22 (0.09) -0.37 (0.20)
Age -0.26 (0.03) -0.12 (0.03) -0.76 (0.06) -0.13 (0.02) -0.08 (0.02) -0.65 (0.08)
ψ
Interc. -2.83 (0.22) -1.58 (0.24) -3.04 (0.45) -2.70 (0.22) -2.43 (0.26) -2.47 (0.43)
General 0.06 (0.16) 0.96 (0.52) 0.34 (0.27) -1.48 (0.17) 0.90 (0.54) -1.14 (0.25)
Partial 0.63 (0.14) -0.77 (0.19) -0.12 (0.41) -0.33 (0.14) -0.57 (0.19) 0.57 (0.46)
Sex -0.32 (0.08) -0.26 (0.09) -0.17 (0.19) 0.20 (0.09) 0.17 (0.10) 0.36 (0.20)
Age 0.01 (0.02) -0.05 (0.02) 0.28 (0.09) -0.15 (0.02) -0.17 (0.02) -0.03 (0.10)
Drug 0.11 (0.12) 0.21 (0.12) 0.36 (0.24) 0.46 (0.12) 0.47 (0.12) -0.21 (0.21)
-Loglik. 10220.15 7718.914 2346.95 9217.77 7155.122 1985.328
Table 4.7: Cowling’s model estimates for the full population, for Arm A only, for
Arm B only, and their corresponding versions with number of seizures< 302.
dard deviation. From the values of α we can also observe that the estimated values
are smaller for the full data set, giving and indication that the data corresponding to
number of seizures larger than 302 confer a higher heterogeneity to the population.
We now consider fitting the joint model and the zero-truncated joint model
to the two arms provided by the SANAD study, as a method of comparison of such
models for the two epilepsy studies. From the log-likelihoods shown in Table 4.7 we
observe that the model provides the best fits for the sub-populations corresponding
to Arm A and Arm B when the patients present no more than 302 seizures, and
thusly we proceed to compare the joint and the truncated joint models under these
sub-populations.
For patients presenting partial seizures only and treated in Arm A, the pre-
randomization coefficient estimates for λ (shown in Table 4.8) present almost no
change in significance among the two models considered. For the post-randomization
coefficients corresponding to ψ, however, the truncated joint model presents a higher
significance for the age covariate, and even reverses the effect of the drugs Gabapentin
(GBP) and Oxcarmazipan (OXC) on the seizure recurrence, relative to the refer-
ence population which is treated with Carbamazepine (CBZ). In contrast, the age
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Cowling SE Truncated SE
α 0.68 0.03 0.86 0.05
λ Intercept -2.55 0.16 -2.54 0.10
Sex -0.27 0.10 -0.27 0.06
Age -0.08 0.03 -0.08 0.02
Age2 0.03 0.01 0.02 0.01
ψ Intercept -2.92 0.37 -1.74 0.33
Sex 0.34 0.24 -0.08 0.21
Age 0.09 0.07 -0.37 0.06
Age2 -0.10 0.02 -0.16 0.02
LTG 1.70 0.54 0.78 0.46
TPM 0.30 0.49 0.21 0.45
GBP -0.58 0.51 0.90 0.45
OXC 1.61 0.58 -0.06 0.55
Sex:LTG -0.89 0.34 -0.09 0.29
Sex:TPM -0.01 0.32 -0.15 0.30
Sex:GBP 1.28 0.32 0.23 0.31
Sex:OXC -0.87 0.37 0.19 0.34
Age:LTG -0.45 0.09 0.20 0.08
Age:TPM -0.23 0.09 0.16 0.09
Age:GBP -0.23 0.10 0.24 0.10
Age:OXC -0.13 0.11 0.08 0.10
-Loglikelihood 6401.20 6514.43
Table 4.8: Joint and zero-truncated joint model’s estimates and their standard
deviations, respectively, for the subpopulation in Arm A only that have experienced
no more than 302 seizures.
covariate shows a diminished significance under the truncated joint model, when
considering patients presenting general seizures in Arm B (shown in Table 4.9).
The effects of the drugs Lamotrigine (LTG) and Topiramite (TPM) are predicted
to have reverse effects on the seizure recurrence when compared to the effect of
Valproate (VPS), when considered under the truncated joint model as opposed to
the predictions under the joint model. Observe, however, that under both Arms
the log-likehood values signal a better fit of the SANAD data under the joint model
than the fit under the truncated model. Although there are reasonable conjectures
about the reason of this discrepancy, mainly the small sample size in Arm B, and
the inherent heterogeneity in Arm A due to partial seizures, a more throughout
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study of goodness of fit is desirable as a future work project. As can be noticed in
the following chapter, the goodness of fit studies are not performed for the SANAD
study, since it is only intended here as an alternative comparison for the model
predictions, but it does not constitute our main aim of study.
Cowling SD1 Truncated SD
α 0.52 0.06 0.73 0.08
λ Intercept -4.53 0.45 -4.48 0.30
Sex -0.10 0.25 -0.08 0.16
Age -0.94 0.19 -0.84 0.11
Age2 0.06 0.07 0.07 0.04
ψ Intercept -2.48 1.03 -4.21 1.73
Sex -0.23 0.45 -0.23 0.68
Ager 0.68 0.21 0.08 0.46
Ager2 0.28 0.07 0.17 0.11
LTG -1.07 1.30 1.92 2.06
TPM -2.44 1.33 2.83 1.95
Sex:LTG 2.33 0.60 0.90 0.91
Sex:TPM 0.84 0.60 -1.47 0.83
Age:LTG 0.26 0.31 0.55 0.52
Age:TPM -0.07 0.35 0.29 0.52
-Loglikelihood 1286.95 1332.27
Table 4.9: Joint and zero-truncated joint model’s estimates and their standard
deviations, respectively, for the subpopulation in Arm B only that have experienced
no more than 302 seizures.
4.2 Frailty term depending on covariates
For all the previous models shown here, we have considered the frailty term α to be
independent of the covariates. However, the change in the values of this parameter
observed in Table 4.2 and in Table 4.3, there is evidence that the frailty term itself
shows variation depending on the type of seizure or the EEG outcome of the patients.
We propose, for each patient i, a joint model of the pre-randomization seizure count
Xi and the post-randomization seizure first occurrences Yi as proposed by Cowling,
with the difference that, for each patient i in the population, the frailty term αi will
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be expressed in the form αi = exp(β3Z3i). Here Z3i will represent the explanatory
variables pre-randomization.
The likelihood, loglikelihood and derivative expressions with respect to β1
and β2 remain the same as the original joint model. The difference in notation will
lie in the use of αi instead of α, for each patient i. The corresponding first derivative
of the log-likelihood with respect to β3 is given by
∂`(α, β1, β2;x, y)
∂β3
=
n∑
i=1
αiz3

xi−1∑
j=0
(
1
αi + j
)
+ log(αi) + 1 +
δi
xi + αi
− log(ζi)
−xi + αi + δi
ζi
}
.
Observe that for this equation, we have used the fact that
n∑
i=1
{log Γ(xi + αi)− log Γ(αi)} =
n∑
i=1

xi−1∑
j=0
log(αi + j)
 .
In the following Table 4.10, we show the fitted values for the covariates
corresponding to each of the parameters λi, ψi and either α for the first two models
or αi for the last two models. From left to right, we observe the fitted values for
the joint model, followed by the values for the zero-truncated joint model discussed
before. The third model consists of the joint model which considers αi to depend on
the type of seizure, and the fourth model considers the joint model with the frailty
term depending on the EEG outcome only.
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Cowling S.E. Trunc. S.E. αType S.E. αEEG S.E.
α 2.095 0.116 10.083 0.125
Int 0.049 0.151 0.873 0.078
T-C 1.138 0.177
2nd. T-C 0.470 0.173
EEG -0.278 0.112
λ
Int -4.131 0.085 -4.411 0.062 -4.116 0.109 -4.153 0.087
Age -0.005 0.002 -0.012 0.001 -0.005 0.002 -0.005 0.002
T-C -1.085 0.094 -1.335 0.076 -1.147 0.116 -1.068 0.096
2nd.T-C -0.697 0.097 -0.738 0.073 -0.700 0.120 -0.686 0.098
ψ
Int -5.303 0.564 -7.219 1.214 -5.294 0.572 -5.335 0.568
Age 0.004 0.003 0.012 0.004 0.004 0.003 0.004 0.003
Trt 1.178 0.532 1.688 1.038 1.280 0.537 1.210 0.534
T-C 2.945 0.569 3.896 1.215 2.920 0.576 2.967 0.572
2nd.T-C 2.322 0.576 3.032 1.225 2.335 0.583 2.348 0.579
Trt*T-C -1.366 0.532 -1.367 1.031 -1.447 0.536 -1.397 0.534
Trt*2nd.T-C -1.446 0.542 -1.655 1.036 -1.566 0.547 -1.479 0.544
EEG 0.059 0.554 0.927 1.093 -0.029 0.560 0.086 0.555
Trt*EEG -0.808 0.199 -1.246 0.270 -0.791 0.197 -0.826 0.200
EEG*T-C 0.410 0.556 0.380 1.089 0.486 0.561 0.417 0.557
EEG*2nd.T-C 0.820 0.566 1.292 1.100 0.885 0.572 0.816 0.567
-Loglikelihood 7031.64 6799.42 7004.65 7028.53
Table 4.10: Cowling, Truncated Cowling, α dependent on seizure type and α de-
pendent on EEG outcome models fitted to the epilepsy data.
For the joint model and the truncated joint model, their estimated α value de-
notes the level of heterogeneity estimated by the models, and as observed previously,
the truncated joint model indicates a much larger homogeneity in the population
than that observed in the joint model. For the models in which the frailty term is
assumed to depend on covariates, we consider the reference population to have par-
tial seizures and a normal EEG outcome, correspondingly. We obtain the estimated
covariate coefficients for α shown in Table 4.10, and from them we obtain the cor-
responding frailty estimates displayed in Table 4.11. In the cases where we consider
α to depend on the seizure type, the model predicts a value of ˆαT−C = 3.277 for
patients presenting Tonic-Clonic seizures only, and a value of αˆ2nd.T−C = 1.680, con-
trasting with αˆPartial = 1.050. This means that for this model, the group of patients
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showing partial seizures are deemed the most heterogenetic, whilst the patients with
Tonic-Clonic seizures only are the most homogenetic between populations. This is
consistent with our knowledge that in patients diagnosed with partial seizures inher-
ently present a larger variability of frequency and symptoms than those presenting
general seizures. Analogously, the model predicts a larger heterogeneity in the pop-
ulation presenting an abnormal EEG (αˆAbNor = 1.813) than the one that does not
(αˆNor = 2.394).
Partial only Tonic-Clonic 2nd. Tonic-Clonic Normal EEG Abnormal EEG
1.050 3.277 1.680 2.394 1.813
Table 4.11: Estimated values of α, first dependent on the type of epilepsy or secondly
on the EEG outcome, resulting from Table 4.10.
Observe in Table 4.10 that although there are minor changes of the esti-
mated covariates between the joint model and the models with dependent frailty
terms, their values remain throughout similar, and the interpretations remain un-
changed. For the zero truncated joint model, as observed in previous model compar-
isons, shows a greater age significance, whilst the treatment allocation’s significance
diminishes in contrast to the other three models. Although the covariate signifi-
cance interpretation is very similar between the joint model and the joint models
with dependent frailty terms, the difference in log-likelihood measures indicate that
the dependency of α on covariates provides a better fit to the data than the joint
model; however, the truncated joint model has an even better fit, which suggests
that a zero-truncation of the models with dependent α could be a better approach
to the epilepsy phenomenon. The computation of the corresponding α covariant-
dependent truncated model, its likelihood and derivatives could be found from the
formulas derived from the truncated joint model, but due to time restraints we leave
this generalization open for further development and research.
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4.3 Truncated Model with Cure Fraction
The following work shows the steps to calculate the likelihood for a zero-truncated
joint model which considers a cure fraction p, or remission, from the first seizure
after randomization. Although the code has already being developed, some specific
parts of the log-likelihood have to be tuned for a proper optimization.
We consider from the original joint model with cure fraction, proposed by
Rogers, the following distributions for the pre-randomization seizure count X and
the first seizure post-randomization Y . Consider as before α > 0, λ > 0, ψ > 0.
Then we have the following distributions:
fY |ν(yi|νi, λi, ψi, pi) = piλiψiνi exp(−λiψiνiyi),
SY |ν(yi|νi, λi, ψi, pi) = 1− pi + pi exp(−λiψiνiyi),
fX|ν(xi|νi, λi, ui) =
(λiνiui)
xi exp(−λiνiui)
xi!
,
gν(νi|α) = α
ανα−1i exp(−ανi)
Γ(α)
,
where
pi =
exp(κωi)
1 + exp(κωi)
is the corresponding cure rate for first seizure post-randomization.
In the following subsections we will proceed to show how the joint distribution
of Xi and Yi is obtained for each patient i in the population, depending on whether
we consider the case in which the seizure time is observed or censored. Once we
have corroborated obtaining the same joint distributions as the ones proposed by
Cowling ([10]), we will obtain the zero-truncated joint distributions.
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4.3.1 Zero Truncated Joint distribution with cure fraction, with Yi
Observed
Let us consider the case when the seizure time for individual i, Yi is observed. Then
the corresponding joint distribution Xi and Yi has the form:
fXi,Yi(xi, yi | ui, λi, ψi, α, pi) =
∫ ∞
0
fX |νi(xi|ui, λi, νi)fY |νi(yi|λi, ψi, νi, pi)gν(νi|α)∂νi
=
∫ ∞
0
(λiνiui)
xie−λiνiui
xi!
piλiψiνie
−λiψiνiyi α
ανα−1i e
−ανi
Γ(α)
∂νi
=
piλ
xi+1
i u
xi
i ψiα
α
xi!Γ(α)
∫ ∞
0
νxi+αi e
−νi(λiui+λiψiyi+α)∂νi
= pi
Γ(xi + α+ 1)α
α(λiui)
xiλiψi
xi!Γ(α)(λiui + λiψiyi + α)xi+α+1
= pi
Γ(xi + α+ 1)α
α(λiui)
xiλiψi
xi!Γ(α)ζi
xi+α+1
,
where ζi = λiui + λiψiyi + α. From this joint density we obtain the corresponding
zero-truncated density for Xi > 0 and Yi, shown below.
fX>0,Y (xi, yi|ui, λi, ψi, α, pi) = piΓ(xi + α+ 1)α
α(λiui)
x
i λiψi
xi!Γ(α)ζi
xi+α+1
/[
1− pi
(
α
λiui + α
)α]
=
piΓ(xi + α+ 1)α
αλiψi(λiui)
xi(λiui + α)
α
xi!Γ(α)ζ
xi+α+1
i [(λiui + α)
α − piαα]
,
and if we denote by ηi = λiui + α, the joint density takes the form
=
piΓ(xi + α+ 1)α
αλiψi(λiui)
xiηαi
xi!Γ(α)ζ
xi+α+1
i [η
α
i − piαα]
.
4.3.2 Zero Truncated Joint distribution with cure fraction, with Yi
Censored
If we now consider the case in which the seizure time Yi is unobserved, we derive
the joint density of Xi and Yi and obtain the following equations.
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fXi,Yi(xi, Yi > yi | ui, λi, ψi, α, pi)
=
∫ ∞
0
fX |νi(xi|ui, λi, νi)SY |νi(yi|λi, ψi, νi, pi)gν(νi|α)∂νi
=
∫ ∞
0
(λiνiui)
xie−λiνiui
xi!
[
1− pi + pie−λiψiνiyi
] αανα−1i exp(−ανi)
Γ(α)
∂νi
=
(λi + α)
xiαα
xi!Γ(α)
[
(1− pi)
∫ ∞
0
νxi+α−1i e
−νi(λiui+α)∂νi
+pi
∫ ∞
0
νxi+α−1i e
−νi(λiui+λiψiyi+α)∂νi
]
= pi
Γ(xi + αi)α
α(λiui)
xi
xi!(λiui + λiψiyi + α)xi+α
+ (1− pi) Γ(xi + α)α
α(λiui)
xi
xi!Γ(α)(λiui + α)xi+α
=
Γ(xi + α)α
α(λiui)
xi
xi!Γ(α)
[
pi
(λiui + λiψiyi + α)xi+α
+
1− pi
(λiui + α)xi+α
]
=
Γ(xi + α)α
α(λiui)
xi
xi!Γ(α)
[
pi
ζi
xi+α
+
1− pi
ηixi+α
]
.
In a similar way as before, we now proceed to find the corresponding joint
density function for the zero-truncated model under the assumption that Yi is un-
observed.
fXi>0,Yi(xi, Yi > yi | ui, λi, ψi, α, pi)
=
Γ(xi + α)α
α(λiui)
xi
xi!Γ(α)
[
pi
ζi
xi+α
+
1− pi
ηixi+α
]/[
1− pi
(
α
λiui + α
)α]
=
Γ(xi + α)α
α(λiui)
xiηαi [piη
xi+α
i + (1− pi)ζxi+αi ]
xi!Γ(α)(ζiηi)xi+α(ηαi − piαα)
.
4.3.3 The Full Log-Likelihood and Derivatives
The likelihood function is the product of the density functions over all patients. We
will use the notation δi to denote whether their survival time has been observed or
censored. As indicated in the section corresponding to the truncated joint model,
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the parameters λi and ψi depend on the covariate vectors β1 and β2 respectively in
the form λi = exp(z1iβ1) and ψi = exp(z2iβ2). If x and y are respectively the sets
of seizure counts and first seizure times post-randomization for all n patients, we
obtain the equation:
L(α, β1, β2, κ;x, y) =
n∏
i=1
[
piΓ(xi + α+ 1)α
αλiψi(λiui)
xiηαi
xi!Γ(α)ζ
xi+α+1
i [η
α
i − piαα]
]δi
×
[
Γ(xi + α)α
α(λiui)
xiηαi [piη
xi+α
i + (1− pi)ζxi+αi ]
xi!Γ(α)(ζiηi)xi+α(ηαi − piαα)
]1−δi
=
n∏
i=1
Γ(xi + α)α
α(λiui)
xiηαi
xi!Γ(α)ζ
xi+α
i (η
α
i − piαα)
[
pi(xi + α)λiψi
ζi
]δi
×
[
piη
xi+α
i + (1− pi)ζxi+αi
ηxi+αi
]1−δi
.
By applying the logarithm to the likelihood function we obtain the log-
likelihood function.
`(α, β1, β2, κ;x, y) = log[L(α, β1, β2, κ;x, y)]
=
n∑
i=1
{log Γ(xi + α)− log Γ(α)− log(xi!) + α log(αηi)
+xi log(λiui)− (xi + α) log(ζi)− log(ηαi − piαα)
δi[log(xi + α) + log(λiψi) + log(pi)− log(ζi)]
+(1− δi)[log(piηxi+αi + (1− pi)ζxi+αi )− (xi + α) log(ηi)]
}
,
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which, after some grouping of the terms, results in the final form:
`(α, β1, β2, κ;x, y) =
n∑
i=1
{log Γ(xi + α)− log Γ(α)− log(xi!) + α log(α) + xi log(ui)
−(xi + α) log(ζi)− log(ηαi − piαα) + [α− δi(xi + α)] log(ηi)
+(xi + δi) log(λi)− (xi + α) log(ζi)
+δi[log(xi + α) + log(ψi) + log(pi)− log(ζi)]
(1− δi)[log(piηxi+αi + (1− pi)ζxi+αi )− (xi + α) log(ηi)]
}
.
The first order derivatives can now be found for each of the parameters of
interest:
∂`(α, β1, β2, κ;x, y)
∂α
=
n∑
i=1
{
∂ log Γ(xi + α)− ∂ log Γ(α)
∂α
+ log(α) + 1 + log(ηi) +
α
ηi
− log(ζi)
−α
ζi
− αη
α−1
i + η
α
i log(ηi)− [log(α) + 1]piαα
ηαi − piαα
+ δi
[
1
xi + α
− 1
ζi
]
+(1− δi)
[
piη
xi+α−1
i [xi + α+ ηi log(ηi)]
piη
xi+α
i + (1− pi)ζxi+αi
+
(1− pi)ζxi+α−1i [xi + α− ζi log(ζi)]
piη
xi+α
i + (1− pi)ζxi+αi
]}
,
∂`(α, β1, β2, κ;x, y)
∂β1
=
n∑
i=1
z1λi
{
αui
ηi
+
xi
λi
− (xi + α)(ui + ψiyi)
ζi
− αη
α−1
i ui
ηαi − piαα
+δi
[
1
λi
− ui + ψiyi
ζi
]
+(1− δi)
[
pi(xi + α)η
xi+α−1
i ui + (1− pi)(xi + α)ζxi+α−1i (ui + ψiyi)
piη
xi+α
i + (1− pi)ζx−i+αi
− (xi + α)ui
ηi
]}
,
∂`(α, β1, β2, κ;x, y)
∂β2
=
n∑
i=1
z2ψi
{
− (xi + α)λiyi
ζi
+ δi
[
1
ψi
− λiyi
ζi
]
+(1− δi)
[
(1− pi)(xi + α)ζxi+α−1i λiyi
piη
xi+α
i + (1− pi)ζxi+αi
]}
,
∂`(α, β1, β2, κ;x, y)
∂κ
=
n∑
i=1
z3piωi
{
− α
α
ηαi − piαα
+
δi
pi
+ (1− δi) η
xi+α
i − ζxi+αi
piη
xi+α
i + (1− pi)ζxi+αi
}
.
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Let us remember that
pi =
exp(κz3)
1 + exp(κz3)
,
hence, the derivative of this quantity with respect to κ is of the form
∂pi
∂κ
=
z3e
κz3(1 + eκz3)− z3(eκz3)2
(1− eκz3)2
=
z3e
κz3(1 + eκz3 − eκz3)
(1 + eκz3)2
= pi
z3
1 + eκz3
= z3pi(1− pi).
Through these equations we can find numerically the second-order deriva-
tives, from which the standard deviation for the corresponding covariates under
consideration are calculated. In Table 4.12 we show the corresponding maximum
likelihood estimates of interest, contrasting the estimates between the zero-truncated
joint model with a cure fraction (truncated Rogers model), the joint model with
and without cure fraction (Cowling and Rogers models respectively) and the zero-
truncated joint model (truncated Cowling model). It can be observed that estimate
of α in truncated models indicates a higher homogeneity in the population than the
non-truncated models, and furthermore, the post-randomization parameter stan-
dard errors are shown to be greater for the former than the latter models.
The truncated Rogers model presents no significant difference in the param-
eter estimates when compared to its non-cure fraction counterpart, the truncated
Cowling model. However, when compared to the non-truncated Rogers model, the
cure fraction parameter estimate, κ shows a difference from its truncated version,
but it is not a significant difference, since the standard deviation is large enough to
deem such differences unimportant. Indeed, when recalling that the cure fraction is
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of the form
p =
exp(κz)
1 + exp(κz)
,
we obtain that p = 0.501 for the Rogers model, and p = 0.496 for the zero-truncated
Rogers model, differing in an additional 0.5% proportion of the population predicted
to attain remission under the non-truncated Rogers model.
The log-likelihood value shows that the zero-truncated model with cure frac-
tion does not seem to provide an improvement over the other three models. However,
further investigation must be made about the properties of this model under extreme
seizure count values, and other possible particularities. Due to the complexity of
some of the expressions in the log-likelihood and its derivatives, when the number of
seizures pre-randomization is high, the terms containing this variable tend to large
or very small numbers which can cause problems during the optimization process.
Further investigation and work for this model are left as a future work of interest.
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Trunc. Trunc.
Cowling SD Cowling SD Rogers SD Rogers SD
α 2.095 0.116 10.083 0.125 2.060 0.113 7.997 0.003
λ Intercept -4.131 0.085 -4.411 0.062 -4.129 0.085 -4.342 0.058
Age -0.005 0.002 -0.012 0.001 -0.005 0.002 -0.008 0.001
T-C -1.085 0.094 -1.335 0.076 -1.075 0.095 -1.227 0.065
2T-C -0.697 0.097 -0.738 0.073 -0.690 0.098 -0.796 0.066
ψ Intercept -5.303 0.564 -7.219 1.214 -4.045 0.615 -6.975 1.439
Age 0.004 0.003 0.012 0.004 0.0001 0.004 0.011 0.005
Trt 1.178 0.532 1.688 1.038 0.702 0.708 1.788 1.235
T-C 2.945 0.569 3.896 1.215 3.513 0.626 4.044 1.442
2T-C 2.322 0.576 3.032 1.225 2.565 0.638 3.120 1.457
Trt*T-C -1.366 0.532 -1.367 1.031 -1.009 0.715 -1.309 1.226
Trt*2T-C -1.446 0.542 -1.655 1.036 -0.942 0.731 -1.619 1.243
EEG 0.059 0.554 0.927 1.093 0.652 0.712 1.024 1.292
Trt*EEG -0.808 0.199 -1.246 0.270 -0.860 0.281 -1.212 0.347
EEG*T-C 0.409 0.556 0.380 1.089 -0.514 0.720 0.434 1.285
EEG*2T-C 0.820 0.566 1.292 1.100 0.480 0.737 1.330 1.303
κ 0.004 0.076 -0.015 0.026
-Loglike. 7031.64 6799.42 6861.38 8020.69
Table 4.12: Maximum likelihood parameter estimates for the Cowling, Rogers and
Truncated joint model with and without cure fraction (Truncated Cowling and Trun-
cated Rogers models).
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Chapter 5
Goodness of Fit Between Cox
and Joint Models
In the following chapter we implement and explore the theory of residual analysis
to four survival models, among other goodness of fit comparisons. We apply such
theory and a few other model-checking techniques specifically to the epilepsy MESS
data set.
When examining the adequacy of a model, the use and analysis of residuals
has the potential for discovering outlying anomalous observations, influential obser-
vations or unexpected patterns. In the following section, we proceed to introduce
the types of residuals that are commonly considered for survival analysis. The types
of residuals are defined in terms of the estimated survival function at every event
time ti, and some of their most relevant properties are discussed. In the second
section, we propose four survival models for the MESS data, and mainly four types
of residuals are shown for each one of them. We then proceed to identify the out-
liers marked by the proportional hazards models, and we compare the model’s fitted
values when considering the original data set and the data set without the outliers.
In the third section we produce a simulation according to the assumptions
from the Cowling model, in an attempt to investigate how the residuals would
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behave under known conditions. Finally, in the last section we present the plots
of Kaplan-Meier survival curves contrasting with the survival functions under the
joint and joint with cure fraction models, taking the maximum likelihood estimated
parameters under the MESS data set.
5.1 Introduction to Residual Analysis
The Cox-Snell residuals are commonly used in survival analysis, and a good dis-
cussion can be found in the book by Collet, 1994[7]. The genesis of such residuals
comes from the principle that, if we denote by Si(t) the survival function for indi-
vidual i at time t, then, by performing a change of variable, the random variable
Y = − logS(T ) is found to be distributed as an exponential distribution with mean
one. Note that the variable is distributed as an exponential, irrespectively of the
form of the survival function, which in particular means that this property holds
for both proportional hazards models, accelerated life models or any other survival
model. Furthermore, if the model fitted to the observed data is satisfactory, then
the estimated survival function of individual i at time ti, Sˆi(ti), will approximate
the real survival function Si(ti), and the two functions will share similar properties.
It will follow that, given that − logSi(Ti) will be distributed as an Exp(1), then
− log Sˆi(Ti), which is defined as the Cox-Snell residual and is denoted by rCi , will
also be distributed thusly.
The Cox-Snell residuals have several properties which make them differ from
the residuals used for linear regression models. The distribution of the residuals will
not be symmetrically distributed around zero, as in fact they cannot be negative-
valued and should have a highly skewed distribution. Since the residuals, under the
right model, are distributed as an Exp(1), they must show a unit mean and variance.
A property of particular interest to us from the Cox-Snell residuals, is that if an
individual has a right-hand censored survival time, then the corresponding value of
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the residual will also be right-censored. This will mean that, if we have estimated the
survival function for each patient in the study, we can propose a Cox-Snell residual
study, where we will have that the censored survival times will in turn produce
censored residuals. This property is of particular interest to us, since it provides a
possible residual study for our epilepsy data, where we encounter different types of
censoring throughout the follow up. How distinguishable would the censored data
be, however, from the uncensored seizure times? Let us then consider the modified
Cox-Snell residuals.
There is a refinement of the Cox-Snell residuals that has been proposed
when in presence of right-censoring in the population. Suppose there is a censored
survival time t∗i for individual i, and that the true, but unknown, survival time for
such individual is ti. Then we will have that ti > t
∗
i , and hence, the cumulative
hazard function evaluated at ti must be greater than that evaluated at t
∗
i , resulting
in the Cox-Snell residual of t∗i (rCi = Hˆi(t
∗
i ) = − log Sˆi(t∗i )) being underweighted.
The modified Cox-Snell residuals aim to solve this problem by adding a positive
quantity ∆ to the original residuals, so that they are defined as
r′Ci = ∆δi + rCi =
 rCi for uncensored observations,rCi + ∆ for censored observations,
where δi is the censoring indicator for an individual i, meaning that it will take
the value zero if the observed survival time is censored, and one if it is uncensored.
Observe that, by the lack of memory property of the exponential distribution, and
since rCi is a unit exponential distributed, then the since the residuals are distributed
as exponentials with mean one, then the excess residual ∆ will also be distributed
as a unit exponential. This will imply that the mean will be one, and we conclude
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that ∆ = 1, leading to the modified Cox-Snell residuals
r′Ci = δi + rCi =
 rCi for uncensored observations,rCi + 1 for censored observations.
This will imply that all censored individuals will produce residuals with values
greater than one. It has been argued, however, by Crowley and Hu[14], that con-
sidering ∆ = 1 results in overweighting the residuals, and propose to use, instead
of the mean of the Exp(1), its median. This will result in considering ∆ = log(2) =
0.693; which will result in the values of the residuals for the censored observations
being greater than ∆. For our particular epilepsy model, this property would be
useful, since it would allow us to observe the influence of the censored seizure times
on the model.
Suppose a transformation is used on the Cox-Snell residuals, relocating the
mean to zero when the observations are uncensored, and then multiplying by minus
one. Then we would obtain the martingale residuals (also known as the Lagakos
residuals), which are defined as
rMi = δi − rCi .
These residuals are originally derived from probabilistic theory denoted as martin-
gale methods, but such procedures are not derived here. This type of residual has
some similarities to the residuals for generalized linear models, such as the residuals
being centered at zero. However, they differ in that the residuals values range from
−∞ to 1, and the residual distribution is asymmetric around zero. However, there
is a way of making the martingale residuals symmetric about zero when the model
is satisfactory. Such a transformation derives to what is known as the deviance
residuals. As the name suggests, these residuals arise from computing the deviance,
which is a statistic designed to measure how much does a saturated model deviate
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from a new proposed model. Such statistic is given by
D = −2
{
log Lˆc − log Lˆf
}
,
where Lˆc is the maximized likelihood function under the new model, and Lˆf is the
maximized likelihood function under the full model. The deviance residuals are then
found to be of the form
rDi = sgn(rMi) [−2 {rMi + δi log(δi − rMi)}]1/2 ,
where sgn(x) is the sign of x, and rMi is the martingale residual for the i
th patient.
Although the deviance residuals are now symmetric around zero, their sum is not
necessarily zero.
5.2 Residual Study for Epilepsy Data
A residual study is performed for four models. The first two models consist of a
Cox proportional hazards models, but each one considers a different set of covari-
ates to explain the times to seizure recurrence. For the model proposed by Kim
et al.[27] the covariates considered are neurological disorder, EEG outcome and
the logarithm of the number of seizures per patient, with the model stratifying by
treatment allocation (immediate or deferred). For the model we denominate as the
”Cox model”, instead we consider the covariates treatment allocation (immediate
or deferred), EEG outcome, logarithm of the number of seizures per patient, age at
randomization and type of epilepsy, along with interactions. The Cowling or joint
model is a Poisson process with over dispersion and a Gamma mixing distribution.
For this model we consider the covariates EEG outcome, age at randomization,
type of epilepsy, treatment allocation and their second order interactions. The final
model is named the Rogers or joint with cure fraction model, and consists of the
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Cowling model with a generalization of considering a cure rate, which represents the
proportion of patients that will not present a seizure recurrence after randomization.
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Figure 5.1: Q-Q plots for Cox-Snell residuals for Kim, Cox, Cowling and Rogers
models.
In Figure 5.1 we observe the Cox-Snell residuals for each of the models.
The ordered residuals are plotted against the theoretical values of an exponential
distribution with unit mean. The straight red line through the origin and unit slope
represents the ideal path of the residuals if the model is correct. Circles represent
residuals obtained from observed times, while triangles correspond to the residuals
from censored times. The three colors represent the three epilepsy types observed.
Tonic-Clonic only (T-C), Second generalized Tonic-Clonic (2nd.T-C) and Partial
seizures are colored red, green and blue respectively. Observe the plot corresponding
to the Kim model shows that, for early seizures, about 40.5% of the data seems well
fitted by the model. For the remaining observations, the straight blue line shown in
the figure seems to fit better except for a few outliers. The blue line has an intercept
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of −1.3 and a slope of 4.2, which means that for the considered model, the Cox-Snell
residuals rC have the form rC = −1.3 + 4.2Y , where Y ∼ Exp(1). Under this new
transformation, we identify four possible outliers, presented in Table 5.2. In order
to compare the number of seizures, period of observation, rate and times to first
seizures post randomization of these patients, we show in Table 5.1 the quartiles,
mean, median, maximum and minimum of such variables. Considering that the
mean number of seizures in the population is 2.49 and the third quartile is 2, the
patients corresponding to the possible outliers experienced a much greater number
of seizures. Observe that the patient with outlier identification number ”1” has the
greatest rate value in the population, due to the high number of seizures (65) in a
short period of time (182 days).
For the Cox model, the Cox-Snell residuals, also shown in Figure 5.1, there is
approximately a 46.7% of the population that is well adjusted by the model. Once
again, the straight line with intercept −1.3 and a slope 4.2 appears to be a better
fit for the remaining proportion of the population, and it can be seen in the plot as
the blue straight line. Observe in Table 5.2 that once again there are three patients
with 2nd.T-C seizures and one patient with partial seizures with the larger values
of the residuals, and which are candidates for possible outliers. Two of these four
residuals coincide with the possible outliers in the Kim model. Mainly, the residuals
corresponding to patients numbered as ”7” and ”1”. Although the four patients
with greatest residual values in the Kim model range in ages from 6 to 40 years
old, the corresponding patients for the Cox model consist of young people from 6 to
27 years old, and all of them present an abnormal EEG outcome. Although their
number of seizures is higher than the mean number of seizures in the population,
their seizure rates are not much greater than expected. Except, of course, for the
patient numbered as ”1”.
An important characteristic that must be noticed for the residuals corre-
sponding to these two models, is that all six outliers found correspond to female
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Minimum 1st. Quartile Median Mean 3rd. Quartile Maximum
Num.Seiz 1 1 1 2.49 2 130
Times 1 109.2 724 949 1590 3161
Period 180 180 180 530 190 21000
Rate 0.0002 0.005 0.005 0.008 0.007 0.357
Table 5.1: Minimum, maximum, mean, and quartiles for number of seizures, times
of first seizures post-randomization, period and rate.
patients; a phenomena that is observed again for the residuals corresponding to the
Cowling and Rogers models, even when the outliers are not the same as the ones
already discussed.
Outlier
1 2 3 4 5 6 7 8 9
Model K,Co C,R C,R C,R K Co K,Co All K
Sex Fem Fem Fem Fem Fem Fem Fem Fem Fem
Age 6 15 15 15 17 18 25 28 40
Type Partial 2.T-C 2.T-C 2.T-C 2.T-C 2.T-C 2.T-C 2.T-C 2.T-C
Trt Imm Imm Imm Imm Def Imm Def Imm Imm
EEG 1 1 1 1 1 1 1 1 0
No.Seiz 65 1 3 1 31 6 104 5 100
Period 182 182 289 182 182 210 9300 769 9825
Time 1518 2497 2591 2978 1069 1440 774 2534 885
Cens 0 0 0 0 1 0 1 0 1
Rate 0.357 0.005 0.010 0.005 0.170 0.029 0.011 0.007 0.010
Centre 4502 1101 1101 1602 1301 4401 1601 1101 207
Table 5.2: Outliers and residuals with highest values corresponding to Kim (K),
Cox (Co), Cowling (C) and Rogers (R) models. here 2.T-C represents the secondary
generalized Tonic-Clonic seizures.
In the corresponding Cox-Snell residual plot in Figure 5.1 for the Cowling
model, a different trend of the residuals can be noted. In this case the residuals
do not appear to be well fitted from the beginning, but rather another straight line
with intercept 0 and slope 2.1, presented in blue, seems to fit the data better. The
residuals appear to oscillate around the new fitted line, and it could be a suggestion
that a transformation could be used, such as a transformation of fourth power,
or a sinusoidal transformation. In this case we also mark the four residuals with
the greatest values, although under the new fit these do not appear to be outliers.
117
When observing the Cox-Snell residuals for the Rogers model in the same figure,
it is noticeable that approximately the 54.8% of the population seem to be well
fitted. For the remaining proportion of the residuals, there appears to be five sub-
populations that could be depending on a covariate not yet considered in the model.
Observe that there does not appear to be a pattern of type of epilepsy except for
the residuals with the highest values, all of which present partial seizures only.
The four residuals with highest values are the same for both the Cowling
and the Rogers model, and they are shown in Table 5.2. Observe however that all
four patients corresponding to these residuals are female, allocated to immediate
treatment, present abnormal EEG and 2nd.T-C seizures and are recorded as not
censored. Additionally, three of these patients are aged 15 years old at the time of
randomization. Another subset of three outliers belong to the same clinical centre,
and their ID numbers are consecutive. This supports earlier suspicions that there
is a centre factor that could be convenient to consider in the models. Observe
that throughout the study 83 centres participated, and the number of patients they
treated ranged from 1 to 238 individuals. In fact, for Outlier No.3, this patient was
the only contribution by the centre to the study. As a part of future work, we are
interested in analyzing further the relationship of the centre covariate to the possible
biases of the seizure time reports.
When considering the joint model with a dependent heterogeneity parameter
α on covariates, in this case, on the type of epilepsy, the corresponding Q-Q plot
for the Cox-Snell residuals is shown in Figure 5.2. Once again the fitted straight
line, as considered for the joint shown in Figure 5.1, is considered to have intercept
0 and slope 2.1, and is shown in blue. Observe that the fundamental contrast to
the joint model with constant α is that the residuals for late seizure occurrences
do not appear to oscillate, but rather remain close to the regression line. Apart
from this variation, the general behaviour of the residuals for the rest of the seizure
times remains similar to the joint model with fixed α. The observed highest valued
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residuals remain the same and the four possible outliers under this model coincide
with those obtained from the joint and joint with cure fraction models. This could
be an indication that α depending on covariates provides a stabilizing effect on the
model fitting.
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Figure 5.2: Q-Q plot for the Cox-Snell residuals for the joint model with α dependent
on the type of epilepsy.
In Figure 5.3, the martingale residuals are shown for the four models. Let us
remember that the martingale residuals are centered at 0, taking values from −1 to
infinity, with the residual density not being symmetrical around 0 and compressing
all censored residuals from −1 to 0. The first two index plots are consistent in
showing the individual with outlier number ”1” (ID number ”4502021”) as an outlier
for both the Kim and Cox models. The martingale residuals for the Cowling model
presents less obvious outliers, but there seems to be a pattern in the data, indicating
once again that there might be a variable that should be considered in the model.
For the Rogers model, the index plot shows a more symmetrical behaviour around 0,
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but the binary nature of the covariates considered in the model make more apparent
the subsets of possible values that the residuals can take. For the Rogers model,
there is no clear indication of an outlier.
The martingale residuals are transformed to obtain the deviance residuals,
with the aim of obtaining a symmetric density of these new residuals around 0. The
deviance is a statistic designed to measure how much does a saturated model deviate
from a new proposed model. Although the deviance residuals are now symmetric
around zero, their sum is not necessarily zero.
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Martingale residuals for Cowling’s model
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Martingale residuals for Rogers’s model
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Figure 5.3: Martingale residuals for Kim, Cox, Cowling and Rogers models.
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Deviance residuals for Kim model
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Deviance residuals for Cox model
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Deviance residuals for Cowling’s model
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Deviance residuals for Rogers’s model
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Figure 5.4: Deviance residuals for Kim, Cox, Cowling and Rogers models.
In Figure 5.4, we observe that the deviance residuals do not appear to be
symmetrical around 0 for any of the four models. The index plots for the Kim and
Cox models support the finding of the outlier previously observed, and the Cowling
and Rogers models do not present outliers. The observed data is noticeably less
sparse than the censored data, and for the four models the observed residuals are
centered at −1, suggesting a deviation of such magnitude.
For neither the martingale nor the deviance residuals appears to be a trend for
treatment allocation, as the density of blue-coloured, immediate-allocated patients
is about the same as the density for the red-coloured, delayed-allocated patients.
Furthermore, since our only continuous covariate is the age at randomization for
these models, we plot the Cox-Snell residuals against this variable. In Figure 5.5
these plots show that there is no perceptible trend for the residuals of any of the
models, although the Rogers model presents once more the effect of considering
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binary covariates.
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Cox−Snell residuals for Cox model
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Cox−Snell residuals for Cowling’s model
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Cox−Snell residuals for Rogers’s model
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Figure 5.5: Cox-Snell residuals for Kim, Cox, Cowling and Rogers models, plotted
against the age at randomization.
In Figure 5.6 we contrast the Cox-Snell residuals between models, in an
attempt to observe if the models are consistent from one to another. The first
plot shows the residuals corresponding to the Kim model against the corresponding
residuals for the Cox model. We observe that, although the variation increases
with time, the residuals are consistently centered around the line passing through
0 with unit slope. A comparison between Kim’s residuals against Rogers’ residuals,
we again have that the residuals are dispersed around the equality line, but they
appear skewed upwards, as roughly happens for the residuals of the Cox model
against the Rogers model. For the plots of the Cowling model against Kim and Cox
models, in both situations there seems to be a translated and re-scaled logarithmic
transformation of the Cowling residuals. For the comparison between the Rogers
and Cowling model, we observe that first seems to be an exponential transformation
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of the second model, and that both models categorize the residuals in the same
treatment-dependent binary combinations.
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Cowling’s model residuals
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Rogers’ model residuals
Ki
m
’s 
m
o
de
l r
es
id
ua
ls
1
2
3
0.2 0.4 0.6 0.8 1.0 1.2 1.4
censoring
0
1
trt
0.0
0.2
0.4
0.6
0.8
1.0
Cowling’s model residuals
Co
x’
s 
m
o
de
l r
es
id
ua
ls
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0.5 1.0 1.5 2.0 2.5 3.0
censoring
0
1
trt
0.0
0.2
0.4
0.6
0.8
1.0
Rogers’ model residuals
Co
x’
s 
m
o
de
l r
es
id
ua
ls
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0.2 0.4 0.6 0.8 1.0 1.2 1.4
censoring
0
1
trt
0.0
0.2
0.4
0.6
0.8
1.0
Rogers’ model residuals
Co
w
lin
g’s
 m
o
de
l r
es
id
ua
ls
0.5
1.0
1.5
2.0
2.5
3.0
0.2 0.4 0.6 0.8 1.0 1.2 1.4
censoring
0
1
trt
0.0
0.2
0.4
0.6
0.8
1.0
Figure 5.6: Cox-Snell residual contrasts between Kim, Cox, Cowling and Rogers
models.
5.3 Residuals without outliers
From the residual plots observed previously, Kim and Cox models indicate six pos-
sible outliers. Since it is still under discussion whether or not the residuals with
greatest values signaled by Cowling and Rogers models are to be considered as
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outliers themselves, we restrict this section to observe the difference of the models
outcomes if the six Kim and Cox’s models outliers were taken out from the study.
We start by comparing the outcomes under Kim’s model for the full data set
and the new data set without the six outliers. In Table 5.3 we observe, for this model,
that there is little variation for the estimates of EEG and neurological disorders. It is
the logarithm of the number of seizures that shows a more substantial increase in the
estimated coefficient, and such an effect becomes clearer in Figure 5.7. The increase
in this estimate was to be expected, since we are modifying the data set precisely
by taking out patients with very high number of seizures, relative to the rest of the
population. Indeed, Kim’s model signals patients with large numbers of seizures
as outliers more frequently than any of the other models. For the likelihood ratio
test, where we consider the current likelihood over the saturated-model likelihood,
we obtained a ratio of 77.8 for the full data set, and a ratio of 96.3 for the reduced
data set. Since these quantities are based in different population sizes, we could
have that the likelihood ratio under the reduced data is greater simply because
it contains less data. For this reason we normalize both quantities by dividing
them by the respective number of patients they are considering. This leaves us
with the normalized likelihood ratio statistics 77.8/1334 = 0.058 and 96.3/1328 =
0.072 respectively. This shows that the model under the reduced data set is more
plausible than the model under the full data set. This type of likelihood ratio
statistic normalization will be carried out for the remaining three models as well.
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Figure 5.7: Kim model’s Cox-Snell residual contrasts between the data sets with
and without outliers.
Consider Figure 5.7(a) where we observe the Q-Q plots for the Cox-Snell
residuals contrasted to an Exp(1) distribution. The residuals for the full data set
are shown in blue, whilst the new residuals are shown in red. Censored data and
observed data are represented by triangles and circles respectively. Although pre-
viously we had observed that the Cox-Snell residuals rC seemed to follow the form
rC = −1.3 + 4.2 × Y , where Y ∼ Exp(1), the new residuals do not fit the same
regression line. Indeed the slope seems to be smaller, therefore fitting the assump-
tions slightly better. In Figure 5.7(b) the Cox-Snell residuals for the same model and
different data sets are contrasted against each other. Here censored and observed
data are plotted in green and red colors respectively. Although the majority of the
early-seizure residuals tend to be the same, as the time to first seizure increases the
value of the newly-fitted residuals also increase with respect to their former values.
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Full Data Reduced Data Ratio
βˆ1 se(βˆ1) p-value βˆ2 se(βˆ2) p-value βˆ1/βˆ2
Ndl 0.40 0.12 1.3e−3 0.42 0.13 7.8e−4 0.95
EEG 0.31 0.08 7.9e−5 0.34 0.08 1.8e−5 0.92
log(No.seiz) 0.38 0.05 6.6e−15 0.52 0.06 1e−15 0.73
Likelihood
ratio/n 0.058 0.072
Table 5.3: Kim’s model fitted coefficients for the data sets including and excluding
the outliers, respectively.
A similar phenomena is observed for the Cox model, where Figure 5.8 repre-
sents censored and observed data as mentioned before. In Figure 5.8b) the residuals
under the new data set are smaller than the residuals for the full data, and in 5.8a)
these new residuals present a slightly better fit under the assumptions. Observe
that the new residuals no longer approximate the previously fit line passing through
0 and slope 2.1.
In Table 5.4, we observe that the estimated regression coefficients for the
two data sets vary more noticeably for the EEG and Treatment covariates and
their interactions with the Tonic-Clonic seizure indicator. This could be a result
from excluding six patients of whom one had partial seizures, and the remaining
presented 2nd. Tonic-Clonic seizures. As before, the likelihood ratio statistics are
normalized by the number of patients under consideration for each case, and these
are found to be 108/1334 = 0.08 and 129/1328 = 0.09 for the full and reduced data
sets respectively. Observe that although there are some noticeable changes in the
estimated coefficients, the likelihood ratio statistics show that the model under the
reduced data set does not present a large improvement over fitting the model to the
full data set.
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Full Data Reduced Data Ratio
βˆ1 se(βˆ1) p-value βˆ2 se(βˆ2) p-value βˆ1/βˆ2
Trt 0.31 0.28 0.26 0.22 0.28 0.42 1.39
T-C -0.25 0.27 0.36 -0.24 0.26 0.36 1.04
2nd.T-C -0.38 0.28 0.17 -0.37 0.27 0.18 1.03
EEG 0.08 0.28 0.79 0.20 0.28 0.46 0.37
Age -0.005 0.002 0.66 -0.001 0.002 0.48 0.62
log(No.seiz) 0.38 0.05 <0.005 0.50 0.06 <0.005 0.75
T-C×EEG 0.36 0.29 0.21 0.25 0.29 0.38 1.43
2nd.T-C×EEG 0.83 0.30 0.01 0.76 0.30 0.01 1.09
Trt×EEG -0.55 0.16 <0.005 -0.59 0.16 <0.005 0.92
Trt×T-C -0.38 0.28 0.18 -0.27 0.28 0.33 1.39
Trt×2nd.T-C -0.45 0.29 0.12 -0.37 0.29 0.21 1.22
Likelihood ratio/n 0.08 0.09
Table 5.4: Cox’s model fitted coefficients for the data sets including and excluding
the outliers, respectively.
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Figure 5.8: Cox model’s Cox-Snell residual contrasts between the data sets with and
without outliers.
Although for the Cox and Kim models the residual analysis for the full and
reduced data sets showed little improvement, in the following analyses for the Cowl-
ing and Rogers models we observe even smaller changes. In the following Table 5.5
we show the covariate coefficient estimates for Cowling’s model, for both data sets
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under consideration. Observe that the heterogeneity measure α does not change
significally, as well as the type of seizure covariates in the pre-randomization rate.
For the rest of the covariate coefficients, however, they usually are doubled for the
full data set with respect to the reduced data set. In particular, the Tonic-Clonic
seizure factor plays a less significant role in the post-randomization seizure rate,
as it decreases by ten times relative to the same coefficient for the full data set,
although its interactions with other factors are not decreased in the same magni-
tude. It would seem that the omission of the six patients with partial and 2nd.
Tonic-Clonic seizures leads to a substantial change in the model, in which having
a Tonic-Clonic seizure leads to a much greater decrease in the seizure rate than
before. For this post-randomization rate, the coefficient estimates for both Tonic-
Clonic seizure factor and its interaction with the EEG outcome are diminished to
the point of becoming negligible. Indeed, their standard errors are greater or equal
to their estimated values, meaning that under the reduced model, we could consider
to simplify the model by taking these two factors out of the analysis.
Although the covariate coefficients tend to change more noticeably in this
model than in Kim or Cox’s models, by observing the resulting standarized log-
likelihoods, the model under the reduced data set fits the data almost in the same
way as for the full data set, if only slightly better. This, in turn, can be corroborated
when observing the contrast plot in 5.9b), where the residuals appear to be smaller
for the reduced data set, in a more consistent form than for the previous models.
In Figure 5.9a) we observe that the new residuals fit the assumptions somewhat
better, although they no longer fit the line with intercept 0 and slope 2.1. They
still, however, deviate from the expected residuals from the beginning.
When considering Rogers model, in Table 5.6 the coefficient estimate changes
behave in a very similar way for the pre-randomization seizure rate as the changes
observed in Cowling’s model. The intercept and types of epilepsy do not present a
significant change, although the rest of the coefficients tend to reduce by half their
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Full Data Reduced Data Ratio
Coef1 SDs Coef2 SDs Coef1/Coef2
α 1.99 0.11 2.08 0.12 0.95
Intercept -4.54 0.15 -4.54 0.15 1.00
T-C -0.69 0.16 -0.69 0.16 0.99
2nd T-C -0.40 0.17 -0.40 0.16 0.97
β1 EEG 0.57 0.19 0.30 0.19 1.89
Age -0.003 0.001 -0.002 0.001 1.58
T-C*EEG -0.53 0.20 -0.26 0.20 2.07
2nd T-C*EEG -0.33 0.21 -0.15 0.21 2.17
Intercept -2.61 0.33 -2.26 0.31 1.15
Trt 0.99 0.33 0.35 0.33 2.80
T-C 0.41 0.34 0.04 0.32 10.13
2nd T-C 0.15 0.35 -0.22 0.34 -0.70
β2 EEG -0.47 0.35 0.19 0.34 -2.47
Trt*T-C -1.22 0.33 -0.54 0.33 2.26
Trt*2nd T-C -1.34 0.35 -0.67 0.34 2.00
Trt*EEG -0.64 0.18 -0.73 0.18 0.87
T-C*EEG 0.97 0.36 0.35 0.35 2.77
2nd T-C*EEG 1.57 0.37 1.16 0.37 1.35
-LogLikelihood/n 5.89 5.82
Table 5.5: Cowling model’s fitted values for the full data set versus the data set
without outliers.
value for the reduced data set. For the post-randomization seizure rate, however, the
coefficient estimates remain generally unchanged, except for the treatment covariate
and its interactions. In these cases the coefficients tend to decrease by more than
one third, but notice that the standard errors are of such magnitudes, that these
factors would lose influence in the seizure rate. The cure fraction, on the other
hand, shows generally increased coefficients for the new data set, save for the EEG
outcome covariate. For the EEG the coefficient decreases more than twice. This
decrease and its standard error size dims the EEG factor negligible to the model, in
contrast to its interaction with the treatment effect, in which case this interaction
becomes more influential to the cure rate.
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Full Data Reduced Data Ratio
Coef1 SDs Coef2 SDs Coef1/Coef2
α 2.08 0.11 2.24 0.13 0.927
Intercept -4.53 0.15 -4.54 0.15 1.00
T-C -0.68 0.16 -0.69 0.16 0.99
β1 2nd T-C -0.38 0.16 -0.40 0.16 0.95
EEG 0.56 0.18 0.29 0.18 1.91
Age -0.004 0.001 -0.003 0.001 1.54
T-C*EEG -0.54 0.20 -0.26 0.20 2.03
2nd T-C*EEG -0.34 0.21 -0.15 0.21 2.32
Intercept -1.06 0.38 -0.95 0.36 1.12
Trt 0.39 0.39 0.17 0.38 2.26
T-C 0.57 0.39 0.51 0.38 1.12
2nd T-C 0.55 0.40 0.50 0.39 1.10
β2 EEG 0.59 0.40 0.52 0.40 1.14
Trt*T-C -0.60 0.41 -0.48 0.40 1.23
Trt*2nd T-C -0.89 0.41 -0.55 0.40 1.62
Trt*EEG -0.78 0.26 -0.45 0.25 1.73
T-C*EEG -0.56 0.42 -0.60 0.42 0.94
2nd T-C*EEG -0.44 0.43 -0.31 0.43 1.41
Intercept 0.88 0.50 0.80 0.48 1.09
Trt 0.10 0.50 0.21 0.50 0.47
T-C -0.82 0.51 -0.78 0.49 1.05
2nd T-C -1.06 0.52 -0.99 0.51 1.08
κ1 EEG -0.30 0.52 -0.12 0.52 2.55
Trt*T-C -0.18 0.50 -0.22 0.50 0.81
Trt*2nd T-C -0.11 0.53 -0.31 0.52 0.35
Trt*EEG -0.40 0.30 -0.64 0.28 0.62
T-C*EEG 0.96 0.54 0.86 0.53 1.12
2nd T-C*EEG 1.78 0.57 1.62 0.55 1.10
-LogLikelihood/n 5.72 5.66
Table 5.6: Rogers model’s fitted values for the full data set versus the data set
without outliers.
When observing the standarized log-likelihoods, we observe that there is little
change in the likelihood fits provided by the model under the two data sets. This
assessment is reinforced by the plots in Figure 5.10, where both the QQ-plot and
the contrasts plot show a negligible change between residual estimates. A change so
small in the expected residuals shows that from the four models under consideration,
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Figure 5.9: Cowling model’s Cox-Snell residual contrasts between the data sets with
and without outliers.
Rogers model is the most robust to the data set’s extreme values for covariates such
as number of seizures and seizure rate. We hold in consideration that, although the
omittance of the six outliers naturally benefits Kim and Cox models more clearly
than for Cowling and Rogers models, the residual analysis still shows a significant
departure from assumptions for all models. We must have under consideration,
however, that literature discusses the interpretation of the departure of residuals
from the expected values, and a more thorough study of residual analysis is required.
For this purpose, in the following section we produce survival data simulations and
fit them under two of these models.
5.4 Residual study for negative binomial residuals
In the previous subsections we have presented and showed the residual studies for
the first post-randomization seizure times Y1 under the assumption of four different
models. Let us now consider the pre-randomization seizure count Xi and remember
that, under both the joint model and the joint model with cure fraction, we consider
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Figure 5.10: Rogers model’s Cox-Snell residual contrasts between the data sets with
and without outliers.
the seizure count to be distributed as a negative binomial. We are interested in
observing, on one hand, how do the residuals under this distribution perform, for
instance, in the case of the Cox-Snell residuals against an exponential distribution
with mean one. Secondly, we wish to compare the residual allocation for the seizure
count, in contrast to the residual allocation for the seizure time for each individual,
and observe if they project consistent behaviours.
Let us consider the joint model for the epilepsy data. In the left-side of
Figure 5.11 we show the plot of the Cox-Snell residuals for the seizure counts, along
the horizontal axis, against the respective residuals for the seizure times, along the
vertical axis. The colours denote the type of epilepsy, where red is Tonic-Clonic
only, green is 2nd generalized and blue are partial seizures. The circles denote an
observed seizure time, whilst the triangles denote censored seizure times. In this
plot we observe that the majority of the individuals under observation produce
small residuals under the negative binomial distribution. The residuals for the
same individuals under the Lomax distribution, however, appear to project a more
uniform span for the residuals.
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The difference in the negative binomial survival functions between the joint
and the joint model with cure, lies in the difference between their estimated pre-
randomization parameters α and λi, since the seizure count considered is recorded
pre-randomization. For this reason, the corresponding residual analysis between
the joint and joint model with cure are similar. In the left-side of Figure 5.11 we
present the Exponential Q-Q plot for the ordered Cox-Snell residuals under the joint
model, whilst the right-side of the Figure shows the corresponding residuals under
the joint model with a cure fraction. As we had observed before, it is apparent that
the distribution of the seizure counts diverges from a negative binomial distribution.
There appears to be no specific seizure type pattern along the curve, nor does it
appear to present a censoring particular behaviour. The blue line represents a fitted
line and in these cases we consider the line to have intercept 0 and slope 3.7 for both
models. Observe that 97.45% for the joint model and 97.37% for the model with a
cure fraction of the Cox-Snell residuals follow the pattern of this fitted line, and the
remaining proportion corresponding to the greatest residuals in value digress under
the fitted line. In these cases we observe that the four highest valued residuals do
not correspond to the same individuals signaled as possible outliers by the same
models under the Lomax distribution.
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Figure 5.11: Q-Q plots of residuals under the negative binomial distribution for the
joint and joint (left) with cure fraction (right) models.
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In Figure 5.12 and Figure 5.13 we present the Modified Cox-Snell, Martingale
and Deviance residuals for the joint and joint with cure fraction models respectively.
For both models, when observing the Modified Cox-Snell (top-left) and Martingale
(top-right) residuals, we observe no particular pattern in their layout, and although
there are a few residuals that digress from the center, the majority of the resid-
uals are clustered about zero and unity. In the Deviance residuals (bottom-left)
there is no particular pattern in the index plot, and as seen before for the corre-
sponding Lomax residuals, they do not appear to be centered at zero, but rather,
these index plots show a heavier right tail. The last plot represents the contrast
of the deviance residuals under the Lomax and negative binomial distributions for
the same model, and are shown in the bottom-right side of the respective Figures.
Observe that the left tail of the deviance residuals tend to be similarly categorized
for the count and the seizure times. The right tail of these residuals also tend to
categorize the residuals in a consistent way, except for a lower number of residuals
corresponding majorally to patients with Tonic-Clonic seizures only, or second gen-
eralized seizures, whilst the individuals with partial seizures only tend to be very
consistently categorized for time and seizure counts.
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(d) Contrast of the Deviance residuals for
time versus seizure count
Figure 5.12: Residual plots for the seizure counts under the joint model.
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(d) Contrast of the Deviance residuals for
time versus seizure count
Figure 5.13: Residual plots for the seizure counts under the joint model with a cure
fraction.
Let us remember that the only semi-continuous covariate we can consider is
the age of the patient at randomization. In the previous figures we have shown the
index plots, but the residual layout is in part aimed at finding possible covariate
influences that have not been properly addressed by a model. For this reason in
Figure 5.14 we plot the Deviance residuals of the joint (left side) and the joint
model with cure fraction (right side). In these plots we observe that there is a
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noticeably higher concentration of the residuals for younger patients, particularly
under 30 years of age. Let us remember that the age of the patients at randomization
has a mean of 30 years, ranging from less than a year old to 62 years of age, and that
the ages have been rescaled so that they are centered at 30 years. From these plots
we have an indication that the population of patients under 30 years of age could be
studied and compared to the results from the population who’s age is greater than
30. We address this topic in Section 5.8.
R
es
id
ua
l v
a
lu
es
−2
−1
0
1
2
3
−20 0 20 40 60
censoring2nb
0
1
Seiz.type2nb
1
2
4
R
es
id
ua
l v
a
lu
es
−2
−1
0
1
2
3
−20 0 20 40 60
censoring2nb
0
1
Seiz.type2nb
1
2
4
Figure 5.14: Deviance residuals for seizure counts under the joint (left) and joint
with cure fraction (right) models.
5.5 Residual study of simulated data
There is little guidance in the literature on the use of residuals to examine closely
related models. From the residual analysis shown previously we observe that the Q-
Q plots for the Cox-Snell residuals indicate a certain proportion of well fitted values,
but the patients with later seizures seem to deviate from the model’s assumptions in
each case. In an attempt to understand the interpretation of the obtained residuals,
we proceed to generate a number of sets of simulated data and contrast the fits
shown under Cox’s proportional hazards model, and under Cowling’s model.
In order to model populations with small and large heterogeneity, we pro-
duced two populations of simulated data considering dispersion parameters α1 = 0.5
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and α2 = 4. For each population we consider 15 sub-populations, each one with a
sample size of 1000 individuals. The number of seizures Xi and first seizure time Ti
for each individual i are modeled from a Poisson-gamma mixture distribution. The
conditional seizure number Xi|νi is generated from a Poisson distribution with pa-
rameter νiλiui, where νi ∼ Gamma(α, α) and ui is the period of pre-randomization
observation. Here we set all pre-randomization observation periods to be 182 days,
according to the minimum period considered for the MESS study. For the pre-
randomization seizure rate λ we considered in each sample 500 individuals having
a rate λ1 = 2 and the remaining 500 patients having a rate λ2 = 6. The purpose
of this mixing is to emulate the different rates that could be observed in a popu-
lation of epilepsy patients that have different types of epilepsy syndromes, such as
Tonic-Clonic and Partial seizures. We must consider, in addition, that a patient is
not diagnosed with epilepsy unless he has had at least one seizure, and hence the
number of seizures were zero-truncated, a consideration that we keep in mind for
later generalizations of the model.
The conditional times to first seizures Ti|νi are generated from an exponential
distribution with parameter λiψiνi, where we consider two post-randomization rate
modifiers ψ1 = 0.35 and ψ2 = 0.65. For each of the 15 sub-populations we then
generate seizure times from combining the two values of λ and the two values of
ψ. Finally, for these simulations we produce a censoring mechanism of the times to
first seizures. Since in real survival data we would expect the early-occurrences to
be observed, and have censored observations after a certain threshold of the period,
we select the 40% quantile t(40) of each sample t1, t2, ..., t1000, and for all ti ≥ t(40),
we produce the censored seizure time t∗i from the same distribution the observed
seizure time ti was simulated. Once we obtain these simulated censored times, we
create the final sample of seizure times yi by selecting yi = min{ti, t∗i }.
We now propose to contrast the residual fits between four proportional haz-
ards models and Cowling’s model. Let us denote by Z and W the indicator vectors
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for the values of λ and ψ respectively. We are interested in contrasting residual
analyses provided by considering all the covariate combination possibilities. We will
fit the simulated data to the following models:
Model 1 : h(y) = h0(y) exp(b1z + b2w),
Model 2 : hz(y) = hz0(y) exp(b2w), stratifying by z,
Model 3 : h(y) = h0(y) exp(b1z + b2w + b3log(x)), with x the number of seizures,
Model 4 : hz(y) = hz0(y) exp(b2w + b3log(x)), stratifying by z,
where b1, b2 and b3 are the regression coefficients. Finally we consider Model 5 to
be Cowling’s model, which proposes that X|ν ∼ Poi(λνu) and Y |ν ∼ Exp(λψν),
with λ = exp(b1Z) and ψ = exp(b1Z + b2W ).
Let us remember that for a Cox proportional hazards framework, we assume
that the general form of the hazard function is of the form
h(t) = h0(t) exp(b1z1 + b2z2 + ...+ bpzp),
when considering p predictor variables z1, z2, ..., zp, and where b1, b2, ..., bp are the
regression coefficients. Hence we have that the logarithm of the hazard ratio will
consequently leave us with the linear combination expression
log
(
h(t)
h0(t)
)
= b1z1 + b2z2 + ...+ bpzp,
and when a predictor zi is dichotomous, its corresponding regression coefficient
estimate exp(bˆi) represents the increase of the risk event for the individuals with
zi = 0 over the risk for individuals with zi = 1. In our case, observe that in all four
Cox models, both z and w predictor variables are dichotomous. A direct comparison
to the real values of the predictor variables can be attained by recalling that the
times to first seizures were modeled from an exponential function, which means that
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the hazard function is a constant; more precisely, is the seizure rate. A hazard ratio
for the pre-randomization rate will be, in this case, be given by
hz1=0(y)
hz1=1(y)
=
hλ1(y)
hλ2(y)
=
λ1
λ2
=
2
6
= 0.33.
In a similar way, for the post-randomization seizure rate, we have that the corre-
sponding hazards ratio is of the form
hw1=0(y)
hw1=1(y)
=
hψ1(y)
hψ2(y)
=
ψ1
ψ2
=
0.35
0.65
= 0.54.
In Cox proportional hazards models, the interpretation of the regression coefficients
is such that, if for a predictor zi the corresponding estimated coefficient bˆi is close to
one, then the predictor in question does not affect the survival. If such coefficient,
however, is less than one, the predictor improves the survival, and conversely it
increases the risk when the coefficient is greater than one.
Each of the five models was fitted to the two populations, leaving us with
estimated coefficient values for 15 sub-populations considering α1 and 15 populations
considering α2 to be the underlying heterogeneity rates. We obtain the regression
coefficient estimates bˆ1j , bˆ2j and bˆ3j with j = 1, ..., 15, and which correspond to
the predictors z, w and log(x) respectively, where x is the number of seizures of
the patient. For simplicity, we represented the estimated regression coefficients in
a graphical manner, omitting their corresponding standard errors. The 15 sets of
regression coefficients for the first four models are shown in 5.15, where each boxplot
corresponds to the estimated hazard ratios (exp( ˆbkj), k = 1, 2, 3 and j = 1, ..., 15)
under a specific model. The boxplots are distinguished by color, where Models 1 to
4 are represented by red, green, blue and yellow respectively.
Observe in Figure 5.15 that, although the scales are slightly different for the
boxplots under the two populations, they share the same trends for all four models.
Considering that the original hazard ratios for z and w are 0.33 and 0.54 respectively,
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we observe that the estimated hazard ratio boxplots in general do not cover such
values. In particular, Model 1 shows that the pre-randomization seizure rate has a
greater impact on the risk of future incidences than the post-randomization modifier,
or in other terms, than the treatment effect itself. Observe that for both Figure
5.15a) and Figure 5.15b), Model 2 does not consider the interaction z × w in the
regression, and it produces undistinguishable hazard ratios for the predictor w as
Model 1, suggesting that, independently of the value of λ, the patients with a
ψ1 = 0.35 change in the seizure rate will experience from 1.1 to 1.3 times a higher
risk than those individuals with a ψ2 = 0.65 change in the rate. A similar behaviour
is observed between Models 3 and 4, where the lack stratification with respect to
z in Model 4 produces very similar hazard ratios for the remaining factors w and
log(x). It is worth noticing that the hazard ratios for z for both populations attain
or are very close to a unit value, which suggests that the factor in question has
little or no effect on the incidence risk. Once we consider the number of seizures
per patient, their underlying pre-randomization seizure rate is deemed negligible.
In fact, the logarithm of the number of seizures has a much greater impact on the
seizure recurrence. Indeed, the predictor log(x) has an impact from 2 to 2.5 for
Model 3 and from 2 to 2.4 for Model 4 in the hazard ratio. The main difference
between the populations lies in that the population with a higher heterogeneity
presents a slightly lower dispersion with higher median values for this factor, and
the population with a lower heterogeneity does not show any extreme values. From
the plots we observe that the presence of a larger heterogeneity tends to produce
more concentrated estimates and deems some observations as extreme values.
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Figure 5.15: Box plots for the 15 sets of estimated hazard ratios, under the four
Cox models proposed.
Although in Figure 5.15 the plots seem to indicate very similar regression
fits between the two populations, we are interested in contrasting their respective
fits in terms of their residual analyses. In Figure 5.16 and Figure 5.17 we present
the resulting Cox-Snell residual Q-Q plots for the Cox proportional hazard models,
corresponding to the underlying value of α1 and α2 respectively. Each of the 15 sub-
populations is indicated by a different colour, where circles and triangles correspond
to observed and censored seizure times respectively.
From the previous boxplots we observed that the estimated hazard ratios for
the first four models do not resemble the true hazard ratios from which the data set
was produced. This same lack of fit is observed in the residual analyses shown in
Figure 5.16. Although the early seizure time residuals are well fitted, the rest of the
residuals quickly diverge from their expected values in a linear form. Indeed, the
observed residual values tend to be half of the expected values, underestimating the
true expected seizure times. The large heterogeneity seems to discriminate better
which regression coefficients the Cox model will estimate, and this in turn produces
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very similar residual sub-populations within the models. In fact, we only observe
some dispersion between the sub-population residuals for approximately the last 5%
of late occurrences. Observe that the observed residuals tend to lie within the same
range of values for the four models, and there appears to be no substantial difference
in the behaviour of residual sub-populations between models, which suggests that
the residual analyses deem all four models to be inadequate in very similar ways for
this population.
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Figure 5.16: Q-Q plots of the Cox-Snell residuals for proportional hazards models.
α = 0.5 is the underlying heterogeneity rate.
When considering a smaller heterogeneity in the population, the residual fits
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confirm once again the slightly greater dispersion of estimates that was observed in
the boxplot figures. In the same way we observed for the population with underlying
α1, the population with α2 shown in Figure 5.17 produces well fitted residuals
under the Cox models, but only for the very early seizure incidences. Later on the
sub-population residuals present a greater sparcity than that observed for largely
heterogeneous populations. Notice that for the population under α2 the observed
residual values range within a smaller interval than those observed in Figure 5.16,
which shows a steeper departure from the expected residual values. In this case the
sub-population residuals underestimate the expected values in a less linear form,
tending to an exponential shape as it is more clearly observed for Models 2 and 4,
which happen to be the models stratified by z. This provides an insight that the
inclusion of the z factor in the Cox model provides a slightly better fit for this kind
of population, as opposed to omitting it. However, as it was noticed before, the
Cox proportional hazards model provides a poor fit for this kind of data. What is
interesting is that the joint models do show, for the two populations considered, a
very similar behaviour as the one observed for the Kim and Cox models considered
for the MESS data set. Let us remember that the Q-Q plots observed in Figure 5.1
fitted well the early seizure times, and then underestimated the expected values in
a linear form. This in principle might signal that Cox proportional hazards model
fits the data in a very similar way that it fits for the MESS data set, and that hence
the simulated and MESS data sets are very similar in nature, or perhaps that there
are other underlying features of the data that the model is not accounting for.
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Figure 5.17: Q-Q plots of the Cox-Snell residuals for proportional hazards models.
α = 4 is the underlying heterogeneity rate.
In an attempt to investigate further the nature of the residual analysis, we
proceed to fit another model to this simulated data. We now fit Cowling’s model,
and since the simulations were designed much in the same framework that Cowling’s
model assumes, we expect the estimated likelihood coefficients to be very similar to
the original coefficients used. Once again we fit the model for both populations with
underlying values of α1 and α2. For each sub-population within the heterogeneity
group we obtain numerically the estimates for the parameters α, λ and ψ, and we
display them in a graphical form by means of plotting the boxplots of their respective
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biases. In Figure 5.18a) we show the bias corresponding to α1 − αˆ1 in green, and
the bias α2 − αˆ2 in yellow. Although the values for both cases are clearly centered
at zero, the presence of a higher heterogeneity appears to produce a much better
identification of the true value of α for this model, as shown by the difference in
dispersion for the boxplots in the figure. This property takes the converse order,
however, when measuring the bias between the true and the estimated values of
λ1 and λ2 under the two underlying values of α. Observe in Figure 5.18b) the
corresponding biases of λi|αj− λˆi|αj for i, j = 1, 2. It is apparent that, although the
higher the level of heterogeneity makes it easier for the model to estimate α, it also
causes that with a large heterogeneity there are numerous types of pre-randomization
rates in the population, making their estimation increasingly variable, although still
taking values in the vicinity of the true value of the parameter. Observe that even
when the dispersions of the boxplots vary, the medians are always close to zero.
For the last parameter ψ, the biases of the form ψk|αj , λi − ψˆk|αj , λi for k = 1, 2,
are shown in Figure 5.18c). Notice that the biases corresponding to the underlying
parameter α2 tend to deviate slightly more from zero than those corresponding to
α1, the scale is sufficiently small to believe that the model estimates the true value
of the seizure rate modifier ψ with good accuracy. Within those small differences,
it is noticeable that a smaller rate modifier ψ1 = 0.35 is in general more identifiable
to the model than the larger rate modifier ψ2 = 0.65.
After obtaining small biases of the three parameters of interest, we would
expect the residual study to reflect an acceptable goodness of fit of the model to
the data set. In Figure 5.19 we show the Q-Q plots of the Cox-Snell residuals
corresponding to Cowling’s model. Observe that for both populations, the observed
Cox-Snell residuals substantially fit their expected values, showing some dispersion
for the late seizure times that does not diverge greatly from the center. Although
the sub-population residuals shown in Figure 5.19a) tend to be slightly less variable
from early seizures than those shown in Figure 5.19b), we notice that their deviance
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Figure 5.18: Box plots of the estimates’ bias, for the three parameters of interest,
when Cowling’s model is fitted.
residuals, shown in Figure 5.20a), are scattered around −1, suggesting a deviation
from the model of the same magnitude. When considering α2, however, we have
that although the Q-Q plot shows a slighter trend to underestimate than their
counterparts for α1, their corresponding deviance residuals, shown in Figure 5.20b),
are centered around 0 and therefore suggest no significant deviation from the true
model. Let us remember that, when fitting Cowling and Rogers models to the MESS
data set, the estimated heterogeneity rate was found to be α = 1.99 and α = 2.08 for
each of the respective models. This would suggest a homogeneity closer in behavior
to the one assumed for the second sub-population of the simulations. Indeed, if we
observe the Q-Q plots for the Cox-Snell residuals obtained in Figure 5.1 for Cowling’s
model, they appear to resemble the patterns produced in the corresponding Q-Q
plots for the sub-populations in Figure 5.19b). The underestimation of the model
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to the true seizure times may be an indication of a further covariate with influence
that remains unaccounted for in the model, or even the indication that further
modifications to the model are needed.
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Figure 5.19: Q-Q plots of the Cox-Snell residuals for Cowling’s model, the first graph
corresponds to the population with α1 and the second graph to the population with
α2.
5.6 Simulation studies for the zero-truncated joint model
In the following figures we observe a series of box-plots for the zero-truncated joint
model under a simulation study. Let us recall that α1 = 0.5 and α2 = 4, hence
the first value of α represents a high heterogeneity in the population, in contrast
to the second value in which a smaller heterogeneity is assumed. We contrast the
results predicted by the joint model always represented to the left of the figures, and
the results presented by the truncated joint distribution, always shown at the right
side of the figures. In order to keep the consistency with previous models under
simulation, here we have 15 simulation runs for each value of the frailty term, with
1500 simulated values of pre-randomization counts and post-randomization times,
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Figure 5.20: Plots of the deviance residuals for Cowling’s model, the first graph
corresponds to the population with α1 = 0.5 and the second graph to the population
with α2 = 4.
under a Poisson-gamma mixture model.
The first great contrast between the findings is the observed bias for the
estimates of α, shown in Figure 5.21, is that for the joint model the estimation bias
lies around zero, with particularly narrow values for α1, which is well represented
for the truncated model as well. Meanwhile, when heterogeneity is small in the
population, the estimation bias for the joint model is much larger, but for the
truncated joint model the estimations are concentrated a unity of distance away.
This might be one of the causes of why, even when the joint truncated model fits
the estimates for λ1|α2 and λ2|α2 particularly well (Figure 5.22, to the right), the
estimates for all values of ψ under α2 deviate from the true value progressively
(Figure 5.23), which also tends to happen for the values of ψ under α2 in the joint
model, but not so strongly.
In general, for the cases when the heterogeneity is high, both the joint model
and the truncated joint model seem to fit well for α, λ and ψ.
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Figure 5.24: Box-plots for the biases between the expected and the estimated values
of α, λ and ψ.
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As an attempt to understand the behavior of the truncated joint model when
the heterogeneity of the population varies, we have performed a simulation study in
which we only estimate the values of α. We proceed by simulating the occurrences
of 1500 individuals as before, with the same values of α1, α2, λ1, λ2, ψ1 and ψ2.
The difference lies in how we fit the truncated model. Instead of using a particular
initial value α0 of α for the process of optimization of the log-likelihood, we provide
a series of 9 initial values of α1 ranging from 0.1 to 1, and nine initial values for
the estimation of α2 ranging from 0.1 to 7. In Figure 5.25(a) we observe that,
when the heterogeneity is high in the population, the truncated joint model tends
to fit well for α even when the initial value is understated. For the case when the
initial value is too small, the model concentrates the estimate either very close to
the original value, or quite far away, as observed for the case in which α0 = 0.1. The
bias however increases noticeably as the initial value surpasses the true value of the
frailty term.
For the case when the original value of α is larger, depicted in Figure 5.25(b),
we observe that the closest values of the parameter estimates are obtained, again,
when the initial value is smaller than the actual value of the parameter. The general
behavior of the estimates tend to be more erratic around the true value, but the
same increasing trend of the bias is observed when the initial value surpasses the
true value of α.
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Figure 5.25: Estimation bias for simulated data under assumption of α = 0.5 and
α = 4 respectively, when fitting a zero-truncated model with initial values for α
shown in the horizontal axis.
We conclude by this simulation study that the joint truncated model tends
to identify better the value of the frailty term when the heterogeneity in the pop-
ulation is large, and that the initial value provided for the optimization is of great
consequence for the estimations.
5.7 Discussion of the residual analysis
In this chapter we were interested in performing a model checking study for four
proposed models in epilepsy data. Our aim was to investigate the goodness of fit
of the commonly used Cox proportional hazards survival model, along with two
previously proposed accelerated-life survival models. For this purpose we selected
Kim’s model, which is a Cox model previously proposed by Kim et al [27] for the
MESS data set, and another Cox model which considered not Kim’s covariates,
but Roger’s covariates ([41]). Two accelerated-life models were considered from the
works by Cowling [11] in his PhD thesis, and Rogers [39]. The first approach to
study their goodness of fit to the MESS study was to introduce the theory and
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methodology of residual data analysis. It was observed that, although the models
did not appear to fit the data set well under the current assumptions, the residual
plots provided insight on the outliers and extreme values found by the four models.
Only Cox and Kim’s models detected six outliers as such, and we refitted the four
models taking out the information of such patients in order to study the difference in
the model fits. Since we are not convinced the extreme values found by Cowling and
Rogers models can yet be defined as outliers, we did not exclude the corresponding
patients from the second study of the data set.
When adjusting the models to the reduced data set, we did find that Cox and
Kim’s models fits were improved to a certain degree, as would be expected. Cowling
and Rogers models, however, improved only slightly and from the residual studies
we observe that the models do not seem to fit the data very differently between
the full and reduced data sets. Although this gives us signs that Rogers model in
particular shows a greater stability over extreme values, the reduced data set did
produce enough changes in the likelihood estimates to suggest that a simpler version
of Cowling and Rogers models could be proposed, obviating some to the covariates
considered previously. As expected, when six of the higher valued residuals were
taken out, both of the latter models produced higher α estimates, suggesting a
higher homogeneity in the data.
Some literature on residual analysis, particularly Collett [7], mention that
there is little guidance as to how will the residual plots look like when the right
model has been assumed for a data set. Given that in our previous studies we
have observed four models being shown as inappropriate to the epilepsy data under
study, we were interested in observing how would the plots change once we were
certain of the right outcome. For this reason we simulated survival data consisting
of exponentially distributed incidence times, and the number of incidences pre-
randomization to be modeled by a Poisson distribution, which is almost the exact
framework assumed for Cowling’s model. The Cox model is deemed inappropriate
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for this kind of data, and Cowling’s model produces residual plots that demonstrate
a much better goodness of fit. Observe that for these simulations we considered zero-
truncated number of seizures, a fact that has not yet been taken into account for both
Cowling and Rogers models. This is a natural generalization that we are interested
in developing for further study, and it is currently under development. A second
residual study that could be of interest but is not developed here, would consist of
producing a series of simulations emulating the epilepsy seizure numbers and times
as previously done, but additionally considering a cure fraction as Rogers’ model
assumes. It would be of interest to observe how would Cowling’s model perform
under this change for the residual analysis.
5.8 Lomax survival function and Kaplan-Meier curves
From the residual analysis methodology we have been able to observe and discuss
several traits from the four survival models under consideration. The conclusions
under such analysis, however, do not always point towards what might be the prob-
lem behind a residual plot with an apparent bad fit, and for this reason, we consider
an alternative approach. Consider the joint and joint with cure fraction models;
considering a relevant set of covariates (such as age, EEG outcome and type of
epilepsy) we can obtain the corresponding covariate estimates for the seizure rate
λi, the post-randomization seizure rate modifier ψi and the cure rate pi for each
individual i. Considering these covariates, we can find the corresponding survival
function for the Lomax distribution, and compare its survival prediction under the
models’ fit for the MESS data, and contrast it to the observed Kaplan-Meier curves.
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Figure 5.26: Kaplan-Meier curves for patients less than 30 years old, contrasted to
survival functions from joint and joint with cure fraction models. The black line
shows the Kaplan-Meier curve, the red and blue curves correspond to the survival
curves corresponding to the joint and joint with cure fraction respectively. The
purple line denotes the estimated cure fraction value.
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Figure 5.27: Kaplan-Meier curves for patients older than 30, contrasted to survival
functions from joint and joint with cure fraction models. The black line shows
the Kaplan-Meier curve, the red and blue curves correspond to the survival curves
corresponding to the joint and joint with cure fraction respectively. The purple line
denotes the estimated cure fraction value.
For the sets of plots in Figure 5.26 and Figure 5.27, we show the correspond-
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ing contrasts for the population of patients younger and older than 30 years old,
respectively. For each plot, we have partitioned the data for the combinations of
presenting an EEG abnormality or not and the type of epilepsy. The Kaplan-Meier
curve, shown in black, corresponds to the partition mentioned in the title. The red
curve corresponds to the Lomax survival curve under the estimated parameters for
that subpopulation, and similarly the blue curve corresponds to the joint model with
a cure fraction, which is the estimated proportion of the population that experiences
remission and is signaled by the purple line.
We observe that under these survival function predictions, the joint model
tends to overestimate the survival of individuals showing an abnormal EEG, regard-
less of their age group. Although the joint model with cure fraction also tends to
overestimate the survival curve for patients younger than 30 years old and presenting
abnormal EEG outcomes, compared to the joint model it overestimates the survival
curve in a lesser measure, and the steep descent for early seizures provides a more
desirable fit. Observe that the predicted curves correspond to a mean age for each
respective age group, and that the corresponding age quartiles for this model are
plausible to contain the observed Kaplan-Meier curves.
For the case of patients younger than 30 years old and presenting a nor-
mal EEG outcome, the joint model survival function approaches the Kaplan-Meier
curve in a much better way, although the early seizure steep descent is always over-
estimated by the model. Precisely in these cases is that the joint model with a
cure fraction approaches the observed survival curves, specially for the Tonic-Clonic
seizures only, almost accurately. This level of a good fit is observed again for the
joint model with cure fraction for patients older than 30 years old and with normal
EEG. In these cases the model lies close to the observed survival curve, whilst the
corresponding predicted survival function for the joint model consistently underes-
timates the Kaplan-Meier curves. A particular case in which the joint model with
cure fraction appears to overestimate the observed survival curve is when patients
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are older than 30 years old, present an abnormal EEG and second generalized Tonic-
Clonic seizures. For this case, it would be of particular interest to plot the respective
predicted survival curves under the upper and lower quartiles of the age group.
For the following Figure 5.28 and Figure 5.29 the contrasts of survival func-
tion predictions are shown for the population randomized to delayed or immediate
treatment respectively. As shown before, in these plots we partition the epilepsy
data for the combinations of EEG outcome and epilepsy type. Note that in these
cases the data is not partitioned by age at randomization.
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Figure 5.28: Kaplan-Meier curves for patients randomized to delayed treatment,
contrasted to survival functions from joint and joint with cure fraction models.
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Figure 5.29: Kaplan-Meier curves for patients randomized to immediate treatment,
contrasted to survival functions from joint and joint with cure fraction models.
In contrast to the plots in which the populations are partitioned by age at
randomization, when we partition according to the treatment allocation the joint
model tends to over and under estimate the Kaplan-Meier curve in a smaller mea-
160
sure. Indeed both models seem to fit the population survival better, except particu-
larly in the cases in which patients are randomized to delayed treatment, present an
abnormal EEG and second generalized tonic-clonic seizures or tonic-clonic seizures
only. In this case the joint model predicts a much steeper descent of the survival
curve, and even the joint model with the cure fraction overestimates the hazard
in the population, since the model estimates a much lower proportion of patients
attaining remission than the actual number of patients not presenting a seizure
post-randomization. This overestimation of the hazard in the population is ob-
served again for both models, but in a more controlled manner, when the patients
present abnormal EEG and second generalized tonic-clonic seizures, but have been
randomized to immediate treatment. From these plots we observe that the discrep-
ancies between observed and predicted survival curves seem to be due to the lack
of fit of the cure fraction estimate. Possible remedies could be found by finding the
covariates that are most descriptive of the proportion of patients who do not expe-
rience a seizure post-randomization, and will be considered as part of the further
work.
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Chapter 6
Conclusions and Discussion
Usually medical epilepsy studies include baseline data of the patients, comprising
the patient’s history previous to the treatment. Either for convenience or because
of familiarity, Cox’s proportional hazards models tend to be commonly used for
medical recurrence data, which usually considers the patient’s historical additional
information as a fixed covariate. It has been argued that these models tend to pro-
vide a deficient fit to medical recurrence data, and for the case of epilepsy specially.
In Kwong & Hutton[30], whilst investigating the proportionality of parameters un-
der model misspecification (as proposed by Hutton & Solomon[25]) for two data
sets, found that for the epilepsy data, this condition does not hold even when the
regression coefficients are assumed small. The AIC measure for the models they
considered showed that the accelerated life models fitted the data better than the
proportional hazards model. Indeed, the AIC statistic indicated a better fit un-
der the log-normal, log-logistic and gamma distributions, whilst the Weibull, being
both a proportional hazards and an accelerated life model distribution provided the
worse fit. The reason the results from Hutton & Solomon do not seem to follow
is due to the high skewness of the hazard function, for which the center of density
concentrates near zero. In our case, the MESS epilepsy data also shows from the
Kaplan Meier curves a high hazard skewness due to a large number of early seizures.
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This observation and the result from Hutton & Monaghan[24], which showed that
accelerated life models are more robust under misspecification, suggest that, as in
Kwong & Hutton, we consider an accelerated life model instead of a proportional
hazards model.
Previous studies have proposed a more informative model for recurrent events
such as epilepsy seizures. The Poisson distribution has been proposed to account
for the overdispersion in the data (Hougaard et al.[23]), joint models have been
developed to account for the pre-randomization and post-randomization recurrence
counts (Marshall & Olkin[34]), and bivariate semi-parametric models have been
presented in an attempt to account for the recurrent event times and counts jointly
(Cook & Wei[9]). In the works by Cowling[10] and Rogers[39] these concepts have
been employed in the form of a Poisson-Gamma mixture model, where the seizure
recurrences can be thought to have an underlying point process to describe the fail-
ure recurrence. Indeed, the model assumes that, conditional on a gamma distributed
frailty term, the epileptic seizures can be modelled as a Poisson distributed number
of occurrences, in exponentially distributed recurrence times. Since the underlying
seizure rate is assumed to be the same for both the Poisson and exponential dis-
tributions, these models propose a joint model which links the seizure counts and
times jointly, but estimates a post-randomization effect that is assumed to have a
multiplicative effect on the seizure recurrence rate. One important improvement
from previous models consists in considering an individual seizure rate for each pa-
tient, and an individual treatment effect on such a rate. This assumption allows
the model to account for a more informative prognosis for each patient, and a more
detailed prognosis for the population by considering the variation between individu-
als. From the Kaplan-Meier curves shown in Chapter 3 (Figures 3.1 and 3.2) it has
been observed that there is a substantial proportion of the population that, after
randomization, do not experience another seizure. This phenomena is included in
the model by Rogers by proposing a cure fraction of the population, such that a set
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of covariates is assumed to have a logistic relationship to the proportion of patients
who do not present a new seizure from randomization.
In this thesis we study the contrast between the commonly accepted Cox
proportional hazards models and the models proposed by Cowling and Rogers, de-
nominated here as the joint and joint with cure fraction models respectively. The
Cox models were presented under two covariate sets, mainly the covariates used
in the paper by Kim et al.[27] (neurological disorder, EEG outcome and the log-
arithm of the number of seizures pre-randomization), and the covariates used for
the Cowling and Rogers models (age at randomization, epilepsy type, treatment
allocation, EEG outcome and interactions). A comparison between their coefficient
parameter estimates (Tables 3.4 and 3.5) show that, under Kim et al.’s original
set of covariates, all factors appear to be significant under the Cox and the Rogers
models, whilst for the Cowling model the neurological disorder outcome is only sig-
nificant for the pre-randomization seizure rate. The joint model with a cure fraction
shows an improvement of the fit from its larger log-likelihood value, but due to the
scarce amount of information of the neurological disorder covariate for this epilepsy
study, we propose a second set of covariates which does not include it. Under this
new set of covariates we compare the joint models with the Cox model, shown in
Table 3.6, and we find that a significant difference between their predictions lies
in the relevance of the seizure type. Whilst the joint models show that the two
types of epilepsy have a relevant contribution to the seizure rates, consistently for
pre and post-randomization rates, whilst in contrast, the Cox model only consider
their interactions with the treatment allocation and the EEG outcome to be of no
significance. The EEG outcome factor contributes a significant change only under
the joint model with a cure fraction, but the EEG interaction with the 2nd. tonic-
clonic seizure provides a non-significant contribution only for this same model. The
number of seizures pre-randomization is a very relevant covariate for the Cox model,
whilst the estimated value of κ translates to 50.10% of the population not experienc-
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ing a seizure post-randomization. The difference between log-likelihoods between
the two joint models shows an improvement of the model fit for the data under the
assumption of the existence of a cure fraction of the population.
6.1 Summary of Thesis
In this thesis we contrast the goodness of fit of models that have been proposed in
the survival analysis framework, producing an extensive residual analysis for pro-
portional and accelerated life models for epilepsy data. This thesis proceeds to
propose a number of models which consider a joint distribution for the number of
seizure counts as well as the first time of occurrence post-randomization, consider-
ing a gamma distributed mixture distribution to account for overdispersion, and a
zero-truncation to account for the known fact that patients must have at least two
unprovoked seizures to be diagnosed with epilepsy. An alternative model studies
the effect of the overdispersion parameter α depending on covariates, and suggests
that for further work it is desirable to implement this covariate dependent frailty
term for the zero-truncated model.
In Chapter 2 we describe the epilepsy fundamental medical definitions, as
well as the nature of the object of our study, the MESS data set. We provide a
brief introduction to likelihood estimation and finally, to survival analysis theory
for censored data. In Chapter 3 presents an extensive discussion of previous models
proposed for medical recurrent events, guiding the reader chronologically from semi-
parametrical univariate models, to the models which constitute our initial interest of
study. We discuss the reasons that lead us to contrast proportional hazards models
to accelerated life models.
In Chapter 4 we propose three models for recurrent events, particularly those
in which the patient is known to have experienced the event of interest at least once
in the past. These models consider a joint distribution where the number of oc-
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currences before randomization are considered to be conditionally distributed as a
Poisson with intensity λ for each patient, and the post-randomization seizures are
assumed to follow an exponential distribution, conditional on a gamma distribution
as the mixture frailty term to account for the overdispersion in the population. The
case in which the zero-truncated model considers a fraction of the population to be
seizure-free post-randomization is still under work, but the joint distribution, the
likelihood and its respective derivatives are shown here. A final model is proposed
which generalizes a Poisson-Gamma mixture model, by considering the gamma pa-
rameter α to depend on covariates. This generalization is shown to perform better
than the original model, according to the difference between their log-likelihood
values.
Finally in Chapter 5 we contrast the performance of four models for the
MESS epilepsy data. These four models have been proposed before in the papers
by Marson et al.[35], Kim et al.[27], Cowling et al.[11],[10] and Rogers et al.[41],[39].
The residual analysis showed that Cox models do not fit well the patients in the
data, except for those producing low-valued residuals. The identification of outliers
is discernable however, which contrasts from the joint models, where the existence
of outliers is not clear. The joint models’ fits also present a departure from the
data observations, in different ways. The joint model proposed by Cowling et al.
produces overestimated residuals, but the pattern is consistent along an alternative
re-scaled line. The model proposed by Rogers et al. seems to fit well more than half
the population, but the remaining residuals deviate from the equality line, showing
a pattern that could possibly be due to a missing covariate from the analysis.
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6.2 Truncated and Covariate-Dependent Frailty Term
Model Conclusions
Aiming to propose a more accurate model for epilepsy, where the patient is recorded
to have at least one seizure, we presented and implemented the zero-truncated joint
model. When fitted to the MESS epilepsy data, the truncated model provides a
larger log-likelihood value than the joint and the joint with cure fraction models.
Judging by the model fits to the partitioned data by epilepsy type, we find that
the truncated model performs best for the population of patients with Tonic-Clonic
seizures only, with the worst performance being provided for the patients with partial
seizures only, in which the estimated heterogeneity in the population is greater.
From this it would appear that the truncated model performs better when the
population is homogeneous, but this is likely to be more a correlation between
the covariates, given that we know that patients with partial seizures are more
heterogeneous in symptom and seizure frequency than patients with generalized
seizures. An indication of such correlation between parameters is given by the box-
plots in Figure 5.18, where subject to simulation, we observe that the estimates of
λ and ψ are more or less biased, depending on the value of α.
The zero truncated model does not consider patients with no seizures pre-
randomization, and hence concentrates its mass towards positive values and con-
siders a lower heterogeneity between the individuals in the study. The value of the
frailty term parameter, α, is estimated to be five times larger under the truncated
model compared to the joint and joint with cure models, predicting a much larger
homogeneity in the population. Another important difference between the models
resides in the fact that the age of the patients at randomization becomes significant
only under the truncated model, for patients with generalized and second general-
ized seizures, as can be observed in the table for the partitioned data according to
epilepsy type. For patients with partial seizures only, however, the age covariate
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becomes nonsignificant for this model.
From the model considering the overdispersion parameter as dependent on
covariates, we observe a consistent estimation of the homogeneity prediction with
the corresponding predictions given by the zero-truncated model. When considering
α as dependent on the type of epilepsy, the patients with partial and Tonic-Clonic
seizures only are deemed to have the highest and the lowest heterogeneity estimates
respectively. When α is considered to be dependent on the EEG outcome, the model
reflects the known similarities and dissimilarities between patients with different
EEG outcomes, i.e. that the patients with a normal EEG will be more homogeneous
than those who have an abnormal EEG outcome. For both α covariate dependencies
we find that the pre-randomization covariate estimates do not present a significant
change from Cowling’s model. For the post-randomization covariate estimates, the
important differences are observed for the EEG outcome, where its pure effect is
deemed negligible compared to the standard deviation size. The EEG’s interactions
with treatment and the second generalized Tonic-Clonic seizures remain significant,
as opposed to the EEG and Tonic-Clonic interaction which remains non statistically
significant.
The zero-truncated model with cure fraction presents no significant prognos-
tic difference from the truncated model without the cure fraction. Furthermore, it
suggests the worst fit to the MESS data among the joint models under consideration,
when compared by log-likelihood value. However, due to the nature of some quo-
tients in the likelihood and the derivatives, the values of the log-likelihood function
tend to be greatly affected by the high number of seizure counts for some of the pa-
tients. Indeed, when the five patients with the largest number of pre-randomization
counts are omitted from the analysis, the estimated level of homogeneity in the
population, indicated by the values of α decreases, since α in turn decreases from
7.997 to 7.441 and the log-likelihood value increases from −8020.696 to −7955.125.
Further investigation of the model’s behaviour is left as a future work, from the
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observation of its parameter relationships between one another and possible future
residual analysis.
6.3 Goodness of Fit Conclusions
The Kaplan-Meier survival curves for the MESS data set (Figures 3.1 and 3.2) show
the first, second and fifth seizure occurrences for the population. The progression
of the survival curves either stratified by drug or by treatment allocation cast a
reasonable doubt about the assumption of a Cox models as the underlying recurrence
model, since the proportionality assumption does not seem to hold between the
subpopulation hazards. In an attempt to understand better the fit performance
between the Cox and the joint models proposed by B. Cowling and J. Rogers, we
provide a brief introduction to residual analysis and proceed to obtain four types of
residuals of the data under two Cox models and Cowling’s and Rogers’ models.
The Cox-Snell residuals plotted in the exponential Q-Q plots show that the
joint model does not fit the data accurately, but rather, that the obtained residuals
from the model are overestimating the exponential residuals by a factor of two, but
otherwise the residuals follow this trend consistently and therefore the reason for
this overestimation would be a natural object of study for this model. Furthermore,
there is no evidence that the censoring nor the type of epileptic seizure produce a
trend in these residual plots. Contrasting with the consistent trend of the residuals
for the joint model we obtain the exponential Q-Q plots for the two Cox models
and the joint model with a cure fraction, where we observe that for all these cases
the models fit well different proportions of patients with early seizures, and then
diverge into an overestimating trend of a factor of three for the Cox models, and
for the joint model with cure fraction, with a sinusoidal ascending pattern. Both
Cox model’s Cox-Snell residuals present a very clear departure from the identity
line, which we expected to observe due to the lack of proportionality of the hazard
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functions observed in the Kaplan-Meier plots, and from the limitation of the model
to use the seizure count as a variable. We are more interested in discerning the
reason behind the residuals behavior observed under the joint models proposed by
Cowling and Rogers.
For the Cox models there are a four individuals that we consider as outliers
and take out of the study. The resulting new Cox-Snell residuals show a slightly
less overestimated fit of the Cox models, which gives evidence that the omittance
of high-valued times to seizure results in a better fit of the Cox models. This same
overestimation decrease is observed in the residual Q-Q plots for the joint models
proposed by Cowling and Rogers when omitting the four patients with the greatest
residual values in the population. In the case of the joint models, the patients cor-
responding to these highest-valued residuals present remarkably high seizure times,
they are all young adult females allocated to immediate treatment, present abnormal
EEG, few pre-randomization seizures and second generalized tonic-clonic seizures.
In the model we have accounted for all these covariates, and in the model fit for the
population omitting these patients we observe no significant change in the underly-
ing seizure rate λi or the homogeneity rate α, but in the post-randomization rate
modifier ψi. Since some of the covariates such as the Tonic-Clonic seizure only and
interactions decrease in significance, a model with a reduced number of covariates
could be an improvement for the model fit. From these patients, three of them be-
long to the same clinical centre, a covariate we have not yet considered for the study,
since we need a deeper analysis of the relationship and possible correlation between
the seizure time reported and the clinical centre. Because of time constraints, we
have not performed a correction measure for this covariate correlations, but remains
as a desirable project for future work.
From the martingale and deviance residuals we find that there is no noticeable
trend due to epilepsy type or treatment allocation, and support the outlier findings
observed in the Cox-Snell residuals for the Cox models. From the various residual
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plots, particularly when plotting against the age at randomization, we observe that
only the joint model considering a cure fraction shows the existence of trends of
residuals, although not corresponding to the age covariate. We observe that the
residuals seem to group around four lines or levels, which seem to correspond to
the levels observed in the exponential Q-Q plot. This behavior could be due to a
covariate that is not being considered in the model, and that with the existence of
the cure fraction becomes relevant. However, the lack of information about how a
residual plot would look like when the model fit is good, we performed a residual
analysis under simulated data. We simulated a Poisson process with different com-
binations of parameters, and from the residual plots concluded that under the Cox
models, the exponential Q-Q plots do resemble the corresponding plots under the
MESS epilepsy data. Under the joint model, however, the exponential Q-Q plots
show that the residuals accumulate around the identity line, and the boxplots of the
estimates’ bias show that the biases are small for all three parameters of interest,
where the larger the heterogeneity in the population, the more accurate is the model
in estimating α and ψi, and the less accurate it is in estimating λi.
As an alternative goodness of fit analysis, we produce plots contrasting the
Kaplan-Meier curves against the survival functions predicted from the Lomax and
Lomax with cure fraction models, which correspond to the Cowling and Rogers
models respectively. These plots under several subpopulations show that for patients
under 30 years of age and presenting a normal EEG, the Lomax survival function
approximates the Kaplan-Meier curve, whilst for the remaining cases it either over or
underestimates the survival of the population. When introducing the cure fraction
the Lomax survival function approaches the observed survival of the population
much more accurately, dependent, however, in the ability of the Rogers model to
estimate the cure fraction in the population. Both age at randomization and the
combination of EEG outcome and epilepsy type appear to be significant covariates
that should be considered for the cure fraction. These plots provide evidence that
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the inclusion of the cure fraction in a Lomax distribution provides a good model fit
for the seizure recurrence times.
6.4 Future Work
From the residual analysis we observed that the joint model which considers the
frailty term as dependent on the epilepsy type controls the behavior of the residuals,
it is of particular interest to analyze further this model under a more clinically
selected set of covariates, as well as implement a joint model with a cure fraction
with a covariate dependent frailty term. We would expect that by considering a
model where both the frailty term and the cure fraction are estimated through a
set of covariates will provide a more accurate fit of predicted survival curves, when
contrasted to the Kaplan-Meier curves. From Figures 5.26 through 5.29 there is
evidence that covariates such as age at randomization, EEG outcome and epilepsy
type are particularly significant for the cure fraction.
Since the residual analysis was carried out before the zero-truncated models
were developed, it is of special interest to implement the goodness of fit analyses
presented in Chapter 5 for this model. In order to obtain the survival function
we will need to approximate numerically the cumulative distribution of the zero-
truncated function. This may be done by finding the integral of the density function
numerically, or by considering the intractable integral in the expression (4.7) as the
−1 moment of a Lomax distribution.
Here we have presented three joint models that derived from the models by
Cowling and Rogers, and we aim as a part of possible future work, to contrast these
models to a competing-risks survival analysis, in which seizure occurrence, death,
drop-out and remission, could be considered as the risks of interest and competing
with each other.
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Appendix A
Parameter Orthogonalization
The importance of parameter orthogonalization, and the means to obtain orthog-
onality, were developed and discussed in the paper by Cox & Reid[12], in 1987.
The main goal of this paper is to address parametric probability models, which in
turn are in term of a set of parameters θ, consisting of a subset of parameters of
interest θ1, and a subset of nuisance parameters θ2. Although it is mentioned that
both sets of parameters could be orthogonalized from each other, the paper focuses
in the direct problem when θ1 is a scalar, and θ2 is the set of remaining nuisance
parameters.
Previously, the maximum likelihood estimator (MLE) θˆ2 of θ2 is used in the
profile likelihood, causing then that such profile likelihood becomes a function only
of θ1, as desired. The difficulty with this method lies in the fact that, when the
number of nuisance parameters is high, the estimators obtained can be inefficient
or even inconsistent. For this and severeal other reasons mentioned later on, Cox
& Reid (1986) proposed using the conditional likelihood function, given the MLE
of the orthogonalized parameters, θ2. Let us then consider the following notation:
let y be a n × 1 vector of observations from a random variable Y , which has a pdf
fY (y; θ) , and where θ is a 1×p vector of unknown parameters. Then, let L(θ; y) and
l(θ; y) denote the Maximum likelihood function and the log-likelihood function of θ
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respectively. From this notation, we can now proceed to the following definition.
If θ = (θ1, θ2) where θ1 and θ2 partition θ, and iθiθj corresponds to the ij
th
entry of the information matrix, then we define θ1 to be orthogonal to θ2 if
iθsθt =
1
n
E
[
dl(θ; y)
dθs
dl(θ; y)
dθt
; θ
]
=
1
n
E
[
−d
2l(θ; y)
dθsdθt
; θ
]
= 0
for all θs ∈ θ1 and for all θt ∈ θ2.
This definition can be extended to the case where more than two sets of
parameters are orthogonal.
Some interesting properties inherent to orthogonality are that, if we suppose
that θ = (ψ, λ) and ψ and λ are orthogonal, then:
1. if ψˆ and λˆ are the Maximum likelihood estimators of ψ and λ respectively,
then they are asymptotically independent.
2. the asymptotic standard error of ψ is equal independently of either λ′s value
being known or unknown.
3. there might be some simplifications in the numerical calculation of (ψˆ, λˆ).
4. if we denote by ψˆλ = ψˆ(λ) the ML estimate of ψ when λ is given, we also have
that if λ and ψ are orthogonal, then ψˆλ varies only slowly with λ.
5. if ψˆλ = ψˆ for all λ, then λ and ψ are orthogonal.
A.1 Construction of orthogonal parameters
Consider a parameter of interest ψ and a vector of nuisance parameters λ = (λ1, λ2, ..., λq),
which we want to orthogonalize from one another. Let φ be a function, such that
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φi = φ1(ψ, λ) for i = 1, 2, ..., q, and suppose the likelihood function is in terms of
the parameters (ψ, φ1, ..., φq), in other words,
l(ψ, λ) = l∗(ψ, φ1, ψ2, ..., ψq),
then the first and second derivatives of the likelihood function have the form
dl(ψ, λ)
dψ
=
dl∗(ψ, φ)
dψ
+
q∑
r=1
dl∗(ψ, φ)
dφr
dφr
dψ
,
hence we obtain
d2l(ψ, λ)
dψdλt
=
q∑
s=1
d2l∗(ψ, φ)
dψdφs
dφs
dλt
+
q∑
r=1
q∑
s=1
d2l∗(ψ, φ)
dφrdφs
dφs
dλt
dφr
dψ
+
q∑
r=1
dl∗(ψ, φ)
dφr
d2φr
dψdλt
.
(A.1)
By taking the expectation of equation A.1, we have
E
[
d2l(ψ, λ)
dψdλt
]
=
q∑
s=1
E
[
d2l∗(ψ, φ)
dψdφ
]
dφs
dλt
+
q∑
r=1
q∑
s=1
E
[
d2l∗(ψ, φ)
dφrdφs
]
dφs
dλt
dφr
dψ
+
q∑
r=1
E
[
dl∗(ψ, φ)
dφr
d2φr
dψdλt
]
=
q∑
s=1
dφs
dλt
i∗ψφs +
q∑
s=1
q∑
r=1
dφr
dψ
dφs
dλt
i∗φrφs ,
where i∗ψφs = E
[
d2l∗(ψ,φ)
dψdφs
]
, i∗φrφs = e
[
d2l∗(ψ,φ)
dφrdφs
]
and
∑q
r=1E
[
dl∗(ψ,φ)
dφr
d2φr
dψdλt
]
is equal to zero.
By definition, ψ and λ are orthogonal if
E
[
d2l(ψ, λ)
dψdλ
]
= 0;
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which leads to the equation
0 = E
[
d2l(ψ, λ)
dψdλ
]
=
q∑
s=1
dφs
dλt
(
i∗ψφs +
q∑
r=1
i∗φrφs
dφr
dψ
)
,
but since the Jacobian of the transformation from (ψ, φ) to (ψ, λ) cannot be zero,
then dφsdλt can’t be zero. This finally leads us to the equation
i∗ψφs +
q∑
r=1
i∗φrφs
dφr
dψ
= 0 ,
and thus the orthogonalizing equation, which determines the dependence between
φ and ψ, is given by
q∑
r=1
i∗φrφs
dφr
dψ
= −i∗ψφs .
Observe that, if ψ had a higher dimension, there is no guarantee, for instance in the
case that ψ = (ψ1, ψ2) , that the condition
d2φs
dψ1dψ2
= d
2φs
dψ2dψ1
holds. For this reason,
global orthogonality of parameters cannot always be obtained.
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Appendix B
Deviations from correctly
specified models
Let us remember that the model proposed in Hutton & Solomon[25] is a mixture of
an accelerated life (AL) model, and a Cox’s proportional hazards (PH) model:
m(t) =
{
g0 (t) e
β′zG0 (t)
exp(β′z)−1
}ψ {
f0
(
teγ
′z
)
eγ
′z
}1−ψ
,
where the survivor functions F0
(
teγ
′z
)
and G0 (t)
exp(β′z) correspond to the accel-
erated life model and the proportional hazards model respectively. F0 and G0 are
the base-line survivor functions with corresponding densities f0 and g0 . Here z is
the vector of fixed covariates, and let β and γ be the associated vectors of unknown
regression parameters for the proportional hazards and accelerated life families of
models. The interest lies in finding expressions for the parameters of interest, β and
γ, while considering ψ as a nuisance parameter.
Let us remember from the Cox & Reid (1987) paper, that the orthogonalizing
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equation between the parameters (ψ, φ) is of the form
q∑
r=1
i∗φrφs
dφr
dψ
= −i∗ψφs ,
where i∗ψφs = E
[
d2l∗(ψ,φ)
dψdφs
]
, i∗φrφs = e
[
d2l∗(ψ,φ)
dφrdφs
]
and l∗ is the log-likelihood function
corresponding to ψ and φ. In the case of this problem the exact expressions of this
orthogonalizing equations are not obtainable, hence the mixture function m(t) is
normalized and equated to the likelihood function
L(ψ, β, γ;α, t, z) =
m(t)∫∞
0 m(t)dt
;
where α, which is assumed as known, are the parameters of the base-line survival
distributions.
B.1 Accelerated Life model true
Supose that the true model is the Accelerated Life model, which implies that ψ = 0,
and that we have the independent failure times t = (t1, t2, ..., tn) and zi a vector of
1× q fixed covariates for the ith individual. Then, in order to calculate ∫∞0 m(t)dt,
we aproximate
m(t)e−ψβ
′ze−(1−ψ)γ
′z
with a first-order Taylor series about (β, γ, ψ) = 0, and find that
∫ ∞
0
m(t)dt ≈ (1− γ′z + c1ψ)eψβ′ze−(1−ψ)γ′z,
where c1 = Ef0 [log {g0(t)/f0(t)}] . Observe that this requires the assumption that
β and γ are small.
184
From this, we obtain that the likelihood function is
L(ψ, β, γ;α, t, z) ≈
n∏
i=1
m(ti)∫∞
0 m(s)ds
=
n∏
i=1
[
g0(ti)G0(ti)
exp(β
′
zi)−1
]ψ
[f0(tie
γzi)](1−ψ)
1− γzi + c1ψ ;
which, with some calculations leads to the log-likelihood expression
l = l(ψ, β, γ;α, t, z) ≈ ψ
n∑
i=1
[
log {g0(ti)}+ (eβ
′
zi − 1) log {G0(ti)}
]
+(1− ψ)
n∑
i=1
log[fo(tie
γ
′
zi)]−
n∑
i=1
log(1− γ′zi + c1ψ).
From this equation, the first and second derivatives of l(ψ, β, γ;α, t, z) are found
with respect to β, γ and ψ, but the expectations of the second derivatives are
analitically intractable, and therefore, they are once again approached by first-order
Taylor aproximations. By doing this, two sets of orthogonalizing equations are
found, but one set is non-informative on the transformation between γ and β, since
the corresponding normalizing constant does not include β. In order to simplify the
expressions, the explanatory variables are orthonormalized, so that
n∑
i=1
zis = 0,
n∑
i=1
ziszir = δrs, r, s = 1, ..., q,
where q is the dimension of the explanatory variables, and δrs is the Kronecker delta.
Finally, from this simplifications the orthogonalization equation is expressed as
−c2ψδβs
δψ
= (c2 + c4)γs + c2βs;
where
c2 = Ef0 [logG0(T )] and c4 = Ef0 [T y˙(T ) logG0(T )] .
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A solution of such partial differential equation is
βs = −γs
(
1 +
c4
c2
)
, (B.1)
and from this it can be observed that when the proportional hazards assumption
is used, when the true model is a life accelerated model, the coefficients are pro-
portional to the first degree. Ultimatly, the expression can be further simplified
to
βs
β1
=
γs
γ1
for s = 2, 3, ..., 1,
which means that the ratios of regression coefficients are consistent. As a special
case, when the true model is an accelerated life model and the analysis is performed
under a proportional hazards model, but the base-line distribution is correct, (or
so to speak, f0 = g0), then the regression coefficients have an even more simple
expression,
βs = −γs(1− c4).
B.2 Cox Proportional Hazards model true
For the case in which the true model is proportional hazards, but for the analysis it
is assumed accelerated life model, the procedure is exactly the same as seen for the
converse case. Once again, β and γ are assumed to be small, and after following the
same steps around the value ψ = 1, we reach the orthogonalization equation
d4 (ψ − 1) δγs
δψ
= d4γs + d6βs,
where
d4 = Eg0 [T y˙(T ) log {g0(T )/f0(T )}] and d6 = Eg0 [T y˙(T ) {1 + logG0(T )}] .
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A solution of such partial differential equation is given by
γs = −βsd6
d4
; (B.2)
observe that this implies that the regression coefficients are linearly related under
model misspecification. Furthermore, this relationship can be re-expressed as
γs
γ1
=
βs
β1
for s = 2, 3, ..., q,
meaning that the ratios of the estimated regression parameters are consistent.
B.3 Inclusion of random censoring
Under the assumption of now having censoring in the data, the likelihood function is
modified in order to include the censoring. The new orthogonalization equations are
approximated by first-order Taylor series, with ψ, β and γ near 0. After calculating
the first and second derivatives of the log-likelihood function, it is found that the
orthogonalizing equations coincide with the orthogonalizing equations corresponding
to the uncensored case. An analogous result is reached when it is considered ψ = 1.
It is concluded that the proportional properties found before still hold when
right-censoring is included in the model.
B.4 Importance of Model selection
Observe that if the orthogonalizing equations (B.1) and (B.2) hold simultaneously,
then it follows that
1 +
c4
c2
=
d4
d6
.
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Furthermore, if the base-line distributions are the same, g0 = f0, then it c2 = −1,
d4 = c5 − 1 and d6 = c4 − 1, where c5 = Ef0
{
T 2y
′′
(T )
}
. Under such a case, the
resulting expression
P =
(1− c4)2
1− c5
is proposed as a measure of how far are the hazards from proportionality. A value of
P far from 1 would indicate a clearer departure from proportionality for the chosen
model. This formula is proposed and named the proportionality factor.
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Appendix C
Hutton & Monaghan[24] results
In this paper, the main objective is to study the properties of misspecification of
two sorts, given that Cox’s proportional hazards and accelerated life models are to
be compared. As it was investigated in previous works (Hutton & Solomon), given
that covariate coefficients are assumed small and that baseline parameters are con-
sidered known, and if a Cox’s proportional hazards is misspecified as an accelerated
life model, then the regression coefficients are consistent between the true and the
assumed models. The result is shown to hold for the converse situation, in which
the assumed model is a proportional hazards, and the true model is an accelerated
life one. When orthonormalizing covariates, it was found that the importance of the
covariates is preserved, although in a following work, Kwong & Hutton (2002), they
suggest that orthonormalization of the covariates is not essential. An important dif-
ference from previous works, is that this paper does not assume that the regression
coefficients are ”small”.
Three categories of misspecification are considered for this paper: when the
base-line distribution is false, but the covariate effects are well specified, when the
covariate effects are false but the right base-line distribution is considered, and
finally when both covariate effects and base-line distribution are misspecified. The
three distributions considered here for the base-line distribution are: log-normal,
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log-logistic and Weibull distributions.
Suppose there are two treatments to be compared, which are the standard
(x = 0) and the new (x = 1) treatment. If the true model is given by f(t;α) while
the fitted model is g(t;β), then for a sample of size n, t1,...,tn , the likelihood function
will be
Lg =
n∏
i=1
g(ti;β).
As quoted from Cox (1961) then the maximum likelihood estimator βˆ under the
misspecified model, will be asymtotically distributed as N(βα,
1
nC(βα)), where βα
is the solution of the set of equations
Ef
[
δ
δβj
log g(T ;β)
]
= 0 for j = 1, ..., p
and
C(βα) = A
−1BA−1
where A is the Fisher information matrix with (j, k)th element −E
[
δ2
δβjβk
logL
]
;
and B has (j, k)th component B(α)jk = Ef
[
δ logL
δβj
δ logL
δβk
]
. In order to calculate
such derivatives, the log-likelihood was split into the failure times belonging to the
standard an the new treatment. The expectation was taken on both sides of the
equation and the asymptotic average was estimated for each treatment.
Ef [log g(T )] = a0Ef0 [log g0(T )] + a1Ef1 [log g1(T )] ,
where g0 and f0 are the assumed and true distributions under the standard treat-
ment, g1 and f1 are the assumed and true distributions under the new treatment and
a0 and a1 are the proportion of observations for the standard and new treatmens
respectively. In order to perform the desired asymptotic average estimation, the
resulting equations were solved analitically if possible, but otherwise the Newton-
Raphson procedure was carried out.
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After all different types of misspecifications are considered and the param-
eters are estimated, a large series of detailed results are stated for every base-line
distribution considered. Among the most important results found by this study are:
• The shape and regression parameters are biased when proportional hazards
models are fitted to accelerated life models.
• For proportional hazards models, the direction of the bias also depends on the
covariate distribution and effect size.
• For orthonormalized covariates, the regression coefficients are proportional
(this was originally obtained in Hutton and Solomon (1997)).
• Consistently with Hutton & Solomon (1997), it was found that the effect of
misspecification decreases as the centre of density of survival times move away
from zero, which means that there are not too many early failures.
• When the fitted model is misspecified, the bias in the lower and upper per-
centiles is usually more substancial than the bias in the median.
• Fully parametric models give narrower confidence limits for quartiles than
non-parametric methods, but they are subjected to the bias of assuming an
incorrect model.
• The accelerated life model is more robust to misspecification because of its
log-linear form.
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